WO2012114268A1 - Benzamide derivatives as p2x7 receptor antagonists - Google Patents

Benzamide derivatives as p2x7 receptor antagonists Download PDF

Info

Publication number
WO2012114268A1
WO2012114268A1 PCT/IB2012/050780 IB2012050780W WO2012114268A1 WO 2012114268 A1 WO2012114268 A1 WO 2012114268A1 IB 2012050780 W IB2012050780 W IB 2012050780W WO 2012114268 A1 WO2012114268 A1 WO 2012114268A1
Authority
WO
WIPO (PCT)
Prior art keywords
chloro
hydroxy
benzamide
cyclohexylmethyl
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2012/050780
Other languages
French (fr)
Inventor
Kurt Hilpert
Francis Hubler
Mark Murphy
Dorte Renneberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actelion Pharmaceuticals Ltd
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Priority to KR1020137024559A priority Critical patent/KR20140009374A/en
Priority to CA2824415A priority patent/CA2824415A1/en
Priority to EP12709177.5A priority patent/EP2678317A1/en
Priority to CN201280009862XA priority patent/CN103391923A/en
Priority to JP2013554962A priority patent/JP2014513671A/en
Priority to US14/001,052 priority patent/US20140073651A1/en
Publication of WO2012114268A1 publication Critical patent/WO2012114268A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/74—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/48—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring being part of a condensed ring system of the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Definitions

  • the present invention relates to benzamide derivatives of formula (I) and their use as pharmaceuticals.
  • the invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of formula (I), and especially their use as P2X 7 receptor antagonists.
  • P2X7 receptors belong to the family of P2X ionotropic receptors that are activated by extracellular nucleotides, in particular adenosine triphosphate (ATP).
  • P2RX7 is distinguished from other P2X family members by the high concentrations (mM range) of ATP required to activate it and its ability to form a large pore upon prolonged or repeated stimulation (North, R. A., Physiol. Rev. 2002, 82(4), 1013-67; Surprenant, A., Rassendren, F. et al., Science 1996, 272(5262), 735-8; Virginio, C, MacKenzie, A. et al., J.
  • P2RX7 is present on many cell types, especially ones known to be involved in inflammatory and immune processes. This is reflected within both the periphery and the CNS as Lipopolysaccharide S (LPS) priming of monocytes and microglia followed by ATP stimulation has been shown to lead to the local release and processing of I L1 ⁇ and other family members including IL18 through a P2RX7 mediated mechanism. Indeed mice lacking the P2X7 receptor are unable to release ⁇ _1 ⁇ following LPS priming and ATP stimulation providing further evidence of its role in this pathway (Solle, M., Labasi, J. et al., J. Biol.
  • LPS Lipopolysaccharide S
  • P2RX7 is also expressed on epithelial and endothelial cells (Ferrari, D., Chiozzi, P. et al., Neuropharmacology 1997, 36(9), 1295-301 ; Wiley, J. S., Chen, J. R. et al., Ciba Found Symp. 1996, 198, 149-60 and 160-5; North, R. A., Physiol. Rev. 2002, 82(4), 1013-67).
  • diseases associated with the central nervous system such as stroke or injury and diseases associated with neuro-degeneration and neuroinflammation such as Alzheimer's disease, Huntington's disease, epilepsy, Amyotrophic lateral sclerosis, acute spinal cord injury additionally to meningitis, sleep disorders, mood and anxiety disorders as well as chronic and neuropathic and inflammatory pain.
  • peripheral inflammatory disorders and autoimmune diseases including but not limited to rheumatoid arthritis, osteoarthritis, psoriasis, allergic dermatitis, asthma, chronic obstructive pulmonary disease, airways hyper-responsiveness, septic shock, bronchitis, glomerulonephritis, irritable bowel disease, skin injury, lung emphysema, Limb girdle dystrophy type 2B, fibrosis, Syndrome of synovitis Acne Pustulosis, atherosclerosis, burn injury, spinal cord injury, Hyperostosis Osteitis, Crohn's disease, ulcerative colitis, growth and metastases of malignant cells, myoblastic leukaemia, diabetes, trauma, meningitis, osteoporosis, burn injury, ischemic heart disease, and varicose veins and trauma, are all examples where the involvement of P2X7 channels has been implicated.
  • P2X7 antagonists that can be efficiently used in treating neuropathic pain, chronic inflammatory pain, inflammation, and neurodegenerative conditions.
  • the present invention relates to benzamide derivatives of formula (I),
  • n 1 , 2, 3 or 4 (and preferably 2, 3 or 4);
  • Y represents -C(R 7 R 8 )-, -N(R 9 )-, -0-, -S-, -S(0)-, or -S(0) 2 -;
  • R 1 represents
  • ⁇ a 6-membered heteroaryl group which is unsubstituted or mono- or di-substituted, wherein the substituents are independently selected from the group consisting of halogen, hydroxy, (C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxy, (C 1 -C 4 )alkylthio, (C 1 -C 4 )alkyl- sulfonyl, (C 1 -C 4 )alkyl-amino and di-[(C 1 -C 4 )alkyl]-amino;
  • R 2 represents chloro or methyl (and preferably chloro);
  • R 3 represents hydrogen and R 4 represents hydroxy, hydroxy-(Ci-C 4 )alkyl, -CONH 2 or (Ci-C 4 )alkoxy (and preferably hydroxy, hydroxymethyl or methoxy); or
  • R 3 represents (Ci-C 4 )alkyl or hydroxy-(Ci-C 4 )alkyl (and preferably methyl or hydroxymethyl) and R 4 represents hydrogen;
  • R 5 represents hydrogen or fluoro
  • R 6 represents hydrogen or fluoro
  • R 7 and R 8 represent independently from each other hydrogen, fluoro, hydroxy or (Ci- C 4 )alkyl, with the proviso that R 8 is different from fluoro or hydroxy if R 7 represents hydroxy;
  • R 7 and R 8 together represent an oxo-group
  • R 9 represents hydrogen, (d-C 4 )alkyl, (C 1 -C 2 )alkoxy-(C 1 -C 4 )alkyl, (C 3 -C 6 )cycloalkyl-(C 1 - C 4 )alkyl, phenyl-(d-C 4 )alkyl, or phenyloxy-(C 1 -C 4 )alkyl;
  • the compounds of formula (I) according to embodiment 1 may contain one or more stereogenic or asymmetric centers, such as one or more asymmetric carbon atoms. Substituents at a double bond may be present in the (Z)- or (E)-configuration unless indicated otherwise.
  • the compounds of formula (I) may thus be present as mixtures of stereoisomers or preferably as pure stereoisomers. Mixtures of stereoisomers may be separated in a manner known to a person skilled in the art.
  • the following paragraphs provide definitions of the various chemical moieties for the compounds according to the invention and are intended to apply uniformly throughout the specification and claims unless an otherwise expressly set out definition provides a broader or narrower definition.
  • alkyl refers to a straight or branched chain alkyl group containing one to four carbon atoms.
  • (C x -C y )alkyl refers to an alkyl group as defined before containing x to y carbon atoms.
  • a (CrC 4 )alkyl group contains from one to four carbon atoms.
  • Representative examples of alkyl groups include methyl, ethyl, n-propyl, / ' so-propyl, n-butyl, / ' so-butyl, sec- butyl and ferf-butyl.
  • (C 1 -C 4 )alkyl group is a substituent to a 5-membered heteroaryl group
  • the term "(C 1 -C 4 )alkyl” means (C 1 -C 4 )alkyl groups as defined above. Examples of said groups are methyl, ethyl, n-propyl, / ' so-propyl, n-butyl, / ' so-butyl, sec-butyl and ferf-butyl. Preferred is methyl.
  • (Ci-C 4 )alkyl group is a substituent to a 6-membered heteroaryl group
  • the term "(CrC 4 )alkyl” means (Ci-C 4 )alkyl groups as defined above. Examples of said groups are methyl, ethyl, n-propyl, / ' so-propyl, n-butyl, / ' so-butyl, sec-butyl and ferf-butyl. Preferred is methyl.
  • (CrC 4 )alkyl group is a substituent to a heterocyclyl group
  • the term "(CrC 4 )alkyl” means (Ci-C 4 )alkyl groups as defined above. Examples of said groups are methyl, ethyl, n-propyl, / ' so-propyl, n-butyl, / ' so-butyl, sec-butyl and ferf-butyl. Preferred is methyl.
  • R 3 represents "(CrC 4 )alkyl”
  • the term means (CrC 4 )alkyl groups as defined above. Examples of said groups are methyl, ethyl, n-propyl, / ' so-propyl, n-butyl, / ' so-butyl, sec-butyl and ferf-butyl. Preferred is methyl.
  • R 7 " or "R 8 " represent "(Ci-C 4 )alkyl”
  • the term means (CrC 4 )alkyl groups as defined above. Examples of said groups are methyl, ethyl, n-propyl, / ' so-propyl, n-butyl, / ' so-butyl, sec-butyl and ferf-butyl. Preferred is methyl.
  • R 9 represents "(C 1 -C 4 )alkyl"
  • the term means (C 1 -C 4 )alkyl groups as defined above. Examples of said groups are methyl, ethyl, n-propyl, / ' so-propyl, n-butyl, / ' so-butyl, sec-butyl and ferf-butyl. Preferred are methyl, ethyl, n-propyl and / ' so-butyl. More preferred are methyl and ethyl and most preferred is methyl.
  • alkoxy refers to an alkyl-O- group wherein the alkyl group is as defined above.
  • (C x -C y )alkoxy refers to an alkoxy group as defined before containing x to y carbon atoms.
  • a (CrC 4 )alkoxy group contains from one to four carbon atoms.
  • Representative examples of alkoxy groups include methoxy, ethoxy, n-propoxy, / ' so-propoxy, n-butoxy, / ' so-butoxy, sec- butoxy and ferf-butoxy.
  • (Ci-C 4 )alkoxy group is a substituent to a 6-membered heteroaryl group
  • the term "(CrC 4 )alkoxy” means (CrC 4 )alkoxy groups as defined above. Examples of said groups are methoxy, ethoxy, n-propoxy, / ' so-propoxy, n-butoxy, / ' so-butoxy, sec-butoxy and ferf- butoxy. Preferred is methoxy.
  • R 4 represents "(CrC 4 )alkoxy"
  • the term means (CrC 4 )alkoxy groups as defined above. Examples of said groups are methoxy, ethoxy, n-propoxy, / ' so-propoxy, n-butoxy, / ' so-butoxy, sec-butoxy and ferf-butoxy. Preferred is methoxy.
  • alkylthio used alone or in combination, refers to an alkyl-S- group wherein the alkyl group is as defined above.
  • (C x -C y )alkylthio (x and y each being an integer) refers to an alkylthio group as defined before containing x to y carbon atoms.
  • a (CrC 4 )alkylthio group contains from one to four carbon atoms.
  • alkylthio groups include methylthio, ethylthio, n-propylthio, / ' so-propylthio, n- butylthio, / ' so-butylthio, sec-butylthio and ferf-butylthio.
  • (CrC 4 )alkylthio group is a substituent to a 6-membered heteroaryl group
  • the term "(d-C 4 )alkylthio" means (CrC 4 )alkylthio groups as defined above. Examples of said groups are methylthio, ethylthio, n-propylthio, / ' so-propylthio, n-butylthio, / ' so-butylthio, sec- butylthio and ferf-butylthio. Preferred is methylthio.
  • (Ci-C 4 )alkyl-amino refers to an amino group (-NH 2 ) in which one hydrogen atom has been replaced by a (CrC 4 )alkyl group as defined above.
  • Representative examples of (Ci-C 4 )alkyl-amino groups include methylamino, ethylamino, n-propylamino, / ' so-propylamino, n-butylamino, / ' so-butylamino, sec-butylamino and ferf-butylamino. Preferred is methylamino.
  • di-[(Ci-C 4 )alkyl]-amino refers to an amino group (-NH 2 ) in which each of the two hydrogen atoms has been replaced by a (C 1 -C 4 )alkyl group as defined above, wherein the two (C 1 -C 4 )alkyl groups may be the same or different.
  • Representative examples of di-[(C 1 -C 4 )alkyl]-amino groups include, but are not limited to, dimethylamino, methyl-ethyl-amino and diethylamino. Preferred is dimethylamino.
  • (Ci-C 4 )alkyl-sulfonyl used alone or in combination, refers to an (d-C 4 )alkyl- S(0) 2 - group wherein the (Ci-C 4 )alkyl group is as defined above.
  • (Ci-C 4 )alkyl-sulfonyl groups include methyl-sulfonyl, ethyl-sulfonyl, n-propyl- sulfonyl, / ' so-propyl-sulfonyl, n-butyl-sulfonyl, / ' so-butyl-sulfonyl, sec-butyl-sulfonyl and tert- butyl-sulfonyl.
  • Preferred is methyl-sulfonyl.
  • hydroxy-(CrC 4 )alkyl refers to an alkyl group as defined before containing from one to four carbon atoms in which one hydrogen atom has been replaced with hydroxy.
  • hydroxy-(Ci-C 4 )alkyl groups include, but are not limited to, hydroxy-methyl, 1 - hydroxy-ethyl, 2-hydroxy-ethyl, 1 -hydroxy-propyl, 2-hydroxy-propyl, 3-hydroxy-propyl, 1 - hydroxy-1 -methyl-ethyl and 2-hydroxy-1 -methyl-ethyl.
  • R 3 represents "hydroxy-(C 1 -C 4 )alkyl"
  • the term means hydroxy-(C 1 -C 4 )alkyl groups as defined above. Examples of said groups include, but are not limited to, hydroxy- methyl, 1 -hydroxy-ethyl, 2-hydroxy-ethyl, 1 -hydroxy-propyl, 2-hydroxy-propyl, 3-hydroxy- propyl, 1 -hydroxy-1 -methyl-ethyl and 2-hydroxy-1 -methyl-ethyl. Preferred is hydroxy- methyl.
  • R 4 represents "hydroxy-(CrC 4 )alkyl"
  • the term means hydroxy-(Ci-C 4 )alkyl groups as defined above. Examples of said groups include, but are not limited to, hydroxy- methyl, 1 -hydroxy-ethyl, 2-hydroxy-ethyl, 1 -hydroxy-propyl, 2-hydroxy-propyl, 3-hydroxy- propyl, 1 -hydroxy-1 -methyl-ethyl and 2-hydroxy-1 -methyl-ethyl. Preferred is hydroxy- methyl.
  • (Ci-C2)alkoxy-(CrC 4 )alkyl refers to an alkyl group as defined before containing from one to four carbon atoms in which one hydrogen atom has been replaced with (d- C 2 )alkoxy as defined before.
  • Examples of (Ci-C 2 )alkoxy-(Ci-C 4 )alkyl groups include, but are not limited to, methoxy-methyl, ethoxy-methyl, 1 -methoxy-ethyl, 1 -ethoxy-ethyl, 2- methoxy-ethyl, 2-ethoxy-ethyl, 1-methoxy-propyl, 1-ethoxy-propyl, 2-methoxy-propyl, 2- ethoxy-propyl, 3-methoxy-propyl, 3-ethoxy-propyl, 1 -methoxy-1 -methyl-ethyl, 1-ethoxy-1 - methyl-ethyl, 2-methoxy-1 -methyl-ethyl and 2-ethoxy-1 -methyl-ethyl.
  • (C 1 -C 2 )alkoxy-(C 1 -C 4 )alkyl group is a substituent to a heterocyclyl group
  • the term "(C 1 -C 2 )alkoxy-(C 1 -C 4 )alkyl” means (C 1 -C 2 )alkoxy-(C 1 -C 4 )alkyl groups as defined above.
  • Examples of said groups include, but are not limited to, methoxy-methyl, ethoxy- methyl, 1 -methoxy-ethyl, 1-ethoxy-ethyl, 2-methoxy-ethyl, 2-ethoxy-ethyl, 1-methoxy- propyl, 1 -ethoxy-propyl, 2-methoxy-propyl, 2-ethoxy-propyl, 3-methoxy-propyl, 3-ethoxy- propyl, 1 -methoxy-1 -methyl-ethyl, 1 -ethoxy-1 -methyl-ethyl, 2-methoxy-1 -methyl-ethyl and 2-ethoxy-1 -methyl-ethyl.
  • Preferred are 2-methoxy-ethyl and 2-ethoxy-ethyl; and most preferred is 2-methoxy-ethyl.
  • R 9 represents "(Ci-C 2 )alkoxy-(Ci-C 4 )alkyl" the term means (Ci-C 2 )alkoxy-(Ci- C 4 )alkyl groups as defined above.
  • said groups include, but are not limited to, methoxy-methyl, ethoxy-methyl, 1-methoxy-ethyl, 1-ethoxy-ethyl, 2-methoxy-ethyl, 2- ethoxy-ethyl, 1 -methoxy-propyl, 1 -ethoxy-propyl, 2-methoxy-propyl, 2-ethoxy-propyl, 3- methoxy-propyl, 3-ethoxy-propyl, 1-methoxy-1 -methyl-ethyl, 1 -ethoxy-1 -methyl-ethyl, 2- methoxy-1 -methyl-ethyl and 2-ethoxy-1 -methyl-ethyl.
  • (C 3 -C 6 )cycloalkyl used alone or in combination, means a cycloalkyl group with 3 to 6 carbon atoms.
  • Examples of (C 3 -C 6 )cycloalkyl groups are cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
  • (C 3 -C 6 )cycloalkyl-(C 1 -C 4 )alkyl refers to an alkyl group as defined before containing from one to four carbon atoms in which one hydrogen atom has been replaced with (C 3 -C 6 )cycloalkyl as defined before.
  • Examples of (C 3 -C 6 )cycloalkyl-(Ci-C 4 )alkyl groups include, but are not limited to, cyclopropyl-methyl, cyclobutyl-methyl, cyclopentyl- methyl, cyclohexyl-methyl, 1 -cyclopropyl-ethyl, 1-cyclobutyl-ethyl, 1 -cyclopentyl-ethyl, 1 - cyclohexyl-ethyl, 2-cyclopropyl-ethyl, 2-cyclobutyl-ethyl, 2-cyclopentyl-ethyl, 2-cyclohexyl- ethyl, 3-cyclopropyl-propyl, 3-cyclobutyl-propyl, 3-cyclopentyl-propyl and 3-cyclohexyl- propyl.
  • phenyl-(CrC 4 )alkyl refers to an alkyl group as defined before containing from one to four carbon atoms in which one hydrogen atom has been replaced with phenyl.
  • phenyl-(d-C 4 )alkyl groups include, but are not limited to, phenyl-methyl (benzyl), 1-phenyl-ethyl, 2-phenyl-ethyl, 1 -phenyl-propyl, 2-phenyl-propyl, 3-phenyl-propyl, 1-phenyl-1 -methyl-ethyl and 2-phenyl-1-methyl-ethyl.
  • Preferred are benzyl and 2-phenyl- ethyl and most preferred is benzyl.
  • phenyloxy-(C 1 -C 4 )alkyl refers to an alkyl group as defined before containing from one to four carbon atoms in which one hydrogen atom has been replaced with phenyloxy (or in an alternative phrase: phenoxy).
  • phenyloxy-(C 1 -C 4 )alkyl groups include, but are not limited to, phenyloxy-methyl, 1 -phenyloxy-ethyl, 2-phenyloxy- ethyl, 1-phenyloxy-propyl, 2-phenyloxy-propyl, 3-phenyloxy-propyl, 1-phenyloxy-1 -methyl- ethyl and 2-phenyloxy-1 -methyl-ethyl.
  • phenyloxy-methyl and 2-phenyloxy- ethyl are preferred and most preferred is 2-phenyloxy-ethyl.
  • halogen means fluoro, chloro, bromo or iodo, preferably fluoro or chloro and most preferably fluoro.
  • 5-membered heteroaryl used alone or in combination, means a 5-membered monocyclic aromatic ring containing 1 , 2 or 3 heteroatoms independently selected from oxygen, nitrogen and sulphur (and preferably containing 1 or 2 nitrogen atoms).
  • Examples of such 5-membered heteroaryl groups are furanyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl and triazolyl.
  • pyrrolyl imidazolyl and pyrazolyl and most preferred is pyrazolyl (notably pyrazol-3-yl).
  • the above-mentioned 5-membered heteroaryl groups are unsubstituted or mono- or di-substituted with (C 1 -C 4 )alkyl (preferably methyl).
  • a preferred example of such unsubstituted or mono- or di-substituted 5-membered heteroaryl groups is 2-methyl-2H- pyrazol-3-yl.
  • 6-membered heteroaryl used alone or in combination, means a 6-membered monocyclic aromatic ring containing 1 or 2 nitrogen atoms.
  • 6- membered heteroaryl groups are pyridyl, pyrimidyl, pyridazinyl and pyrazinyl. Preferred is pyridyl.
  • the above-mentioned 6-membered heteroaryl groups are unsubstituted or mono- or di-substituted, wherein the substituents are independently selected from the group consisting of halogen, hydroxy, (Ci-C 4 )alkyl, (Ci-C 4 )alkoxy, (Ci-C 4 )alkylthio, (Ci- C 4 )alkyl-sulfonyl, (C-i-C 4 )alkyl-amino and di-[(C-i-C 4 )alkyl]-amino.
  • the substituents are independently selected from the group consisting of halogen (notably fluoro or chloro), hydroxy and (Ci-C 4 )alkoxy (notably methoxy).
  • halogen notably fluoro or chloro
  • hydroxy and (Ci-C 4 )alkoxy notably methoxy.
  • 6-membered heteroaryl groups are pyridin-2-yl, 4-fluoro-pyridin-2-yl, 6-fl uoro-py rid in-2-yl , 6-chloro-pyridin-2-yl, 6-hydroxy-pyridin-2-yl, 6- methoxy-pyridin-2-yl, 6-methylamino-pyridin-2-yl, 6-dimethylamino-pyridin-2-yl, pyridin-3- yl, pyridin-4-yl, 2-chloro-pyridin-4-yl, pyrimidin-2-yl, 4-hydroxy-pyrimidin-2-yl, 4-methoxy
  • pyridin-2-yl 4-fluoro-pyridin-2-yl, 6-fluoro- pyridin-2-yl, 6-hydroxy-pyridin-2-yl, 6-methoxy-pyridin-2-yl and 2-hydroxy-pyrimidin-4-yl.
  • 6-membered heteroaryl groups may be present in different tautomeric forms (e.g. in case said heteroaryl groups are substituted with at least one hydroxy group). Examples of such tautomers are given in the formulas below:
  • tautomers are within the scope of the present invention. Even though one tautomer may be described, the present invention includes all tautomers of the present compounds. Especially, any given chemical name does represent not only the specifically named chemical compound but also the different tautomeric forms thereof. In solution, tautomers exist usually as mixtures of different tautomeric forms; in the solid state usually one tautomeric form predominates.
  • heterocyclyl used alone or in combination, means a 6-membered monocyclic ring containing 1 or 2 double bonds (preferably 2 double bonds) and 1 or 2 nitrogen atoms, wherein one or two carbon atoms adjacent to said nitrogen atoms are substituted with an oxo-group.
  • the heterocyclyl group may be attached to the rest of the molecule via a nitrogen atom or a carbon atom.
  • a heterocyclyl group representing R 1 is preferably attached to the rest of the molecule via a nitrogen atom.
  • a heterocyclyl group representing R 1 is preferably attached to the rest of the molecule via a carbon atom.
  • heterocyclyl groups are unsubstituted or mono- or di- substituted with (C 1 -C 4 )alkyl or (C 1 -C 2 )alkoxy-(C 1 -C 4 )alkyl (and preferably unsubstituted or mono-substituted with (C 1 -C 4 )alkyl).
  • Preferred heterocyclyl groups are selected from the group of radicals as depicted in groups G1 and/or G2 below:
  • G1 heterocyclyl groups, attached to the rest of the molecule via a nitrogen atom (as depicted by the arrow):
  • G2 heterocyclyl groups, attached to the rest of the molecule via a carbon atom (; depicted by the arrow):
  • a further embodiment of the invention relates to benzamide derivatives according to embodiment 1 ), wherein
  • n 1 , 2, 3 or 4 (and preferably 2, 3 or 4);
  • Y represents -C(R 7 R 8 )-, -N(R 9 )-, -0-, -S-, -S(O)-, or -S(0) 2 -;
  • R 1 represents • a 5-membered heteroaryl group which is unsubstituted or mono- or di-substituted with (Ci-C 4 )alkyl;
  • R 2 represents chloro or methyl (and preferably chloro);
  • R 3 represents hydrogen and R 4 represents hydroxy, hydroxy-(Ci-C 4 )alkyl, -CONH 2 or (Ci-C 4 )alkoxy (and preferably hydroxy, hydroxymethyl or methoxy); or
  • R 3 represents (Ci-C 4 )alkyl or hydroxy-(Ci-C 4 )alkyl (and preferably methyl or hydroxymethyl) and R 4 represents hydrogen;
  • R 5 represents hydrogen or fluoro
  • R 6 represents hydrogen or fluoro
  • R 7 and R 8 represent independently from each other hydrogen or fluoro; or R 7 and R 8 together represent an oxo-group;
  • R 9 represents hydrogen, (Ci-C 4 )alkyl, (Ci-C 2 )alkoxy-(Ci-C 4 )alkyl, (C 3 -C 6 )cycloalkyl-(Ci- C 4 )alkyl, phenyl-(Ci-C 4 )alkyl, or phenyloxy-(Ci-C 4 )alkyl;
  • a further embodiment of the invention relates to benzamide derivatives according to embodiment 1 ), wherein
  • n 2, 3 or 4;
  • Y represents -C(R 7 R 8 )-, -N(R 9 )-, -0-, or -S-;
  • R 1 represents a 6-membered heteroaryl group which is unsubstituted or mono- or di- substituted, wherein the substituents are independently selected from the group consisting of halogen, hydroxy, (Ci-C 4 )alkoxy, (Ci-C 4 )alkylthio, (Ci-C 4 )alkyl-sulfonyl, (Ci-C 4 )alkyl- amino and di-[(Ci-C 4 )alkyl]-amino (preferably halogen, hydroxy and (Ci-C 4 )alkoxy);
  • R 2 represents chloro;
  • R 3 represents hydrogen and R 4 represents hydroxy or hydroxy-(Ci-C 4 )alkyl (and preferably hydroxy or hydroxymethyl); or
  • R 3 represents (Ci-C 4 )alkyl or hydroxy-(Ci-C 4 )alkyl (and preferably methyl or hydroxymethyl) and R 4 represents hydrogen;
  • R 5 represents hydrogen or fluoro
  • R 6 represents hydrogen or fluoro
  • R 7 and R 8 represent independently from each other hydrogen, fluoro, hydroxy or (Ci- C 4 )alkyl, with the proviso that R 8 is different from fluoro or hydroxy if R 7 represents hydroxy;
  • R 7 and R 8 together represent an oxo-group
  • R 9 represents hydrogen, (d-C 4 )alkyl, (C 1 -C 2 )alkoxy-(C 1 -C 4 )alkyl, (C 3 -C 6 )cycloalkyl-(C 1 - C 4 )alkyl, phenyl-(d-C 4 )alkyl, or phenyloxy-(C 1 -C 4 )alkyl (and preferably hydrogen or (d- C 4 )alkyl);
  • a further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) or 2), wherein
  • n 2, 3 or 4;
  • Y represents -C(R 7 R 8 )-, -N(R 9 )-, -0-, or -S-;
  • R 1 represents a 6-membered heteroaryl group which is unsubstituted or mono- or di- substituted, wherein the substituents are independently selected from the group consisting of halogen, hydroxy, (Ci-C 4 )alkoxy, (Ci-C 4 )alkylthio, (Ci-C 4 )alkyl-sulfonyl, (Ci-C 4 )alkyl- amino and di-[(Ci-C 4 )alkyl]-amino (preferably halogen, hydroxy and (Ci-C 4 )alkoxy);
  • R 2 represents chloro
  • R 3 represents hydrogen and R 4 represents hydroxy or hydroxy-(Ci-C 4 )alkyl (and preferably hydroxy or hydroxymethyl); or
  • R 3 represents (C 1 -C 4 )alkyl or hydroxy-(C 1 -C 4 )alkyl (and preferably methyl or hydroxymethyl) and R 4 represents hydrogen;
  • R 5 represents hydrogen or fluoro
  • R 6 represents hydrogen or fluoro
  • R 7 and R 8 represent independently from each other hydrogen or fluoro; or R 7 and R 8 together represent an oxo-group;
  • R 9 represents hydrogen, (d-C 4 )alkyl, (Ci-C 2 )alkoxy-(Ci-C 4 )alkyl, (C 3 -C 6 )cycloalkyl-(Ci- C 4 )alkyl, phenyl-(Ci-C 4 )alkyl, or phenyloxy-(Ci-C 4 )alkyl (and preferably hydrogen or (Ci- C 4 )alkyl);
  • a further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) or 2), wherein
  • n 1 , 2, 3 or 4 (and preferably 2, 3 or 4);
  • Y represents -C(R 7 R 8 )-, -N(R 9 )-, -0-, -S-, -S(O)-, or -S(0) 2 -;
  • R 1 represents
  • R 2 represents chloro or methyl (and preferably chloro);
  • R 3 represents hydrogen and R 4 represents hydroxy, hydroxy-(C 1 -C 4 )alkyl, -CONH 2 or (C 1 -C 4 )alkoxy (and preferably hydroxy, hydroxymethyl or methoxy);
  • R 5 represents hydrogen or fluoro
  • R 6 represents hydrogen or fluoro
  • R 7 and R 8 represent independently from each other hydrogen or fluoro; or R 7 and R 8 together represent an oxo-group; and R 9 represents hydrogen, (d-C 4 )alkyl, (Ci-C 2 )alkoxy-(Ci-C 4 )alkyl, (C 3 -C 6 )cycloalkyl-(Ci- C 4 )alkyl, phenyl-(Ci-C 4 )alkyl, or phenyloxy-(Ci-C 4 )alkyl;
  • a further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) or 2), wherein
  • n 2, 3 or 4;
  • Y represents -C(R 7 R 8 )-, -N(R 9 )-, -0-, or -S-;
  • R 1 represents a 6-membered heteroaryl group which is unsubstituted or mono- or di- substituted (preferably unsubstituted or mono-substituted), wherein the substituents are independently selected from the group consisting of halogen, hydroxy, (C 1 -C 4 )alkoxy, (C 1 -C 4 )alkylthio, (C 1 -C 4 )alkyl-sulfonyl, (C 1 -C 4 )alkyl-amino and di-[(C 1 -C 4 )alkyl]-amino (preferably halogen, hydroxy and (C 1 -C 4 )alkoxy);
  • R 2 represents chloro
  • R 3 represents hydrogen and R 4 represents hydroxy or hydroxy-(Ci-C 4 )alkyl (and preferably hydroxy or hydroxymethyl);
  • R 5 represents hydrogen or fluoro
  • R 6 represents hydrogen or fluoro
  • R 7 and R 8 represent independently from each other hydrogen or fluoro; or R 7 and R 8 together represent an oxo-group;
  • R 9 represents hydrogen, (Ci-C 4 )alkyl, (Ci-C 2 )alkoxy-(Ci-C 4 )alkyl, (C 3 -C 6 )cycloalkyl-(Ci- C 4 )alkyl, phenyl-(Ci-C 4 )alkyl, or phenyloxy-(Ci-C 4 )alkyl (and preferably hydrogen or (Ci- C 4 )alkyl);
  • a further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) or 2), wherein
  • n 1 , 2, 3 or 4 (and preferably 2, 3 or 4);
  • Y represents -C(R 7 R 8 )-, -N(R 9 )-, -0-, or -S- (preferably -N(R 9 )-);
  • R 1 represents a 6-membered heteroaryl group which is unsubstituted or mono- or di- substituted, wherein the substituents are independently selected from the group consisting of halogen, hydroxy, (Ci-C 4 )alkyl, (Ci-C 4 )alkoxy, (Ci-C 4 )alkylthio, (Ci-C 4 )alkyl-sulfonyl, (Ci-C 4 )alkyl-amino and di-[(Ci-C 4 )alkyl]-amino (preferably halogen, hydroxy and (Ci- C 4 )alkylthio);
  • R 2 represents chloro
  • R 3 represents (Ci-C 4 )alkyl or hydroxy-(Ci-C 4 )alkyl (and preferably methyl or hydroxymethyl) and R 4 represents hydrogen;
  • R 5 represents hydrogen or fluoro (preferably hydrogen);
  • R 6 represents hydrogen or fluoro (preferably hydrogen);
  • R 7 and R 8 represent independently from each other hydrogen or fluoro; or R 7 and R 8 together represent an oxo-group;
  • R 9 represents hydrogen, (d-C 4 )alkyl, (C 1 -C 2 )alkoxy-(C 1 -C 4 )alkyl, (C 3 -C 6 )cycloalkyl-(C 1 - C 4 )alkyl, phenyl-(d-C 4 )alkyl, or phenyloxy-(C 1 -C 4 )alkyl (preferably hydrogen or (d- C 4 )alkyl);
  • a further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) or 2), wherein
  • n 2;
  • Y represents -N(R 9 )-
  • R 1 represents a 6-membered heteroaryl group which is unsubstituted or mono- or di- substituted (preferably mono-substituted), wherein the substituents are independently selected from the group consisting of halogen, hydroxy and (Ci-C 4 )alkylthio (preferably halogen and hydroxy);
  • R 2 represents chloro
  • R 3 represents (Ci-C 4 )alkyl or hydroxy-(Ci-C 4 )alkyl (and preferably methyl or hydroxymethyl) and R 4 represents hydrogen;
  • R 5 represents hydrogen
  • R 6 represents hydrogen; and R 9 represents hydrogen or (Ci-C 4 )alkyl (and preferably hydrogen or methyl);
  • a further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 7), wherein
  • n 2, 3 or 4 (preferably 2 or 3 and most preferably 2);
  • a further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 7), wherein
  • n 3 or 4;
  • a further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 7), 9) or 10), wherein
  • Y represents -C(R 7 R 8 )-, -N(R 9 )-, -0-, or -S-;
  • a further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 7), 9) or 10), wherein
  • Y represents -C(R 7 R 8 )-, -0-, or -S-;
  • a further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 7), 9) or 10), wherein
  • Y represents -C(R 7 R 8 )-
  • a further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 10), wherein
  • Y represents -N(R 9 )-
  • a further embodiment of the invention relates to benzamide derivatives accord any one of embodiments 1 ) to 7), 9) or 10), wherein Y represents -0-;
  • a further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 7), 9) or 10), wherein
  • Y represents -S-, -S(O)-, or -S(0) 2 - (preferably -S-);
  • a further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ), 2), 5) or 9) to 16), wherein
  • R 1 represents
  • a further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ), 2), 5) or 9) to 16), wherein
  • R 1 represents
  • a further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ), 2), 5) or 9) to 16), wherein R 1 represents a 5-membered heteroaryl group which is unsubstituted or mono- or di- substituted (preferably mono-substituted) with (Ci-C 4 )alkyl (preferably methyl);
  • a further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 16), wherein
  • R 1 represents a 6-membered heteroaryl group which is unsubstituted or mono- or di- substituted, wherein the substituents are independently selected from the group consisting of halogen, hydroxy, (Ci-C 4 )alkyl, (Ci-C 4 )alkoxy, (Ci-C 4 )alkylthio, (Ci-C 4 )alkyl-sulfonyl, (Ci-C 4 )alkyl-amino and di-[(C-i-C 4 )alkyl]-amino (preferably from halogen, hydroxy and methoxy; and most preferably from halogen and hydroxy);
  • a further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 16), wherein
  • R 1 represents a 6-membered heteroaryl group which is unsubstituted or mono-substituted (preferably mono-substituted), wherein the substituents are independently selected from the group consisting of halogen, hydroxy and (Ci-C 4 )alkoxy (preferably from fluoro, chloro, hydroxy and methoxy; and most preferably from fluoro, chloro and hydroxy);
  • a further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ), 2), 5) or 9) to 16), wherein
  • R 1 represents a phenyl group which is unsubstituted or mono- or di-substituted with halogen (preferably fluoro);
  • a further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ), 2), 5) or 9) to 16), wherein
  • R 1 represents a heterocyclyl group which is unsubstituted or mono- or di-substituted (preferably unsubstituted or mono-substituted) with (Ci-C 4 )alkyl or (d-C 2 )alkoxy-(Ci- C 4 )alkyl;
  • a further embodiment of the invention relates to benzamide derivatives according to embodiment 23), wherein the heterocyclyl group is selected from groups G1 and/or G2;
  • a further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 24), wherein
  • R 2 represents chloro
  • a further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ), 2), 5) or 9) to 24), wherein
  • R 2 represents methyl
  • a further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ), 2), 5) or 9) to 26), wherein
  • R 3 represents hydrogen and R 4 represents hydroxy, hydroxy-(C 1 -C 4 )alkyl, -CONH 2 or (C 1 -C 4 )alkoxy (and preferably hydroxy, hydroxymethyl or methoxy);
  • a further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 6) or 9) to 26), wherein
  • R 3 represents hydrogen and R 4 represents hydroxy or hydroxy-(Ci-C 4 )alkyl (and preferably hydroxy or hydroxymethyl);
  • a further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 6) or 9) to 26), wherein
  • R 3 represents hydrogen and R 4 represents hydroxy
  • a further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 6) or 9) to 26), wherein
  • R 3 represents hydrogen and R 4 represents hydroxy-(Ci-C 4 )alkyl (preferably hydroxymethyl);
  • a further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 4) or 7) to 26), wherein
  • R 3 represents (Ci-C 4 )alkyl or hydroxy-(Ci-C 4 )alkyl (and preferably methyl or hydroxymethyl) and R 4 represents hydrogen;
  • a further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 4) or 7) to 26), wherein
  • R 3 represents (Ci-C 4 )alkyl (preferably methyl) and R 4 represents hydrogen;
  • a further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 4) or 7) to 26), wherein
  • R 3 represents hydroxy-(C 1 -C 4 )alkyl (preferably hydroxymethyl) and R 4 represents hydrogen;
  • a further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 33), wherein
  • R 5 and R 6 both represent hydrogen
  • a further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 7) or 9) to 33), wherein
  • R 5 and R 6 both represent fluoro
  • a further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 7) or 9) to 33), wherein
  • R 5 represents hydrogen and R 6 represents fluoro
  • a further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ), 3) or 9) to 36), wherein R 7 and R 8 represent independently from each other hydrogen, fluoro, hydroxy or (Ci- C 4 )alkyl, with the proviso that R 8 is different from fluoro or hydroxy if R 7 represents hydroxy;
  • a further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 7) or 9) to 36), wherein
  • R 7 and R 8 represent independently from each other hydrogen or fluoro
  • a further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 7) or 9) to 36), wherein
  • R 7 and R 8 both represent hydrogen
  • a further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 7) or 9) to 36), wherein
  • R 7 and R 8 both represent fluoro
  • a further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 7) or 9) to 36), wherein
  • R 7 represents hydrogen and R 8 represents fluoro
  • a further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ), 3) or 9) to 36), wherein
  • R 7 represents hydrogen or (Ci-C 4 )alkyl (preferably (Ci-C 4 )alkyl) and R 8 represents hydroxy;
  • a further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 7) or 9) to 36), wherein
  • R 7 and R 8 together represent an oxo-group
  • a further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 7) or 9) to 43), wherein
  • R 9 represents hydrogen, methyl, ethyl, n-propyl, / ' so-propyl, / ' so-butyl, 2-methoxy-ethyl, cyclopentyl-methyl, benzyl, or 2-phenyloxy-ethyl;
  • a further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 43), wherein
  • R 9 represents hydrogen or (d-C 4 )alkyl (preferably methyl, ethyl, n-propyl, / ' so-propyl or /so-butyl);
  • a further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 7), 9) to 38), 41 ), 42) or 44) to 45), wherein,
  • a further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 7), 9) to 38), 41 ), 42) or 44) to 45), wherein,
  • a further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 4), 7) to 26) or 31 ) to 47), wherein
  • a further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 4), 7) to 26) or 31 ) to 47), wherein
  • a further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 7), 9) to 33) or 35) to 49), wherein, in case n is different from 2 and at least one of R 5 and R 6 is different from hydrogen, the carbon atom, which is attached to the group R 4 , has (S)-configuration;
  • a further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 7), 9) to 33) or 35) to 49), wherein,
  • n is different from 2 and at least one of R 5 and R 6 is different from hydrogen, the carbon atom, which is attached to the group R 4 , has (R)-configuration;
  • a further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 7), 9) to 33) or 35) to 51 ), wherein,
  • n is different from 2 and one of R 5 or R 6 represents fluoro, the carbon atom, which is attached to the groups R 5 and R 6 , has (S)-configuration;
  • a further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 7), 9) to 33) or 35) to 51 ), wherein,
  • n is different from 2 and one of R 5 or R 6 represents fluoro, the carbon atom, which is attached to the groups R 5 and R 6 , has (R)-configuration;
  • Preferred compounds of formula (I) as defined in embodiment 1 ) are selected from the group consisting of:
  • stereogenic center which is not specifically assigned, may be in absolute (R)- or absolute (S)-configuration.
  • stereogenic center which is not specifically assigned, may be in absolute (R)- or absolute (S)-configuration.
  • the present invention also includes isotopically labelled, especially 2 H (deuterium) labelled compounds of formula (I), which compounds are identical to the compounds of formula (I) except that one or more atoms have each been replaced by an atom having the same atomic number but an atomic mass different from the atomic mass usually found in nature.
  • Isotopically labelled, especially 2 H (deuterium) labelled compounds of formula (I) and salts thereof are within the scope of the present invention. Substitution of hydrogen with the heavier isotope 2 H (deuterium) may lead to greater metabolic stability, resulting e.g. in increased in-vivo half-life or reduced dosage requirements, or may lead to reduced inhibition of cytochrome P450 enzymes, resulting e.g. in an improved safety profile.
  • the compounds of formula (I) are not isotopically labelled, or they are labelled only with one or more deuterium atoms. In a sub-embodiment, the compounds of formula (I) are not isotopically labelled at all. Isotopically labelled compounds of formula (I) may be prepared in analogy to the methods described hereinafter, but using the appropriate isotopic variation of suitable reagents or starting materials.
  • salts refers to non-toxic, inorganic or organic acid and/or base addition salts, Lit. e.g. "Salt selection for basic drugs", Int. J. Pharm. (1986), 33, 201-217. Where the plural form is used for compounds, salts, pharmaceutical compositions, diseases and the like, this is intended to mean also a single compound, salt, or the like.
  • compounds of formula (I) are suitable for use as medicaments.
  • compounds of formula (I) modulate the P2X 7 receptor, i.e. they act as P2X 7 receptor antagonists, and are useful for the prevention or treatment of diseases which are associated with the activation of the P2X 7 receptor such as pain; neurodegenerative and neuroinflammatory diseases; bone and joint diseases; obstructive diseases of the airways; cardiovascular diseases; eye diseases; skin diseases; abdominal and gastrointestinal tract diseases; genitourinary diseases; cancer; other auto-immune and allergic disorders; and other disorders with an inflammatory or immunological component.
  • Pain refers to acute pain; chronic pain; pain associated with sprains and strains; chronic articular pain; pain associated with rheumatic fever; musculoskeletal pain; lower back and neck pain; inflammatory pain; neuropathic pain; visceral pain; pain associated with influenza or other viral infections; pain associated with cancer and tumor invasion; joint and bone pain; atypical facial pain; pain associated with migraine, toothache and dysmenorrhea; headache including tension headache and cluster headaches; pain associated with myocardial ischemia; pain associated with functional bowel disorders; sympathetically maintained pain; myositis; pain associated with cancer chemotherapy; and post operative pain.
  • Neuropathic pain includes especially diabetic neuropathy, sciatica, non-specific lower back pain, trigeminal neuralgia, multiple sclerosis pain, fibromyalgia, HIV-related neuropathy, post-herpetic neuralgia, trigeminal neuralgia, and pain resulting from physical trauma, amputation, phantom limb syndrome, spinal surgery, cancer, toxins or chronic inflammatory conditions.
  • neuropathic pain conditions include pain associated with normally non-painful sensations such as "pins and needles" (paraesthesias and dysesthesias), increased sensitivity to touch (hyperesthesia), painful sensation following innocuous stimulation (dynamic, static, thermal or cold allodynia), increased sensitivity to noxious stimuli (thermal, cold, mechanical hyperalgesia), continuing pain sensation after removal of the stimulation (hyperpathia) or an absence of or deficit in selective sensory pathways (hypoalgesia).
  • normally non-painful sensations such as "pins and needles” (paraesthesias and dysesthesias), increased sensitivity to touch (hyperesthesia), painful sensation following innocuous stimulation (dynamic, static, thermal or cold allodynia), increased sensitivity to noxious stimuli (thermal, cold, mechanical hyperalgesia), continuing pain sensation after removal of the stimulation (hyperpathia) or an absence of or deficit in selective sensory pathways (hypoalgesia).
  • Chronic articular pain conditions include especially rheumatoid arthritis, osteoarthritis, rheumatoid spondylitis, gouty arthritis and juvenile arthritis.
  • Pain associated with functional bowel disorders includes especially non-ulcer dyspepsia, non-cardiac chest pain and irritable bowel syndrome.
  • Neurodegenerative and neuro- inflammatory diseases include Alzheimer's disease and other dementing disorders including, but not limited to, Creutzfeldt-Jakob disease (CJD) and new variant Creutzfeldt-Jakob disease (nvCJD); Amyotrophic lateral sclerosis, amyloidosis; multiple sclerosis and other demyelinating syndromes; cerebral atherosclerosis and vasculitis; temporal arteritis; myasthenia gravis; Huntington's disease; Lewy Body dementia; and Parkinson's disease.
  • CJD Creutzfeldt-Jakob disease
  • nvCJD new variant Creutzfeldt-Jakob disease
  • cerebral atherosclerosis and vasculitis cerebral atherosclerosis and vasculitis
  • temporal arteritis myasthenia gravis
  • Huntington's disease Lewy Body dementia
  • Bone and joint diseases include arthritides such as rheumatoid arthritis, osteoarthritis, gout or crystal arthropathy; intervertebral disc degeneration; temporomandibular joint degeneration; bone remodelling disease such as osteoporosis, Paget's disease or osteonecrosis; polychondritis; scleroderma; mixed connective tissue disorder; spondyloarthropathies; periodontal disease such as periodontitis; arthritides associated with or including osteoarthritis/osteoarthrosis, both primary and secondary to, for example, congenital hip dysplasia; cervical and lumbar spondylitis; Still's disease; seronegative spondyloarthropathies including ankylosing spondylitis, psoriatic arthritis, reactive arthritis and un
  • Obstructive diseases of the airways include asthma, including bronchial, allergic, intrinsic, and extrinsic asthma, exercise-induced, drug- induced (including aspirin and NSAID-induced) and dust- induced asthma, both intermittent and persistent and of all severities, and other causes of airway hyper- responsiveness; chronic obstructive pulmonary disease (COPD); bronchitis, including infectious and eosinophilic bronchitis; emphysema; bronchiectasis; cystic fibrosis; sarcoidosis; farmer's lung and related diseases; hypersensitivity pneumonitis; lung fibrosis, including cryptogenic fibrosing alveolitis, idiopathic interstitial pneumonias, fibrosis complicating anti-neoplastic therapy and chronic infection
  • COPD chronic obstructive pulmonary disease
  • bronchitis including infectious and eosinophilic bronchitis; emphysema; bronchie
  • Cardiovascular diseases include atherosclerosis, affecting the coronary and peripheral circulation; pericarditis; myocarditis; inflammatory and autoimmune cardiomyopathies including myocardial sarcoid; ischaemic reperfusion injuries; endocarditis, valvulitis, and aortitis including infective (for example syphilitic); vasculitides; and disorders of the proximal and peripheral veins including phlebitis and thrombosis, including deep vein thrombosis and complications of varicose veins.
  • Eye diseases include blepharitis; conjunctivitis, including perennial and vernal allergic conjunctivitis; ulceris; anterior and posterior uveitis; choroiditis; autoimmune, degenerative or inflammatory disorders affecting the retina; ophthalmitis including sympathetic ophthalmitis; sarcoidosis; and infections of the eyes including viral , fungal, and bacterial infections.
  • the compounds of formula (I) according to any one of embodiments 1 ) to 55), or pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of skin diseases.
  • Skin diseases include psoriasis, skin burn, atopic dermatitis, contact dermatitis or other eczematous dermatoses, and delayed-type hypersensitivity reactions; phyto- and photodermatitis; seborrhoeic dermatitis, dermatitis herpetiformis, lichen planus, lichen sclerosus et atrophica, pyoderma gangrenosum, skin sarcoid, discoid lupus erythematosus, pemphigus, pemphigoid, epidermolysis bullosa, urticaria, angioedema, vasculitides, toxic erythemas, cutaneous eosinophilias, alopecia areata, male-pattern baldness, Sweet's syndrome, Web
  • the compounds of formula (I) according to any one of embodiments 1 ) to 55), or pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of abdominal and gastrointestinal tract diseases.
  • Abdominal and gastrointestinal tract diseases include hepatitis, including autoimmune, alcoholic and viral hepatitis; fibrosis and cirrhosis of the liver; cholecystitis; pancreatitis, both acute and chronic; non-inflammatory diarrhea; glossitis, gingivitis, periodontitis; oesophagitis, including reflux; eosinophilic gastro-enteritis, mastocytosis, Crohn's disease, colitis including ulcerative colitis, proctitis, pruritis ani; Coeliac disease, irritable bowel disease/syndrome, and food-related allergies which may have effects remote from the gut, for example migraine, rhinitis or eczema; allograft rejection including acute and chronic allograft rejection following, for example, transplantation of kidney,
  • the compounds of formula (I) according to any one of embodiments 1 ) to 55), or pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of genitourinary diseases.
  • Genitourinary diseases include nephritis including interstitial and glomerulonephritis; nephrotic syndrome; cystitis including acute and chronic (interstitial) cystitis and Hunner's ulcer; acute and chronic urethritis, prostatitis, epididymitis, oophoritis and salpingitis; vulvovaginitis; Peyronie's disease; and erectile dysfunction, both male and female.
  • the compounds of formula (I) according to any one of embodiments 1 ) to 55), or pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of cancer.
  • the treatment of cancer includes the treatment of brain tumors, prostate, lung, breast, ovarian, bowel and colon, stomach, pancreatic, skin and bone marrow (including leukaemias) and lymphoproliferative systems, such as non-Hodgkin's and Hodgkin's lymphoma; including the prevention and treatment of metastatic disease and tumor recurrences, and paraneoplastic syndromes.
  • the compounds of formula (I) according to any one of embodiments 1 ) to 55), or pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of other auto-immune and allergic disorders.
  • Other auto-immune and allergic disorders include Hashimoto's thyroiditis, Graves' disease, Addison's disease, diabetes mellitus, idiopathic thrombocytopaenic purpura, eosinophilic fasciitis, hyper-lgE syndrome, and antiphospholipid syndrome.
  • the compounds of formula (I) according to any one of embodiments 1 ) to 55), or pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of other disorders with an inflammatory or immunological component.
  • Other disorders with an inflammatory or immunological component include acquired immune deficiency syndrome (AIDS), leprosy, Sezary syndrome, and paraneoplastic syndromes.
  • AIDS acquired immune deficiency syndrome
  • leprosy leprosy
  • Sezary syndrome Sezary syndrome
  • paraneoplastic syndromes paraneoplastic syndromes.
  • the compounds of formula (I) according to any one of embodiments 1 ) to 55), or pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of mood, sleep and anxiety disorders.
  • the compounds of formula (I) according to any one of embodiments 1 ) to 55), or pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of injury induced trauma and spinal cord injury.
  • compounds of formula (I) according to any one of embodiments 1 ) to 55), or pharmaceutically acceptable salts thereof are suitable for the prevention or treatment of diseases selected from one, several or all of the following groups of diseases and disorders:
  • Pain wherein pain refers to acute pain; chronic pain; pain associated with sprains and strains; chronic articular pain; pain associated with rheumatic fever; musculoskeletal pain; lower back and neck pain; inflammatory pain; neuropathic pain; visceral pain; pain associated with influenza or other viral infections; pain associated with cancer and tumor invasion; joint and bone pain; atypical facial pain; pain associated with migraine, toothache and dysmenorrhea; headache including tension headache and cluster headaches; pain associated with myocardial ischemia; pain associated with functional bowel disorders; sympathetically maintained pain; myositis; pain associated with cancer chemotherapy; and post operative pain;
  • Neuropathic pain includes especially diabetic neuropathy, sciatica, non-specific lower back pain, trigeminal neuralgia, multiple sclerosis pain, fibromyalgia, HIV- related neuropathy, post-herpetic neuralgia, trigeminal neuralgia, and pain resulting from physical trauma, amputation, phantom limb syndrome, spinal surgery, cancer, toxins or chronic inflammatory conditions.
  • neuropathic pain conditions include pain associated with normally non-painful sensations such as "pins and needles" (paraesthesias and dysesthesias), increased sensitivity to touch (hyperesthesia), painful sensation following innocuous stimulation (dynamic, static, thermal or cold allodynia), increased sensitivity to noxious stimuli (thermal, cold, mechanical hyperalgesia), continuing pain sensation after removal of the stimulation (hyperpathia) or an absence of or deficit in selective sensory pathways
  • Chronic articular pain conditions include especially rheumatoid arthritis, osteoarthritis, rheumatoid spondylitis, gouty arthritis and juvenile arthritis;
  • Pain associated with functional bowel disorders includes especially non-ulcer dyspepsia, non-cardiac chest pain and irritable bowel syndrome;
  • Neurodegenerative and neuro-inflammatory diseases such as Alzheimer's disease and other dementing disorders including, but not limited to, Creutzfeldt-Jakob disease (CJD) and new variant Creutzfeldt-Jakob disease (nvCJD); amyloidosis; Amyotrophic lateral sclerosis, multiple sclerosis and other demyelinating syndromes; cerebral atherosclerosis and vasculitis; temporal arteritis; myasthenia gravis; Huntington's disease; Lewy Body dementia; and Parkinson's disease;
  • CJD Creutzfeldt-Jakob disease
  • nvCJD new variant Creutzfeldt-Jakob disease
  • amyloidosis amyloidosis
  • Amyotrophic lateral sclerosis multiple sclerosis and other demyelinating syndromes
  • cerebral atherosclerosis and vasculitis cerebral atherosclerosis and vasculitis
  • temporal arteritis myasthenia gravis
  • Huntington's disease
  • Bone and joint diseases such as arthritides such as rheumatoid arthritis, osteoarthritis, gout or crystal arthropathy; intervertebral disc degeneration; temporomandibular joint degeneration; bone remodelling disease such as osteoporosis, Paget's disease or osteonecrosis; polychondritis; scleroderma; mixed connective tissue disorder; spondyloarthropathies; periodontal disease such as periodontitis; Behcet's disease; primary and secondary Sjogren's syndrome; systemic sclerosis and limited scleroderma; systemic lupus erythematosus, mixed connective tissue disease, and undifferentiated connective tissue disease; inflammatory myopathies including dermatomyositits and polymyositis; juvenile arthritis including idiopathic inflammatory arthritides of whatever joint distribution and associated syndromes, and rheumatic fever and its systemic
  • Obstructive diseases of the airways such as chronic obstructive pulmonary disease (COPD); cystic fibrosis; lung emphysema; sarcoidosis; farmer's lung and related diseases; lung fibrosis, including fibrosis complicating tuberculosis; and chronic cough associated with inflammatory and secretory conditions of the airways;
  • COPD chronic obstructive pulmonary disease
  • cystic fibrosis fibrosis
  • lung emphysema sarcoidosis
  • farmer's lung and related diseases lung fibrosis, including fibrosis complicating tuberculosis
  • chronic cough associated with inflammatory and secretory conditions of the airways such as chronic obstructive pulmonary disease (COPD); cystic fibrosis; lung emphysema; sarcoidosis; farmer's lung and related diseases; lung fibrosis, including fibrosis complicating tuberculosis; and chronic cough associated with inflammatory and
  • Cardiovascular diseases such as inflammatory and auto-immune cardiomyopathies
  • Eye diseases such as degenerative or inflammatory disorders affecting the retina
  • Skin diseases such as psoriasis, skin burn, atopic dermatitis, contact dermatitis or other eczematous dermatoses; and discoid lupus erythematosus;
  • Abdominal and gastrointestinal tract diseases such as fibrosis and cirrhosis of the liver; cholecystitis; pancreatitis, both acute and chronic; Crohn's disease; colitis including ulcerative colitis; and irritable bowel disease/syndrome;
  • Genitourinary diseases such as nephritis including interstitial and glomerulonephritis; nephrotic syndrome; and cystitis including acute and chronic (interstitial) cystitis; and
  • compounds of formula (I) according to any one of embodiments 1 ) to 55), or pharmaceutically acceptable salts thereof are suitable for the prevention or treatment of diseases selected from one, several or all of the following groups of diseases and disorders:
  • Pain wherein pain refers to acute pain; chronic pain; pain associated with sprains and strains; chronic articular pain; pain associated with rheumatic fever; musculoskeletal pain (preferred); lower back and neck pain; inflammatory pain; neuropathic pain (preferred); visceral pain; pain associated with influenza or other viral infections; pain associated with cancer and tumor invasion; joint and bone pain; atypical facial pain; pain associated with migraine, toothache and dysmenorrhea; headache including tension headache and cluster headaches; pain associated with myocardial ischemia; pain associated with functional bowel disorders; sympathetically maintained pain; myositis; pain associated with cancer chemotherapy; and post operative pain;
  • Neuropathic pain includes especially diabetic neuropathy, sciatica, non-specific lower back pain, trigeminal neuralgia, multiple sclerosis pain, fibromyalgia, HIV- related neuropathy, post-herpetic neuralgia, trigeminal neuralgia, and pain resulting from physical trauma, amputation, phantom limb syndrome, spinal surgery, cancer, toxins or chronic inflammatory conditions.
  • neuropathic pain conditions include pain associated with normally non-painful sensations such as "pins and needles" (paraesthesias and dysesthesias), increased sensitivity to touch (hyperesthesia), painful sensation following innocuous stimulation (dynamic, static, thermal or cold allodynia), increased sensitivity to noxious stimuli (thermal, cold, mechanical hyperalgesia), continuing pain sensation after removal of the stimulation (hyperpathia) or an absence of or deficit in selective sensory pathways (hypoalgesia);
  • normally non-painful sensations such as "pins and needles” (paraesthesias and dysesthesias), increased sensitivity to touch (hyperesthesia), painful sensation following innocuous stimulation (dynamic, static, thermal or cold allodynia), increased sensitivity to noxious stimuli (thermal, cold, mechanical hyperalgesia), continuing pain sensation after removal of the stimulation (hyperpathia) or an absence of or deficit in selective sensory pathways (hypoalgesia);
  • Chronic articular pain conditions include especially rheumatoid arthritis, osteoarthritis, rheumatoid spondylitis, gouty arthritis and juvenile arthritis;
  • Pain associated with functional bowel disorders includes especially non-ulcer dyspepsia, non-cardiac chest pain and irritable bowel syndrome;
  • COPD Chronic obstructive pulmonary disease
  • the invention also relates to the use of a compound of formula (I) according to any one of embodiments 1 ) to 55) for the preparation of pharmaceutical compositions for the treatment and/or prophylaxis of the above-mentioned diseases.
  • the present invention also relates to pharmaceutically acceptable salts and to pharmaceutical compositions and formulations of compounds of formula (I) according to any one of embodiments 1 ) to 55).
  • a pharmaceutical composition according to the present invention contains at least one compound of formula (I) according to any one of embodiments 1 ) to 55) (or a pharmaceutically acceptable salt thereof) as the active agent and optionally carriers and/or diluents and/or adjuvants.
  • the compounds of formula (I) according to any one of embodiments 1 ) to 55) and their pharmaceutically acceptable salts can be used as medicaments, e.g. in the form of pharmaceutical compositions for enteral (such especially oral) or parenteral administration (including topical application or inhalation).
  • compositions can be effected in a manner which will be familiar to any person skilled in the art (see for example Remington, The Science and Practice of Pharmacy, 21 st Edition (2005), Part 5, "Pharmaceutical Manufacturing” [published by Lippincott Williams & Wilkins]) by bringing the described compounds of formula (I) or their pharmaceutically acceptable salts, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, therapeutically compatible solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants.
  • the present invention also relates to a method for the prevention or treatment of a disease or disorder mentioned herein comprising administering to a subject a pharmaceutically active amount of a compound of formula (I) according to any one of embodiments 1 ) to 55), or a pharmaceutically acceptable salt thereof.
  • any reference to a compound of formula (I) in this text is to be understood as referring also to the salts (and especially the pharmaceutically acceptable salts) of such compounds, as appropriate and expedient.
  • the preferences indicated for the compounds of formula (I) of course apply mutatis mutandis to the salts and pharmaceutically acceptable salts of the compounds of formula (I).
  • the term “about” (or alternatively “around”) placed before a numerical value "X” refers in the current application to an interval extending from X minus 10% of X to X plus 10% of X, and preferably to an interval extending from X minus 5% of X to X plus 5% of X.
  • the term “about” (or alternatively “around”) placed before a temperature “Y” refers in the current application to an interval extending from the temperature Y minus 10 °C to Y plus 10 °C, and preferably to an interval extending from Y minus 5 °C to Y plus 5 °C.
  • room temperature rt as used herein refers to a temperature of about 25°C.
  • the compounds of Formula (I) can be manufactured by the methods given below, by the methods given in the Examples or by analogous methods. Optimum reaction conditions may vary with the particular reactants or solvents used, but such conditions can be determined by a person skilled in the art by routine optimisation procedures.
  • the generic groups R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , n and Y might be incompatible with the assembly illustrated in the schemes below and will therefore require the use of protecting groups (PG).
  • protecting groups is well known in the art (see for example "Protective Groups in Organic Synthesis", T.W. Greene, P.G.M. Wuts, Wiley-lnterscience, 1999). For the purposes of this discussion, it will be assumed that such protecting groups are as necessary in place.
  • the compounds of formula V can be prepared (Scheme 1 ) by a Buchwald-Hartwig type of reaction, using a commercially available iodide of formula VII (or a commercially available aniline of formula VIII, respectively) and an aniline of formula R 1 -NH 2 (or a halide, preferably an iodide of formula R 1 -X, respectively), in the presence of a suitable palladium catalyst such as palladium(ll) acetate or tris(dibenzylideneacetone) dipalladium, in the presence of a suitable ligand such as 2,2'-bis(diphenylphosphino)-1 , 1 '- binaphthalene or 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene, in the presence of a suitable base such as Cs 2 C0 3 or sodium phenoxide and heating in a suitable solvent such as dioxane at a temperature between 90°C and 120°C.
  • the compounds of formula VI can be prepared (Scheme 1 ) by alkylation of a compound of formula V using an appropriate alkyl iodide or bromide of formula R 9 -X, in the presence of a suitable base such as Cs 2 C0 3 or potassium carbonate and in the presence of a suitable organic solvent such as DMF or THF, preferably at a temperature between RT and 60°C.
  • a suitable base such as Cs 2 C0 3 or potassium carbonate
  • a suitable organic solvent such as DMF or THF
  • the compounds of formula III (or IV, respectively) can be prepared (Scheme 1 ) by hydrolysis of a compound of formula V (or VI, respectively) using standard conditions such as NaOH or LiOH in a mixture of water and a suitable organic solvent such as THF, MeOH or EtOH, preferably at a temperature between RT and 45°C.
  • the compounds of formula la can be prepared (Scheme 1 ) by coupling an acid of formula III (or IV, respectively) with an amine of formula II using standard amide coupling reagents such as TBTU, EDC.HCI / HOBT, HATU, PyBOP or PyCloP in the presence of a suitable base such as NEt 3 or DIPEA and in a suitable solvent such as DCM, THF or DMF, preferably at a temperature between RT and 45°C.
  • standard amide coupling reagents such as TBTU, EDC.HCI / HOBT, HATU, PyBOP or PyCloP
  • a suitable base such as NEt 3 or DIPEA
  • a suitable solvent such as DCM, THF or DMF
  • the compounds of formula lb can be prepared (Scheme 1 ) by alkylation of a compound of formula la with an appropriate alkyl iodide or bromide of formula R 9 -X using standard conditions such as a suitable base (preferably Cs 2 C0 3 ) and a suitable organic solvent such as DMF or THF, preferably at a temperature between RT and 45°C.
  • a suitable base preferably Cs 2 C0 3
  • a suitable organic solvent such as DMF or THF
  • the compounds of formula IX can be prepared (Scheme 2) by an aromatic nucleophilic substitution of a commercially available phenol or thiophenol, respectively of formula XI with a halide (preferably a bromide or iodide) of formula R 1 -X, in the presence of a suitable base such as Cs 2 C0 3 and heating in a suitable sovent such as DMSO at a temperature between 60°C and 1 10°C.
  • a suitable base such as Cs 2 C0 3
  • a suitable sovent such as DMSO
  • the compounds of formula lc can be prepared (Scheme 2) by coupling an acid of formula IX with an amine of formula II using standard amide coupling conditions such as those already described for the synthesis of the compounds of formula la and lb (Scheme 1 ).
  • the compounds of formula Id can be prepared (Scheme 2) by oxidation of a compound of formula lc, wherein Y represents S, using a suitable oxidating reagent such as 3- chloroperbenzoic acid in a suitable solvent such as DCM at a temperature around 0°C.
  • the compounds of formula le can be prepared (Scheme 2) by oxidation of a compound of formula lc, wherein Y represents S, using a suitable oxidating reagent such as 3- chloroperbenzoic acid in a suitable solvent such as DCM at a temperature around RT.
  • the compounds of formula XX can be prepared (Scheme 3) by bromination of a commercially available compound of formula XXI, wherein R 2 represents chloro, using a suitable brominating reagent such as N-bromosuccinimide in the presence of a radical initiator such as 2,2'-azobis(2-methylpropionitrile) and heating in a suitable solvent such as chlorobenzene at a temperature between 90 and 120°C.
  • a suitable brominating reagent such as N-bromosuccinimide
  • a radical initiator such as 2,2'-azobis(2-methylpropionitrile
  • the compounds of formula XVIII can be prepared (Scheme 3) by coupling an acid of formula XX with an amine of formula II using standard amide coupling conditions such as EDC.HCI / HOBT, PyBOP in the presence of a suitable base such as DIPEA and in a suitable solvent such as DCM, preferably at a temperature between RT and 45°C. In such conditions, the consecutive substitution of the bromide atom in compound of formula XX with the 1 -oxy-benzotriazole group (-OBt) from HOBT is observed.
  • standard amide coupling conditions such as EDC.HCI / HOBT, PyBOP
  • a suitable base such as DIPEA
  • a suitable solvent such as DCM
  • a suitable base such as potassium carbonate or Cs 2 C0 3
  • a suitable solvent such as DMF or 1 ,2-dimethoxyethane at a temperature around 90°C.
  • the compounds of formula XVI can be prepared (Scheme 3) by esterification of compounds of formula XX using standard conditions such as heating in a suitable solvent such as MeOH in the presence of a suitable acid such as sulphuric acid at a temperature around 70°C.
  • the compounds of formula XVII, wherein Z represents -CH 2 CN can be prepared (Scheme 3) by nucleophilic substitution of a compound of formula XVI with a cyanide precursor such as trimethylsilylcyanide in the presence of a suitable base such as potassium carbonate or Cs 2 C0 3 and heating in a suitable solvent such as CH 3 CN at a temperature between RT and 60°C.
  • a cyanide precursor such as trimethylsilylcyanide
  • the compounds of formula XVII, wherein Z represents -CHO can be prepared (Scheme 3) by an oxidative cleavage of a compound of formula XVI with an oxidative reagent such as 4-methylmorpholine-N-oxide and heating in a suitable solvent such as dioxane at a temperature around 100°C.
  • the compounds of formula XIII can be prepared (Scheme 3) by a Negishi type reaction.
  • the compound of formula XVI can be transformed into an organozinc reagent in the presence of preactivated zinc dust in a suitable solvent such as THF.
  • the cross coupling reaction proceeds by the reaction of the organozinc reagent with a halide of formula R 1 -X, in the presence of a suitable palladium catalyst such as tetrakis(triphenylphosphine)palladium (0) or tris(dibenzylideneacetone)dipalladium, in the optional presence of a suitable ligand such as tri-2-furylphosphine and in a suitable solvent such as THF at a temperature around RT.
  • a suitable palladium catalyst such as tetrakis(triphenylphosphine)palladium (0) or tris(dibenzylideneacetone)dipalladium
  • the compounds of formula XIV can be prepared (Scheme 3) by deprotonation of a cyanomethyl derivative of formula XVII, wherein Z represents -CH 2 CN, at the ocarbon atom with a base such as NaH in a suitable solvent such as DMF at a temperature around RT and subsequent reaction of the obtained anion with a halide of formula R 1 -X wherein R 1 is a 2-chloro-pyrimidin-4-yl or 2-(2-(trimethylsilyl)ethoxy)-pyrimidin-4-yl group.
  • the consecutive oxidative cleavage of the carbon-cyanide bond proceeds in the presence of atmospheric air and additional amounts of a suitable base such as NaH in a suitable solvent such as DMF at a temperature around RT.
  • the compounds of formula XIV can be prepared (Scheme 3) by an aroylation of a halide of formula R 1 -X wherein R 1 is a 2-methoxy-pyrimidin-4-yl group by an aromatic adehyde of formula XVII, wherein Z represents -CHO, in the presence of an azolium salt such as 1 ,3-dimethylimidazolium iodide and a base such as NaH in a suitable solvent such as dioxane at a temperature around 100°C.
  • an azolium salt such as 1 ,3-dimethylimidazolium iodide
  • a base such as NaH
  • the compounds of formula XV, wherein R 7 and/or R 8 represent fluoro can be prepared (Scheme 3) by the fluorination of a ketone of formula XIV, in the presence of a fluorinating reagent such as bis(2-methoxyethyl)aminosulfur trifluoride at a temperature around 90°C.
  • a fluorinating reagent such as bis(2-methoxyethyl)aminosulfur trifluoride at a temperature around 90°C.
  • the compounds of formula XV, wherein one of R 7 or R 8 represents hydrogen and the other represents fluoro can be prepared (Scheme 3) by a two-step procedure.
  • the ketone of formula XIV can be reduced using standard conditions such as NaBH 4 in the presence of a suitable solvent such as MeOH at a temperature around RT.
  • the resulting alcohol can be fluorinated using a fluorinating reagent such as bis(2- methoxyethyl)
  • the compounds of formula XV wherein one of R 7 or R 8 represents (C C 4 )alkyl and the other represents hydroxy, can be prepared (Scheme 3) by the addition of a Grignard reagent of formula R 7 -MgX or R 8 -MgX (wherein X represents a bromine or a chlorine atom) to the ketone of formula XIV in the presence of a suitable solvent such as THF or Et 2 0 at a temperature between -15°C and RT.
  • a suitable solvent such as THF or Et 2 0 at a temperature between -15°C and RT.
  • the compounds of formula XII can be prepared (Scheme 3) by hydrolysis of a compound of formula XIII, XIV or XV using standard conditions such as those already described for the synthesis of the compounds of formula III and IV (Scheme 1 ).
  • the compounds of formula Ig can be prepared (Scheme 3) by coupling an acid of formula XII with an amine of formula II using standard amide coupling conditions such as those already described for the synthesis of the compounds of formula la and lb (Scheme 1 ).
  • Y represents C(R 7 R 8 )
  • compounds of formula li, Ij, Ik, Im, In and lo can be prepared following the procedures outlined in Scheme 4 below.
  • one of the letter code, a,b,c or d represents a carbon atom, which is attached to the rest of the molecule via the substituent Y, and the other remaining letter codes are selected from N, CH and CR 10 , wherein R 10 represents chloro, to form a 6-membered heteroaryl or a heterocyclyl group R 1 as defined above.
  • the compounds of formula li wherein X represents S0 2 CH 3 can be prepared (Scheme 4) by oxidation of a compound of formula Ih in the presence of a suitable oxidating reagent such as 3-chloroperbenzoic acid and in the presence of a suitable solvent such as DCM at a temperature between 0°C and RT.
  • a suitable oxidating reagent such as 3-chloroperbenzoic acid
  • a suitable solvent such as DCM
  • the compounds of formula Ij can be prepared (Scheme 4) by an aromatic nucleophilic substitution of a compound of formula li with a commercially available or freshly prepared solution of sodium alkoxide of formula NaOR 11 , wherein R 11 represents (Ci-C 4 )alkyl, in the corresponding alcohol of formula HOR 11 , the reaction being carried out in the presence of a solvent such as the corresponding alcohol of formula HOR 11 or THF at a temperature between 0°C and 90°C.
  • the compounds of formula Ik can be prepared (Scheme 4) by an aromatic nucleophilic substitution of a compound of formula li with an amine of formula HNR 11 R 12 , wherein R 11 represents (Ci-C 4 )alkyl and R 12 represents hydrogen or (Ci-C 4 )alkyl, optionally in the presence of a suitable base such as NEt 3 or DIPEA and heating in a suitable solvent such as H 2 0, THF, CH 3 CN or DMF at a temperature between RT and 120°C.
  • a suitable base such as NEt 3 or DIPEA
  • the compound of formula Im can be prepared (Scheme 4) by aromatic nucleophilic substitution of a compound of formula li with an aqueous sodium hydroxide solution and heating in a suitable solvent such as dioxane or THF at a temperature between RT and 100°C.
  • the compound of formula In (or lo, respectively) can be prepared (Scheme 4) by alkylation of a compound of formula Im wherein Y represents NH (or Im wherein Y is different from NH, respectively) using a suitable alkylating reagent such as an alkyl iodide or bromide of formula R 13 -X, wherein R 13 represents (C 1 -C 4 )alkyl, in the presence of a suitable base such as Cs 2 C0 3 or potassium carbonate and carrying out the reaction in a suitable solvent such as DMF or THF at a temperature between RT and 45°C.
  • a suitable alkylating reagent such as an alkyl iodide or bromide of formula R 13 -X, wherein R 13 represents (C 1 -C 4 )alkyl
  • the compounds of formula Im can be prepared (Scheme 5) by cleavage of the protecting group (PG) in intermediates XXII or intermediates XXIII wherein PG represents a trimethylsilylethoxymethyl group by treatment with a tetrabutylammonium fluoride solution in THF and carrying out the reaction in a suitable solvent such as THF at a temperature between RT and 70°C.
  • PG protecting group
  • the compounds of formula Im can be prepared (Scheme 5) by cleavage of the protecting group (PG) in intermediates XXIII wherein PG represents a trimethylsilylethyl group by treatment with a suitable acid such as TFA and carrying out the reaction in a suitable solvent such as DCM at a temperature around RT.
  • PG protecting group
  • the compounds of formula XXV can be prepared (Scheme 6) by hydrolysis of a compound of formula XXIV using standard conditions such as those already described for the synthesis of the compounds of formula III and IV (Scheme 1 ).
  • the compounds of formula Iq can be prepared (Scheme 6) by coupling an acid of formula XXV with ammonia as an ethanolic solution using standard amide coupling conditions such as an activation with isobutylchloroformate in the presence of a base such as 4- methylmorpholine and a suitable solvent such as DCM at a temperature between -70°C to RT.
  • the compounds of formula Ir can be prepared (Scheme 6) by reduction of a compound of formula XXIV using a suitable reducing reagent such as diisobutylaluminum hydride, in the presence of a suitable solvent such as THF at a temperature around RT.
  • a suitable reducing reagent such as diisobutylaluminum hydride
  • intermediates of formula R 1 -X can be prepared following the procedures outlined in Scheme 7 below.
  • one of the letter code, a,b,c or d represents a carbon atom bearing the halogen atom X
  • the other remaining letter codes are selected from N, CH and CR 10 , wherein R 10 represents chloro, to form a 6-membered heteroaryl or a heterocyclyl group R 1 as defined above.
  • the compounds of formula XXVII can be prepared (Scheme 7) by alkylation of a compound of formula XXVI using a suitable alkyl halide of formula R 14 -X wherein R 14 represents a (CrC 4 )alkyl or a (Ci-C 2 )alkoxy-(CrC 4 )alkyl group (or of formula PG-X wherein PG represents a tnmethylsilylethoxymethyl protecting group, respectively), in the presence of a suitable base such as potassium carbonate and carrying out the reaction in a suitable solvent such as acetone, CH 3 CN or DMF at a temperature between RT and 45°C.
  • a suitable alkyl halide of formula R 14 -X wherein R 14 represents a (CrC 4 )alkyl or a (Ci-C 2 )alkoxy-(CrC 4 )alkyl group (or of formula PG-X wherein PG represents a tnmethylsilyleth
  • the O-alkylated by-product of formula XXVIII can also be isolated.
  • the compounds of formula XXVIII, wherein PG represents a trimethylsilylethyl protecting group can be prepared (Scheme 7) by an aromatic nucleophilic substitution of a compound of formula XXIX with a freshly prepared lithium 2- (trimethylsilyl)ethanolate (by treatment of 2-(trimethylsilyl)ethanol with n-butyllithium in THF at a temperature between -70°C and -30°C), the reaction being carried out in the presence of a suitable solvent such as THF at a temperature between -70°C and RT.
  • a suitable solvent such as THF at a temperature between -70°C and RT.
  • Scheme 7 synthesis of R 1 -X, wherein R 14 represents a (C ⁇ -C ⁇ alkyl or (Ci-Cg)alkoxy-(Ci- C ⁇ alkyl group and PG represents a trimethylsilylethoxymethyl or a trimethylsilylethyl protecting group
  • the compounds of formula XXXII wherein R 15 represents trimethylsilyl or hydrogen can be prepared (Scheme 8) by cyanosilylation of a ketone of formula XXX using a suitable cyanation reagent such as trimethylsilylcyanide, in the presence of a lewis acid such as gold (III) chloride and carrying out the reaction in a suitable solvent such as DCM at a temperature around RT (Synthesis, 2008, 4, 507-510).
  • the compounds of formula XXXII wherein R 15 represents (C 1 -C 4 )alkyl can be prepared (Scheme 8) by cyanation of a ketal of formula XXXI with a suitable cyanation reagent such as ferf-butyl isocyanide in the presence of a suitable lewis acid such as titanium tetrachloride and carrying out the reaction in a suitable solvent such as DCM at a temperature between -70°C and RT (Chemistry Lett., 1984, 937-940).
  • the compounds of formula II wherein R 3 represents hydrogen and R 4 represents hydroxy or (Ci-C 4 )alkoxy, can be prepared (Scheme 8) by reduction of a compound of formula XXXII using a suitable reducing reagent such as lithium aluminum hydride, in the presence of a suitable solvent such as Et 2 0 or THF at a temperature between 0°C and RT. In those conditions, the consecutive hydrolysis of the possible trimethylsilyl group R 15 is observed.
  • a suitable reducing reagent such as lithium aluminum hydride
  • LC-MS Thermo Finnigan MSQ Surveyor MS with Agilent 1 100 Binary Pump and DAD.
  • Eluents acidic conditions: A: H 2 0 + 0.04% TFA; B: CH 3 CN; gradient: 5% B ⁇ 95% B ; runtime: 1.5 min ; flow: 4.5 mL/min ; detection: UV/Vis + MS, t R is given in min.
  • Atlantis column Waters Atlantis T3, 10 ⁇ , 30x75 mm
  • This compound was prepared using a method analogous to that of Example 1 (intermediate 1.2), intermediate 2.1 replacing intermediate 1.1 .
  • This compound was prepared using a method analogous to that of Example 1 (intermediate 1.3), intermediate 2.2 replacing intermediate 1.2.
  • This compound was prepared using a method analogous to that of Example 2 (intermediate 2.1 ), intermediate 1.3 replacing intermediate 1.1 and 2-bromoethyl methyl ether replacing methyl iodide except that the reaction mixture was stirred for 3 days at RT and for 3 days at 70°C and that the crude was purified by CC (Hept/EtOAc 9/1 to 3/7).
  • This compound was prepared using a method analogous to that of Example 1 (intermediate 1.1 ), 1 -bromo-2-fluorobenzene replacing iodobenzene.
  • This compound was prepared using a method analogous to that of Example 1 (intermediate 1.2), intermediate 4.1 replacing intermediate 1.1 .
  • This compound was prepared using a method analogous to that of Example 1 (intermediate 1.3), intermediate 4.2 replacing intermediate 1.2.
  • This compound was prepared using a method analogous to that of Example 2 (intermediate 2.1 ), intermediate 4.1 replacing intermediate 1.1 .
  • This compound was prepared using a method analogous to that of Example 1 (intermediate 1 .2), intermediate 5.1 replacing intermediate 1 .1 except that a 1 M solution of NaOH was used instead of lithium hydroxide in H 2 0.
  • This compound was prepared using a method analogous to that of Example 1 (intermediate 1.3), intermediate 5.2 replacing intermediate 1.2.
  • This compound was prepared using a method analogous to that of Example 1 (intermediate 1.1 ), 2,4-difluoroiodobenzene replacing iodobenzene.
  • This compound was prepared using a method analogous to that of Example 1 (intermediate 1.2), intermediate 6.1 replacing intermediate 1.1 .
  • This compound was prepared using a method analogous to that of Example 1 (intermediate 1.3), intermediate 6.2 replacing intermediate 1.2.
  • This compound was prepared using a method analogous to that of Example 1 (intermediate 1.2), intermediate 7.1 replacing intermediate 1.1 .
  • This compound was prepared using a method analogous to that of Example 1 (intermediate 1.3), intermediate 7.2 replacing intermediate 1.2.
  • This compound was prepared using a method analogous to that of Example 1 (intermediate 1.2), intermediate 8.1 replacing intermediate 1.1 .
  • This compound was prepared using a method analogous to that of Example 1 (intermediate 1.3), intermediate 8.2 replacing intermediate 1 .2, except that the crude was purified by preparative LC-MS using conditions I.
  • This compound was prepared using a method analogous to that of Example 2 (intermediate 2.1 ), intermediate 8.1 replacing intermediate 1.1 except that the crude was purified by CC (Hept/EtOAc 1/0 to 0/1 ).
  • This compound was prepared using a method analogous to that of Example 1 (intermediate 1 .2), intermediate 9.1 replacing intermediate 1 .1 except that a 1 M solution of NaOH was used instead of lithium hydroxide in H 2 0.
  • This compound was prepared using a method analogous to that of Example 1 , intermediate 1.1 , 2,4-dichloropyrimidine replacing iodobenzene.
  • This compound was prepared using a method analogous to that of Example 1 (intermediate 1.2), intermediate 10.1 replacing intermediate 1.1.
  • This compound was prepared using a method analogous to that of Example 1 (intermediate 1.2), intermediate 1 1 .1 replacing intermediate 1.1.
  • This compound was prepared using a method analogous to that of Example 1 1 (intermediate 1 1.1 ), example 12 replacing intermediate 10.1 and the reaction mixture was stirred ON at 40°C.
  • This compound was prepared using a method analogous to that of Example 10 (intermediate 10.3), intermediate 16.1 replacing intermediate 10.2 except that it was purified by preparative LC-MS using method III.
  • This compound was prepared using a method analogous to that of Example 16 (intermediate 16.1 ), intermediate 1 1 .3 replacing intermediate 10.2 except that it was purified by preparative LC-MS using method III.
  • This compound was prepared using a method analogous to that of Example 18 and was isolated as second regioisomer.
  • This compound was prepared using a method analogous to that of Example 1 1 (intermediate 1 1 .1 ), ethyl iodide replacing methyl iodide except that the reaction mixture was stirred for 18h at RT.
  • This compound was prepared using a method analogous to that of Example 1 (intermediate 1.2), intermediate 20.1 replacing intermediate 1 .1.
  • This compound was prepared using a method analogous to that of Example 16 (intermediate 16.1 ), intermediate 20.3 replacing intermediate 10.2 except that it was purified by preparative LC-MS using method V.
  • This compound was prepared using a method analogous to that of Example 1 1 (intermediate 1 1.1 ), propyl iodide replacing methyl iodide except that the reaction mixture was stirred for 18h at RT.
  • This compound was prepared using a method analogous to that of Example 1 (intermediate 1.2), intermediate 22.1 replacing intermediate 1 .1.
  • This compound was prepared using a method analogous to that of Example 16 (intermediate 16.1 ), intermediate 22.3 replacing intermediate 10.2 except that it was purified by preparative LC-MS using method V.
  • This compound was prepared using a method analogous to that of Example 1 1 (intermediate 1 1 .1 ), isopropyl iodide replacing methyl iodide except that the reaction mixture was stirred for 18h at RT.
  • This compound was prepared using a method analogous to that of Example 1 (intermediate 1.2), intermediate 24.1 replacing intermediate 1 .1.
  • This compound was prepared using a method analogous to that of Example 16 (intermediate 16.1 ), intermediate 24.3 replacing intermediate 10.2 except that it was purified by preparative LC-MS using method V.
  • This compound was prepared using a method analogous to that of Example 1 1 (intermediate 1 1.1 ), 1-iodo-2-methylpropane replacing methyl iodide except that the reaction mixture was stirred for 18h at RT and for 18h at 40°C.
  • This compound was prepared using a method analogous to that of Example 1 (intermediate 1 .2), intermediate 26.1 replacing intermediate 1 .1 except that a 2M solution of NaOH was used instead of lithium hydroxide in H 2 0.
  • This compound was prepared using a method analogous to that of Example 16 (intermediate 16.1 ), intermediate 26.3 replacing intermediate 10.2 except that it was purified by CC (EtOAc/MeOH 1/0 to 8/2).
  • This compound was prepared using a method analogous to that of Example 12, intermediate 26.3 replacing intermediate 10.3 except that the reaction mixture was stirred for 45 min at 50°C.
  • This compound was prepared using a method analogous to that of Example 1 1 (intermediate 1 1 .1 ), benzyl bromide replacing methyl iodide except that the reaction mixture was stirred for 18h at RT.
  • This compound was prepared using a method analogous to that of Example 1 (intermediate 1 .2), intermediate 29.1 replacing intermediate 1 .1 except that a 2M solution of NaOH was used instead of lithium hydroxide in H 2 0.
  • This compound was prepared using a method analogous to that of Example 16 (intermediate 16.1 ), intermediate 29.3 replacing intermediate 10.2 except that it was purified by CC (EtOAc/MeOH 1/0 to 8/2).
  • This compound was prepared using a method analogous to that of Example 12, intermediate 29.3 replacing intermediate 10.3 except that the reaction mixture was stirred for 45 min at 50°C.
  • This compound was prepared using a method analogous to that of Example 1 1 (intermediate 1 1 .1 ), 2-bromoethyl methyl ether replacing methyl iodide except that the reaction mixture was stirred for 18h at 40°C.
  • This compound was prepared using a method analogous to that of Example 1 (intermediate 1 .2), intermediate 32.1 replacing intermediate 1 .1 except that a 2M solution of NaOH was used instead of lithium hydroxide in H 2 0.
  • This compound was prepared using a method analogous to that of Example 16 (intermediate 16.1 ), intermediate 32.3 replacing intermediate 10.2 except that it was purified by CC (EtOAc/MeOH 1/0 to 8/2).
  • This compound was prepared using a method analogous to that of Example 12, intermediate 32.3 replacing intermediate 10.3 except that the reaction mixture was stirred for 18h at 30°C.
  • This compound was prepared using a method analogous to that of Example 1 1 (intermediate 1 1.1 ), iodomethylcyclopentane replacing methyl iodide except that the reaction mixture was stirred for 4 days at 40°C.
  • This compound was prepared using a method analogous to that of Example 1 (intermediate 1 .2), intermediate 35.1 replacing intermediate 1 .1 except that a 2M solution of NaOH was used instead of lithium hydroxide in H 2 0.
  • This compound was prepared using a method analogous to that of Example 16 (intermediate 16.1 ), intermediate 35.3 replacing intermediate 10.2 except that it was purified by CC (EtOAc/MeOH 1/0 to 8/2).
  • This compound was prepared using a method analogous to that of Example 12, intermediate 35.3 replacing intermediate 10.3 except that the reaction mixture was stirred for 2h at 50°C.
  • This compound was prepared using a method analogous to that of Example 1 1 (intermediate 1 1 .1 ), 2-bromoethyl phenyl ether replacing methyl iodide except that the reaction mixture was stirred for 3 days at RT.
  • This compound was prepared using a method analogous to that of Example 1 (intermediate 1 .2), intermediate 38.1 replacing intermediate 1 .1 except that a 2M solution of NaOH was used instead of lithium hydroxide in H 2 0.
  • This compound was prepared using a method analogous to that of Example 16 (intermediate 16.1 ), intermediate 38.3 replacing intermediate 10.2 except that it was purified by CC (EtOAc/MeOH 1/0 to 8/2).
  • This compound was prepared using a method analogous to that of Example 12, intermediate 38.3 replacing intermediate 10.3 except that the reaction mixture was stirred for 18h at 30°C.
  • This compound was prepared using a method analogous to that of Example 10 (intermediate 10.3), intermediate 1 1.2 replacing intermediate 10.2 and (R)-(-)-1- cyclohexylethylamine replacing 1 -aminomethyl-cyclohexanol hydrochloride.
  • This compound was prepared using a method analogous to that of Example 16 (intermediate 16.1 ), example 41 replacing intermediate 10.2 except that it was purified by preparative LC-MS using method V.
  • This compound was prepared using a method analogous to that of Example 10 (intermediate 10.3), intermediate 1 1 .2 replacing intermediate 10.2 and L- cyclohexylglycinol replacing 1-aminomethyl-cyclohexanol hydrochloride.
  • This compound was prepared using a method analogous to that of Example 10 (intermediate 10.3), intermediate 1 1.2 replacing intermediate 10.2 and intermediate 45.2 replacing 1 -aminomethyl-cyclohexanol hydrochloride.
  • This compound was prepared using a method analogous to that of Example 16 (intermediate 16.1 ), intermediate 45.3 replacing intermediate 10.2 except that the reaction mixture was stirred for 72h at 80°C and the crude was purified by preparative LC-MS using method I and then by CC (EtOAc/MeOH 1/0 to 1/1 ).
  • This compound was prepared using a method analogous to that of Example 45 (intermediate 45.1 ), cyclooctanone replacing cycloheptanone except that the reaction mixture was stirred for 2h at RT.
  • This compound was prepared using a method analogous to that of Example 45 (intermediate 45.2), intermediate 47.1 replacing intermediate 45.1 except that the reaction mixture was stirred for 2h at RT.
  • This compound was prepared using a method analogous to that of Example 10 (intermediate 10.3), intermediate 1 1.2 replacing intermediate 10.2 and intermediate 47.2 replacing 1 -aminomethyl-cyclohexanol hydrochloride.
  • This compound was prepared using a method analogous to that of Example 16 (intermediate 16.1 ), intermediate 47.3 replacing intermediate 10.2 except that the reaction mixture was stirred for 6h at 90°C and the crude was purified by preparative LC-MS using method I.
  • This compound was prepared using a method analogous to that of Example 45 (intermediate 45.1 ), cyclopentanone replacing cycloheptanone except that the reaction mixture was stirred for 2h at RT and the desilylated product was isolated.
  • This compound was prepared using a method analogous to that of Example 10 (intermediate 10.3), intermediate 1 1.2 replacing intermediate 10.2 and intermediate 49.2 replacing 1 -aminomethyl-cyclohexanol hydrochloride.
  • This compound was prepared using a method analogous to that of Example 16 (intermediate 16.1 ), intermediate 49.3 replacing intermediate 10.2 except that the reaction mixture was stirred for 18h at 80°C and the crude was purified by preparative LC-MS using method IV.
  • This compound was prepared using a method analogous to that of Example 10 (intermediate 10.3), intermediate 1 1.2 replacing intermediate 10.2 and intermediate 51 .2 replacing 1 -aminomethyl-cyclohexanol hydrochloride.
  • This compound was prepared using a method analogous to that of Example 16 (intermediate 16.1 ), intermediate 51.3 replacing intermediate 10.2 except that the reaction mixture was stirred for 72h at 80°C and the crude was purified by preparative LC-MS using method VII.
  • This compound was prepared using a method analogous to that of Example 10 (intermediate 10.3), intermediate 1 1 .2 replacing intermediate 10.2 and methyl 1- aminomethyl-cyclohexanecarboxylate replacing 1-aminomethyl-cyclohexanol hydrochloride.
  • This compound was prepared using a method analogous to that of Example 1 (intermediate 1.2), intermediate 53.1 replacing intermediate 1.1.
  • This compound was prepared using a method analogous to that of Example 16 (intermediate 16.1 ), intermediate 53.3 replacing intermediate 10.2 except that the reaction mixture was stirred for 72h at 80°C and the crude was purified by preparative LC-MS using method IV.
  • This compound was prepared using a method analogous to that of Example 16 (intermediate 16.1 ), example 55 replacing intermediate 10.2 except that the reaction mixture was stirred for 18h at 90°C and the crude was purified by preparative LC-MS using method III.
  • This compound was prepared using a method analogous to that of Example 10 (intermediate 10.3), intermediate 1 1.2 replacing intermediate 10.2 and intermediate 57.2 replacing 1 -aminomethyl-cyclohexanol hydrochloride.
  • This compound was prepared using a method analogous to that of Example 16 (intermediate 16.1 ), intermediate 57.3 replacing intermediate 10.2 except that the reaction mixture was stirred for 18h at 90°C and the crude was purified by preparative LC-MS using method IV.
  • This compound was prepared using a method analogous to that of Example 1 (intermediate 1.1 ), 4-chloro-2-methylthiopyrimidine replacing iodobenzene.
  • This compound was prepared using a method analogous to that of Example (intermediate 1.2), intermediate 59.1 replacing intermediate 1.1.
  • This compound was prepared using a method analogous to that of Example 1 (intermediate 1 .3), intermediate 59.2 replacing intermediate 1 .2 and (R)-(-)-1 - cyclohexylethylamine replacing 1 -aminomethyl-cyclohexanol hydrochloride.
  • This compound was prepared using a method analogous to that of Example 1 (intermediate 1 .3), intermediate 59.2 replacing intermediate 1.2 and L-cyclohexylglycinol replacing 1 -aminomethyl-cyclohexanol hydrochloride.
  • This compound was prepared using a method analogous to that of Example 1 (intermediate 1 .3), intermediate 59.2 replacing intermediate 1 .2 and intermediate 45.2 replacing 1 -aminomethyl-cyclohexanol hydrochloride.
  • This compound was prepared using a method analogous to that of Example 1 (intermediate 1.1 ), 2,4,6-trichloropyrimidine replacing iodobenzene.
  • This compound was prepared using a method analogous to that of Example 1 1 (intermediate 1 1 .1 ), intermediate 62.1 replacing intermediate 10.1.
  • This compound was prepared using a method analogous to that of Example 1 (intermediate 1.2), intermediate 62.2 replacing intermediate 1 .1. This compound was contaminated with 2-chloro-5-[(6-chloro-2-methoxy-pyrimidin-4-yl)-methyl-amino]-benzoic acid.
  • This compound was prepared using a method analogous to that of Example 1 (intermediate 1.3), intermediate 62.3 replacing intermediate 1 .2.
  • This compound was prepared using a method analogous to that of Example 16 (intermediate 16.1 ), intermediate 62.4 replacing intermediate 10.2 except that it was purified by preparative LC-MS using method V.
  • This compound was prepared using a method analogous to that of Example 1 (intermediate 1.1 ), 2,4,6-trichloropyrimidine replacing iodobenzene.
  • This compound was prepared using a method analogous to that of Example 1 (intermediate 1.2), intermediate 65.2 replacing intermediate 1 .1.
  • This compound was prepared using a method analogous to that of Example 1 (intermediate 1.3), intermediate 65.3 replacing intermediate 1.2.
  • Example 66 (48 mg) was mixed with a 5.4 M solution of NaOMe in MeOH (0.196 ml.) and the reaction mixture was stirred ON at RT. It was quenched with H 2 0 and extracted with EtOAc. The organic phase was washed with a sat. solution of NaHC0 3 and brine, dried over MgS0 4 and concentrated in vacuo. The crude material was purified by CC (Hept/EtOAc 1/1 to 0/1 ) to give 32 mg of the titled compound as a white foam.
  • This compound was prepared using a method analogous to that of Example 16 (intermediate 16.1 ), example 66 replacing intermediate 10.2 except that it was purified by preparative LC-MS using method V.
  • This compound was prepared using a method analogous to that of Example 1 (intermediate 1.1 ), 2-chloropyrimidine replacing iodobenzene.
  • This compound was prepared using a method analogous to that of Example 1 (intermediate 1.2), intermediate 69.1 replacing intermediate 1.1.
  • This compound was prepared using a method analogous to that of Example 1 (intermediate 1.3), intermediate 69.2 replacing intermediate 1.2.
  • This compound was prepared using a method analogous to that of Example 1 1 (intermediate 1 1 .1 ), intermediate 69.3 replacing intermediate 10.1.
  • This compound was prepared using a method analogous to that of Example 1 1 (intermediate 1 1.1 ), intermediate 69.3 replacing intermediate 10.1 and 2-bromoethyl methyl ether replacing methyl iodide.
  • This compound was prepared using a method analogous to that of Example 1 (intermediate 1.1 ), 2-chloro-4-methylsulfanylpyrimidine replacing iodobenzene.
  • This compound was prepared using a method analogous to that of Example 1 (intermediate 1.2), intermediate 72.1 replacing intermediate 1.1.
  • This compound was prepared using a method analogous to that of Example 1 (intermediate 1.3), intermediate 72.2 replacing intermediate 1.2.
  • This compound was prepared using a method analogous to that of Example 1 1 (intermediate 1 1 .1 ), intermediate 72.3 replacing intermediate 10.1.
  • This compound was prepared using a method analogous to that of Example 66, example 73 replacing intermediate 65.4.
  • This compound was prepared using a method analogous to that of Example 67, intermediate 74.1 replacing example 66.
  • This compound was prepared using a method analogous to that of Example 16 (intermediate 16.1 ), intermediate 74.1 replacing intermediate 10.2 except that the reaction mixture was stirred for 1 h at 45°C and that the crude was purified by preparative LC-MS using method V.
  • This compound was prepared using a method analogous to that of Example 1 (intermediate 1.1 ), 5-bromopyrimidine replacing iodobenzene.
  • This compound was prepared using a method analogous to that of Example 1 (intermediate 1.2), intermediate 76.1 replacing intermediate 1.1.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention relates to benzamide derivatives of formula (I),wherein R1, R2, R3, R4, R5, R6, n and Y are as defined in the description, their preparation and their use as pharmaceutically active compounds.

Description

Benzamide Derivatives as P2X? receptor antagonists
The present invention relates to benzamide derivatives of formula (I) and their use as pharmaceuticals. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of formula (I), and especially their use as P2X7 receptor antagonists.
The P2X7 receptors (P2RX7) belong to the family of P2X ionotropic receptors that are activated by extracellular nucleotides, in particular adenosine triphosphate (ATP). P2RX7 is distinguished from other P2X family members by the high concentrations (mM range) of ATP required to activate it and its ability to form a large pore upon prolonged or repeated stimulation (North, R. A., Physiol. Rev. 2002, 82(4), 1013-67; Surprenant, A., Rassendren, F. et al., Science 1996, 272(5262), 735-8; Virginio, C, MacKenzie, A. et al., J. Physiol., 1999, 519, 335-46). P2RX7 is present on many cell types, especially ones known to be involved in inflammatory and immune processes. This is reflected within both the periphery and the CNS as Lipopolysaccharide S (LPS) priming of monocytes and microglia followed by ATP stimulation has been shown to lead to the local release and processing of I L1 β and other family members including IL18 through a P2RX7 mediated mechanism. Indeed mice lacking the P2X7 receptor are unable to release ΙΙ_1 β following LPS priming and ATP stimulation providing further evidence of its role in this pathway (Solle, M., Labasi, J. et al., J. Biol. Chem., 2001 , 276(1 ), 125-32). In addition L-selectin shedding from monocytes, macrophages and lymphocytes, degranulation in mast cells and apoptosis in lymphocytes are all associated with P2RX7 stimulation. P2RX7 is also expressed on epithelial and endothelial cells (Ferrari, D., Chiozzi, P. et al., Neuropharmacology 1997, 36(9), 1295-301 ; Wiley, J. S., Chen, J. R. et al., Ciba Found Symp. 1996, 198, 149-60 and 160-5; North, R. A., Physiol. Rev. 2002, 82(4), 1013-67). In addition to its role in the periphery it may have an important function in neurotransmission within the CNS through its activation on postsynaptic and / or presynaptic central and peripheral neurons and glia (Deuchars, S. A., Atkinson, L. et al., J. Neurosci. 2001 , 21 (18), 7143-52; Sperlagh, B., Kofalvi, A. et al., J. Neurochem. 2002, 81 (6), 1 196-21 1 ). Recent data that has emerged using in situ hybridization demonstrated that P2X7 receptor mRNA was widely distributed throughout the rat brain. Specifically, among the areas of high P2X7mRNA expression noted were the piriform cortex, hippocampus, pontine nuclei and the anterior horn of the spinal cord (Yu, Y., Ugawa, S. et al., Brain. Res. 2008, 1 194, 45-55). Hence there is therapeutic rationale for the use of P2X7 ion channel blockers in the treatment of a variety of disease states. These include but are not limited to diseases associated with the central nervous system such as stroke or injury and diseases associated with neuro-degeneration and neuroinflammation such as Alzheimer's disease, Huntington's disease, epilepsy, Amyotrophic lateral sclerosis, acute spinal cord injury additionally to meningitis, sleep disorders, mood and anxiety disorders as well as chronic and neuropathic and inflammatory pain. Furthermore, peripheral inflammatory disorders and autoimmune diseases including but not limited to rheumatoid arthritis, osteoarthritis, psoriasis, allergic dermatitis, asthma, chronic obstructive pulmonary disease, airways hyper-responsiveness, septic shock, bronchitis, glomerulonephritis, irritable bowel disease, skin injury, lung emphysema, Limb girdle dystrophy type 2B, fibrosis, Syndrome of synovitis Acne Pustulosis, atherosclerosis, burn injury, spinal cord injury, Hyperostosis Osteitis, Crohn's disease, ulcerative colitis, growth and metastases of malignant cells, myoblastic leukaemia, diabetes, trauma, meningitis, osteoporosis, burn injury, ischemic heart disease, and varicose veins and trauma, are all examples where the involvement of P2X7 channels has been implicated. In addition a recent report suggests a link between P2RX7 and chronic, inflammatory and neuropathic pain (Chessell, I. P., Hatcher, J. P. et al., Pain, 2005, 1 14(3), 386-96). Overall, these findings indicate a role for the P2X7 receptor in the process of neuronal synaptic transmission and therefore a potential role for P2X7 antagonists as novel therapeutic tools to treat neuropathic pain.
In view of the above observations, there is significant requirement for P2X7 antagonists that can be efficiently used in treating neuropathic pain, chronic inflammatory pain, inflammation, and neurodegenerative conditions.
Different benzamide derivatives, which are also P2X7 receptor antagonists, have been disclosed in WO 2003/042191 , WO 2004/058270, WO 2004/058731 , WO 2004/099146 and in WO 2005/019182.
Various embodiments of the invention are presented hereafter:
1 ) The present invention relates to benzamide derivatives of formula (I),
Figure imgf000003_0001
(I)
wherein
n represents 1 , 2, 3 or 4 (and preferably 2, 3 or 4); Y represents -C(R7R8)-, -N(R9)-, -0-, -S-, -S(0)-, or -S(0)2-;
R1 represents
• a 5-membered heteroaryl group which is unsubstituted or mono- or di-substituted with (Ci-C4)alkyl;
· a 6-membered heteroaryl group which is unsubstituted or mono- or di-substituted, wherein the substituents are independently selected from the group consisting of halogen, hydroxy, (C1-C4)alkyl, (C1-C4)alkoxy, (C1-C4)alkylthio, (C1-C4)alkyl- sulfonyl, (C1-C4)alkyl-amino and di-[(C1-C4)alkyl]-amino;
• a phenyl group which is unsubstituted or mono- or di-substituted with halogen; or · a heterocyclyl group which is unsubstituted or mono- or di-substituted with (Ci- C4)alkyl or (Ci-C2)alkoxy-(d-C4)alkyl;
R2 represents chloro or methyl (and preferably chloro);
R3 represents hydrogen and R4 represents hydroxy, hydroxy-(Ci-C4)alkyl, -CONH2 or (Ci-C4)alkoxy (and preferably hydroxy, hydroxymethyl or methoxy); or
R3 represents (Ci-C4)alkyl or hydroxy-(Ci-C4)alkyl (and preferably methyl or hydroxymethyl) and R4 represents hydrogen;
R5 represents hydrogen or fluoro;
R6 represents hydrogen or fluoro;
R7 and R8 represent independently from each other hydrogen, fluoro, hydroxy or (Ci- C4)alkyl, with the proviso that R8 is different from fluoro or hydroxy if R7 represents hydroxy;
or R7 and R8 together represent an oxo-group; and
R9 represents hydrogen, (d-C4)alkyl, (C1-C2)alkoxy-(C1-C4)alkyl, (C3-C6)cycloalkyl-(C1- C4)alkyl, phenyl-(d-C4)alkyl, or phenyloxy-(C1-C4)alkyl;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
The compounds of formula (I) according to embodiment 1 ) may contain one or more stereogenic or asymmetric centers, such as one or more asymmetric carbon atoms. Substituents at a double bond may be present in the (Z)- or (E)-configuration unless indicated otherwise. The compounds of formula (I) may thus be present as mixtures of stereoisomers or preferably as pure stereoisomers. Mixtures of stereoisomers may be separated in a manner known to a person skilled in the art. The following paragraphs provide definitions of the various chemical moieties for the compounds according to the invention and are intended to apply uniformly throughout the specification and claims unless an otherwise expressly set out definition provides a broader or narrower definition.
The term "alkyl", used alone or in combination, refers to a straight or branched chain alkyl group containing one to four carbon atoms. The term "(Cx-Cy)alkyl" (x and y each being an integer), refers to an alkyl group as defined before containing x to y carbon atoms. For example a (CrC4)alkyl group contains from one to four carbon atoms. Representative examples of alkyl groups include methyl, ethyl, n-propyl, /'so-propyl, n-butyl, /'so-butyl, sec- butyl and ferf-butyl.
In case a (C1-C4)alkyl group is a substituent to a 5-membered heteroaryl group, the term "(C1-C4)alkyl" means (C1-C4)alkyl groups as defined above. Examples of said groups are methyl, ethyl, n-propyl, /'so-propyl, n-butyl, /'so-butyl, sec-butyl and ferf-butyl. Preferred is methyl.
In case a (Ci-C4)alkyl group is a substituent to a 6-membered heteroaryl group, the term "(CrC4)alkyl" means (Ci-C4)alkyl groups as defined above. Examples of said groups are methyl, ethyl, n-propyl, /'so-propyl, n-butyl, /'so-butyl, sec-butyl and ferf-butyl. Preferred is methyl.
In case a (CrC4)alkyl group is a substituent to a heterocyclyl group, the term "(CrC4)alkyl" means (Ci-C4)alkyl groups as defined above. Examples of said groups are methyl, ethyl, n-propyl, /'so-propyl, n-butyl, /'so-butyl, sec-butyl and ferf-butyl. Preferred is methyl.
In case "R3" represents "(CrC4)alkyl" the term means (CrC4)alkyl groups as defined above. Examples of said groups are methyl, ethyl, n-propyl, /'so-propyl, n-butyl, /'so-butyl, sec-butyl and ferf-butyl. Preferred is methyl.
In case "R7" or "R8" represent "(Ci-C4)alkyl" the term means (CrC4)alkyl groups as defined above. Examples of said groups are methyl, ethyl, n-propyl, /'so-propyl, n-butyl, /'so-butyl, sec-butyl and ferf-butyl. Preferred is methyl.
In case "R9" represents "(C1-C4)alkyl" the term means (C1-C4)alkyl groups as defined above. Examples of said groups are methyl, ethyl, n-propyl, /'so-propyl, n-butyl, /'so-butyl, sec-butyl and ferf-butyl. Preferred are methyl, ethyl, n-propyl and /'so-butyl. More preferred are methyl and ethyl and most preferred is methyl.
The term "alkoxy", used alone or in combination, refers to an alkyl-O- group wherein the alkyl group is as defined above. The term "(Cx-Cy)alkoxy" (x and y each being an integer) refers to an alkoxy group as defined before containing x to y carbon atoms. For example a (CrC4)alkoxy group contains from one to four carbon atoms. Representative examples of alkoxy groups include methoxy, ethoxy, n-propoxy, /'so-propoxy, n-butoxy, /'so-butoxy, sec- butoxy and ferf-butoxy.
In case a (Ci-C4)alkoxy group is a substituent to a 6-membered heteroaryl group, the term "(CrC4)alkoxy" means (CrC4)alkoxy groups as defined above. Examples of said groups are methoxy, ethoxy, n-propoxy, /'so-propoxy, n-butoxy, /'so-butoxy, sec-butoxy and ferf- butoxy. Preferred is methoxy.
In case "R4" represents "(CrC4)alkoxy" the term means (CrC4)alkoxy groups as defined above. Examples of said groups are methoxy, ethoxy, n-propoxy, /'so-propoxy, n-butoxy, /'so-butoxy, sec-butoxy and ferf-butoxy. Preferred is methoxy.
The term "alkylthio", used alone or in combination, refers to an alkyl-S- group wherein the alkyl group is as defined above. The term "(Cx-Cy)alkylthio" (x and y each being an integer) refers to an alkylthio group as defined before containing x to y carbon atoms. For example a (CrC4)alkylthio group contains from one to four carbon atoms. Representative examples of alkylthio groups include methylthio, ethylthio, n-propylthio, /'so-propylthio, n- butylthio, /'so-butylthio, sec-butylthio and ferf-butylthio.
In case a (CrC4)alkylthio group is a substituent to a 6-membered heteroaryl group, the term "(d-C4)alkylthio" means (CrC4)alkylthio groups as defined above. Examples of said groups are methylthio, ethylthio, n-propylthio, /'so-propylthio, n-butylthio, /'so-butylthio, sec- butylthio and ferf-butylthio. Preferred is methylthio.
The term "(Ci-C4)alkyl-amino", used alone or in combination, refers to an amino group (-NH2) in which one hydrogen atom has been replaced by a (CrC4)alkyl group as defined above. Representative examples of (Ci-C4)alkyl-amino groups include methylamino, ethylamino, n-propylamino, /'so-propylamino, n-butylamino, /'so-butylamino, sec-butylamino and ferf-butylamino. Preferred is methylamino.
The term "di-[(Ci-C4)alkyl]-amino", used alone or in combination, refers to an amino group (-NH2) in which each of the two hydrogen atoms has been replaced by a (C1-C4)alkyl group as defined above, wherein the two (C1-C4)alkyl groups may be the same or different. Representative examples of di-[(C1-C4)alkyl]-amino groups include, but are not limited to, dimethylamino, methyl-ethyl-amino and diethylamino. Preferred is dimethylamino. The term "(Ci-C4)alkyl-sulfonyl", used alone or in combination, refers to an (d-C4)alkyl- S(0)2- group wherein the (Ci-C4)alkyl group is as defined above. Representative examples of (Ci-C4)alkyl-sulfonyl groups include methyl-sulfonyl, ethyl-sulfonyl, n-propyl- sulfonyl, /'so-propyl-sulfonyl, n-butyl-sulfonyl, /'so-butyl-sulfonyl, sec-butyl-sulfonyl and tert- butyl-sulfonyl. Preferred is methyl-sulfonyl.
The term "hydroxy-(CrC4)alkyl" refers to an alkyl group as defined before containing from one to four carbon atoms in which one hydrogen atom has been replaced with hydroxy. Examples of hydroxy-(Ci-C4)alkyl groups include, but are not limited to, hydroxy-methyl, 1 - hydroxy-ethyl, 2-hydroxy-ethyl, 1 -hydroxy-propyl, 2-hydroxy-propyl, 3-hydroxy-propyl, 1 - hydroxy-1 -methyl-ethyl and 2-hydroxy-1 -methyl-ethyl.
In case "R3" represents "hydroxy-(C1-C4)alkyl" the term means hydroxy-(C1-C4)alkyl groups as defined above. Examples of said groups include, but are not limited to, hydroxy- methyl, 1 -hydroxy-ethyl, 2-hydroxy-ethyl, 1 -hydroxy-propyl, 2-hydroxy-propyl, 3-hydroxy- propyl, 1 -hydroxy-1 -methyl-ethyl and 2-hydroxy-1 -methyl-ethyl. Preferred is hydroxy- methyl.
In case "R4" represents "hydroxy-(CrC4)alkyl" the term means hydroxy-(Ci-C4)alkyl groups as defined above. Examples of said groups include, but are not limited to, hydroxy- methyl, 1 -hydroxy-ethyl, 2-hydroxy-ethyl, 1 -hydroxy-propyl, 2-hydroxy-propyl, 3-hydroxy- propyl, 1 -hydroxy-1 -methyl-ethyl and 2-hydroxy-1 -methyl-ethyl. Preferred is hydroxy- methyl.
The term "(Ci-C2)alkoxy-(CrC4)alkyl" refers to an alkyl group as defined before containing from one to four carbon atoms in which one hydrogen atom has been replaced with (d- C2)alkoxy as defined before. Examples of (Ci-C2)alkoxy-(Ci-C4)alkyl groups include, but are not limited to, methoxy-methyl, ethoxy-methyl, 1 -methoxy-ethyl, 1 -ethoxy-ethyl, 2- methoxy-ethyl, 2-ethoxy-ethyl, 1-methoxy-propyl, 1-ethoxy-propyl, 2-methoxy-propyl, 2- ethoxy-propyl, 3-methoxy-propyl, 3-ethoxy-propyl, 1 -methoxy-1 -methyl-ethyl, 1-ethoxy-1 - methyl-ethyl, 2-methoxy-1 -methyl-ethyl and 2-ethoxy-1 -methyl-ethyl.
In case a (C1-C2)alkoxy-(C1-C4)alkyl group is a substituent to a heterocyclyl group, the term "(C1-C2)alkoxy-(C1-C4)alkyl" means (C1-C2)alkoxy-(C1-C4)alkyl groups as defined above. Examples of said groups include, but are not limited to, methoxy-methyl, ethoxy- methyl, 1 -methoxy-ethyl, 1-ethoxy-ethyl, 2-methoxy-ethyl, 2-ethoxy-ethyl, 1-methoxy- propyl, 1 -ethoxy-propyl, 2-methoxy-propyl, 2-ethoxy-propyl, 3-methoxy-propyl, 3-ethoxy- propyl, 1 -methoxy-1 -methyl-ethyl, 1 -ethoxy-1 -methyl-ethyl, 2-methoxy-1 -methyl-ethyl and 2-ethoxy-1 -methyl-ethyl. Preferred are 2-methoxy-ethyl and 2-ethoxy-ethyl; and most preferred is 2-methoxy-ethyl.
In case "R9" represents "(Ci-C2)alkoxy-(Ci-C4)alkyl" the term means (Ci-C2)alkoxy-(Ci- C4)alkyl groups as defined above. Examples of said groups include, but are not limited to, methoxy-methyl, ethoxy-methyl, 1-methoxy-ethyl, 1-ethoxy-ethyl, 2-methoxy-ethyl, 2- ethoxy-ethyl, 1 -methoxy-propyl, 1 -ethoxy-propyl, 2-methoxy-propyl, 2-ethoxy-propyl, 3- methoxy-propyl, 3-ethoxy-propyl, 1-methoxy-1 -methyl-ethyl, 1 -ethoxy-1 -methyl-ethyl, 2- methoxy-1 -methyl-ethyl and 2-ethoxy-1 -methyl-ethyl. Preferred are 2-methoxy-ethyl and 2-ethoxy-ethyl; and most preferred is 2-methoxy-ethyl.
The term "(C3-C6)cycloalkyl", used alone or in combination, means a cycloalkyl group with 3 to 6 carbon atoms. Examples of (C3-C6)cycloalkyl groups are cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
The term "(C3-C6)cycloalkyl-(C1-C4)alkyl" refers to an alkyl group as defined before containing from one to four carbon atoms in which one hydrogen atom has been replaced with (C3-C6)cycloalkyl as defined before. Examples of (C3-C6)cycloalkyl-(Ci-C4)alkyl groups include, but are not limited to, cyclopropyl-methyl, cyclobutyl-methyl, cyclopentyl- methyl, cyclohexyl-methyl, 1 -cyclopropyl-ethyl, 1-cyclobutyl-ethyl, 1 -cyclopentyl-ethyl, 1 - cyclohexyl-ethyl, 2-cyclopropyl-ethyl, 2-cyclobutyl-ethyl, 2-cyclopentyl-ethyl, 2-cyclohexyl- ethyl, 3-cyclopropyl-propyl, 3-cyclobutyl-propyl, 3-cyclopentyl-propyl and 3-cyclohexyl- propyl. Preferred are cyclopropyl-methyl, cyclobutyl-methyl, cyclopentyl-methyl and cyclohexyl-methyl and most preferred is cyclopentyl-methyl.
The term "phenyl-(CrC4)alkyl" refers to an alkyl group as defined before containing from one to four carbon atoms in which one hydrogen atom has been replaced with phenyl. Examples of phenyl-(d-C4)alkyl groups include, but are not limited to, phenyl-methyl (benzyl), 1-phenyl-ethyl, 2-phenyl-ethyl, 1 -phenyl-propyl, 2-phenyl-propyl, 3-phenyl-propyl, 1-phenyl-1 -methyl-ethyl and 2-phenyl-1-methyl-ethyl. Preferred are benzyl and 2-phenyl- ethyl and most preferred is benzyl.
The term "phenyloxy-(C1-C4)alkyl" refers to an alkyl group as defined before containing from one to four carbon atoms in which one hydrogen atom has been replaced with phenyloxy (or in an alternative phrase: phenoxy). Examples of phenyloxy-(C1-C4)alkyl groups include, but are not limited to, phenyloxy-methyl, 1 -phenyloxy-ethyl, 2-phenyloxy- ethyl, 1-phenyloxy-propyl, 2-phenyloxy-propyl, 3-phenyloxy-propyl, 1-phenyloxy-1 -methyl- ethyl and 2-phenyloxy-1 -methyl-ethyl. Preferred are phenyloxy-methyl and 2-phenyloxy- ethyl and most preferred is 2-phenyloxy-ethyl. The term halogen means fluoro, chloro, bromo or iodo, preferably fluoro or chloro and most preferably fluoro.
The term "5-membered heteroaryl", used alone or in combination, means a 5-membered monocyclic aromatic ring containing 1 , 2 or 3 heteroatoms independently selected from oxygen, nitrogen and sulphur (and preferably containing 1 or 2 nitrogen atoms). Examples of such 5-membered heteroaryl groups are furanyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl and triazolyl. Preferred are pyrrolyl, imidazolyl and pyrazolyl and most preferred is pyrazolyl (notably pyrazol-3-yl). The above-mentioned 5-membered heteroaryl groups are unsubstituted or mono- or di-substituted with (C1-C4)alkyl (preferably methyl). A preferred example of such unsubstituted or mono- or di-substituted 5-membered heteroaryl groups is 2-methyl-2H- pyrazol-3-yl.
The term "6-membered heteroaryl", used alone or in combination, means a 6-membered monocyclic aromatic ring containing 1 or 2 nitrogen atoms. Examples of such 6- membered heteroaryl groups are pyridyl, pyrimidyl, pyridazinyl and pyrazinyl. Preferred is pyridyl. The above-mentioned 6-membered heteroaryl groups are unsubstituted or mono- or di-substituted, wherein the substituents are independently selected from the group consisting of halogen, hydroxy, (Ci-C4)alkyl, (Ci-C4)alkoxy, (Ci-C4)alkylthio, (Ci- C4)alkyl-sulfonyl, (C-i-C4)alkyl-amino and di-[(C-i-C4)alkyl]-amino. Preferably the substituents are independently selected from the group consisting of halogen (notably fluoro or chloro), hydroxy and (Ci-C4)alkoxy (notably methoxy). Examples of such unsubstituted or mono- or di-substituted 6-membered heteroaryl groups are pyridin-2-yl, 4-fluoro-pyridin-2-yl, 6-fl uoro-py rid in-2-yl , 6-chloro-pyridin-2-yl, 6-hydroxy-pyridin-2-yl, 6- methoxy-pyridin-2-yl, 6-methylamino-pyridin-2-yl, 6-dimethylamino-pyridin-2-yl, pyridin-3- yl, pyridin-4-yl, 2-chloro-pyridin-4-yl, pyrimidin-2-yl, 4-hydroxy-pyrimidin-2-yl, 4-methoxy- pyrimidin-2-yl, 4-methylthio-pyrimidin-2-yl, pyrimidin-4-yl, 2-chloro-pyrimidin-4-yl, 2,6- dichloro-pyrimidin-4-yl, 2-hydroxy-pyrimidin-4-yl, 6-hydroxy-pyrimidin-4-yl, 6-chloro-2- hydroxy-pyrimidin-4-yl, 2-methoxy-pyrimidin-4-yl, 6-methoxy-pyrimidin-4-yl, 6-chloro-2- methoxy-pyrimidin-4-yl, 2-methylthio-pyrimidin-4-yl, 6-methylthio-pyrimidin-4-yl, 2- methylamino-pyrimidin-4-yl, 2-dimethylamino-pyrimidin-4-yl, 6-methylsulfonyl-pyrimidin-4- yl, pyrimidin-5-yl, pyridazin-3-yl, 6-chloro-pyridazin-3-yl, 6-hydroxy-pyridazin-3-yl, 5- methoxy-pyridazin-3-yl, 6-methoxy-pyridazin-3-yl, pyrazin-2-yl, 3-chloro-pyrazin-2-yl, 5- chloro-pyrazin-2-yl, 6-chloro-pyrazin-2-yl, 6-hydroxy-pyrazin-2-yl, 5-methoxy-pyrazin-2-yl, 6-methoxy-pyrazin-2-yl, 6-methylamino-pyrazin-2-yl and 6-dimethylamino-pyrazin-2-yl. Preferred are pyridin-2-yl, 4-fluoro-pyridin-2-yl, 6-fluoro-pyridin-2-yl, 6-chloro-pyridin-2-yl, 6-hydroxy-pyridin-2-yl, 6-methoxy-pyridin-2-yl, 6-methylamino-pyridin-2-yl, pyridin-3-yl, 2- chloro-pyrimidin-4-yl, 2-hydroxy-pyrimidin-4-yl, 2-methoxy-pyrimidin-4-yl, pyridazin-3-yl, 6- chloro-pyridazin-3-yl, 6-hydroxy-pyridazin-3-yl, 6-methoxy-pyridazin-3-yl, pyrazin-2-yl, 3- chloro-pyrazin-2-yl, 6-methoxy-pyrazin-2-yl, 6-methylamino-pyrazin-2-yl and 6- dimethylamino-pyrazin-2-yl. Most preferred are pyridin-2-yl, 4-fluoro-pyridin-2-yl, 6-fluoro- pyridin-2-yl, 6-hydroxy-pyridin-2-yl, 6-methoxy-pyridin-2-yl and 2-hydroxy-pyrimidin-4-yl.
It is well known in the art that 6-membered heteroaryl groups, as defined above, may be present in different tautomeric forms (e.g. in case said heteroaryl groups are substituted with at least one hydroxy group). Examples of such tautomers are given in the formulas below:
Figure imgf000010_0001
It is to be understood that in any such case all different tautomers are within the scope of the present invention. Even though one tautomer may be described, the present invention includes all tautomers of the present compounds. Especially, any given chemical name does represent not only the specifically named chemical compound but also the different tautomeric forms thereof. In solution, tautomers exist usually as mixtures of different tautomeric forms; in the solid state usually one tautomeric form predominates.
6-membered heteroaryl groups which are substituted with at least one (Ci-C4)alkylamino group may also be present in different tautomeric forms which are all included in the present invention. The term "heterocyclyl", used alone or in combination, means a 6-membered monocyclic ring containing 1 or 2 double bonds (preferably 2 double bonds) and 1 or 2 nitrogen atoms, wherein one or two carbon atoms adjacent to said nitrogen atoms are substituted with an oxo-group. The heterocyclyl group may be attached to the rest of the molecule via a nitrogen atom or a carbon atom. In case Y represents -C(R7R8)-, a heterocyclyl group representing R1 is preferably attached to the rest of the molecule via a nitrogen atom. In case Y represents -N(R9)-, -0-, -S-, -S(O)-, or -S(0)2- (and notably -N(R9)- or -0-), a heterocyclyl group representing R1 is preferably attached to the rest of the molecule via a carbon atom. The above-mentioned heterocyclyl groups are unsubstituted or mono- or di- substituted with (C1-C4)alkyl or (C1-C2)alkoxy-(C1-C4)alkyl (and preferably unsubstituted or mono-substituted with (C1-C4)alkyl). Preferred heterocyclyl groups are selected from the group of radicals as depicted in groups G1 and/or G2 below:
G1 : heterocyclyl groups, attached to the rest of the molecule via a nitrogen atom (as depicted by the arrow):
Figure imgf000011_0001
G2: heterocyclyl groups, attached to the rest of the molecule via a carbon atom (; depicted by the arrow):
Figure imgf000011_0002
2) A further embodiment of the invention relates to benzamide derivatives according to embodiment 1 ), wherein
n represents 1 , 2, 3 or 4 (and preferably 2, 3 or 4);
Y represents -C(R7R8)-, -N(R9)-, -0-, -S-, -S(O)-, or -S(0)2-;
R1 represents • a 5-membered heteroaryl group which is unsubstituted or mono- or di-substituted with (Ci-C4)alkyl;
• a 6-membered heteroaryl group which is unsubstituted or mono- or di-substituted, wherein the substituents are independently selected from the group consisting of halogen, hydroxy, (Ci-C4)alkyl, (Ci-C4)alkoxy, (Ci-C4)alkylthio, (Ci-C4)alkyl- sulfonyl, (Ci-C4)alkyl-amino and di-[(Ci-C4)alkyl]-amino;
• a phenyl group which is unsubstituted or mono- or di-substituted with halogen; or
• a heterocyclyl group which is unsubstituted or mono- or di-substituted with (C-i- C4)alkyl or (Ci-C2)alkoxy-(d-C4)alkyl;
R2 represents chloro or methyl (and preferably chloro);
R3 represents hydrogen and R4 represents hydroxy, hydroxy-(Ci-C4)alkyl, -CONH2 or (Ci-C4)alkoxy (and preferably hydroxy, hydroxymethyl or methoxy); or
R3 represents (Ci-C4)alkyl or hydroxy-(Ci-C4)alkyl (and preferably methyl or hydroxymethyl) and R4 represents hydrogen;
R5 represents hydrogen or fluoro;
R6 represents hydrogen or fluoro;
R7 and R8 represent independently from each other hydrogen or fluoro; or R7 and R8 together represent an oxo-group; and
R9 represents hydrogen, (Ci-C4)alkyl, (Ci-C2)alkoxy-(Ci-C4)alkyl, (C3-C6)cycloalkyl-(Ci- C4)alkyl, phenyl-(Ci-C4)alkyl, or phenyloxy-(Ci-C4)alkyl;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
3) A further embodiment of the invention relates to benzamide derivatives according to embodiment 1 ), wherein
n represents 2, 3 or 4;
Y represents -C(R7R8)-, -N(R9)-, -0-, or -S-;
R1 represents a 6-membered heteroaryl group which is unsubstituted or mono- or di- substituted, wherein the substituents are independently selected from the group consisting of halogen, hydroxy, (Ci-C4)alkoxy, (Ci-C4)alkylthio, (Ci-C4)alkyl-sulfonyl, (Ci-C4)alkyl- amino and di-[(Ci-C4)alkyl]-amino (preferably halogen, hydroxy and (Ci-C4)alkoxy); R2 represents chloro;
R3 represents hydrogen and R4 represents hydroxy or hydroxy-(Ci-C4)alkyl (and preferably hydroxy or hydroxymethyl); or
R3 represents (Ci-C4)alkyl or hydroxy-(Ci-C4)alkyl (and preferably methyl or hydroxymethyl) and R4 represents hydrogen;
R5 represents hydrogen or fluoro;
R6 represents hydrogen or fluoro;
R7 and R8 represent independently from each other hydrogen, fluoro, hydroxy or (Ci- C4)alkyl, with the proviso that R8 is different from fluoro or hydroxy if R7 represents hydroxy;
or R7 and R8 together represent an oxo-group; and
R9 represents hydrogen, (d-C4)alkyl, (C1-C2)alkoxy-(C1-C4)alkyl, (C3-C6)cycloalkyl-(C1- C4)alkyl, phenyl-(d-C4)alkyl, or phenyloxy-(C1-C4)alkyl (and preferably hydrogen or (d- C4)alkyl);
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
4) A further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) or 2), wherein
n represents 2, 3 or 4;
Y represents -C(R7R8)-, -N(R9)-, -0-, or -S-;
R1 represents a 6-membered heteroaryl group which is unsubstituted or mono- or di- substituted, wherein the substituents are independently selected from the group consisting of halogen, hydroxy, (Ci-C4)alkoxy, (Ci-C4)alkylthio, (Ci-C4)alkyl-sulfonyl, (Ci-C4)alkyl- amino and di-[(Ci-C4)alkyl]-amino (preferably halogen, hydroxy and (Ci-C4)alkoxy);
R2 represents chloro;
R3 represents hydrogen and R4 represents hydroxy or hydroxy-(Ci-C4)alkyl (and preferably hydroxy or hydroxymethyl); or
R3 represents (C1-C4)alkyl or hydroxy-(C1-C4)alkyl (and preferably methyl or hydroxymethyl) and R4 represents hydrogen;
R5 represents hydrogen or fluoro; R6 represents hydrogen or fluoro;
R7 and R8 represent independently from each other hydrogen or fluoro; or R7 and R8 together represent an oxo-group; and
R9 represents hydrogen, (d-C4)alkyl, (Ci-C2)alkoxy-(Ci-C4)alkyl, (C3-C6)cycloalkyl-(Ci- C4)alkyl, phenyl-(Ci-C4)alkyl, or phenyloxy-(Ci-C4)alkyl (and preferably hydrogen or (Ci- C4)alkyl);
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
5) A further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) or 2), wherein
n represents 1 , 2, 3 or 4 (and preferably 2, 3 or 4);
Y represents -C(R7R8)-, -N(R9)-, -0-, -S-, -S(O)-, or -S(0)2-;
R1 represents
• a 5-membered heteroaryl group which is unsubstituted or mono- or di-substituted (preferably mono-substituted) with (Ci-C4)alkyl;
• a 6-membered heteroaryl group which is unsubstituted or mono- or di-substituted, wherein the substituents are independently selected from the group consisting of halogen, hydroxy, (Ci-C4)alkyl, (Ci-C4)alkoxy, (Ci-C4)alkylthio, (Ci-C4)alkyl- sulfonyl, (Ci-C4)alkyl-amino and di-[(Ci-C4)alkyl]-amino;
· a phenyl group which is unsubstituted or mono- or di-substituted with halogen; or
• a heterocyclyl group which is unsubstituted or mono- or di-substituted (preferably unsubstituted or mono-substituted) with (C1-C4)alkyl or (C1-C2)alkoxy-(C1- C4)alkyl;
R2 represents chloro or methyl (and preferably chloro);
R3 represents hydrogen and R4 represents hydroxy, hydroxy-(C1-C4)alkyl, -CONH2 or (C1-C4)alkoxy (and preferably hydroxy, hydroxymethyl or methoxy);
R5 represents hydrogen or fluoro;
R6 represents hydrogen or fluoro;
R7 and R8 represent independently from each other hydrogen or fluoro; or R7 and R8 together represent an oxo-group; and R9 represents hydrogen, (d-C4)alkyl, (Ci-C2)alkoxy-(Ci-C4)alkyl, (C3-C6)cycloalkyl-(Ci- C4)alkyl, phenyl-(Ci-C4)alkyl, or phenyloxy-(Ci-C4)alkyl;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds. 6) A further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) or 2), wherein
n represents 2, 3 or 4;
Y represents -C(R7R8)-, -N(R9)-, -0-, or -S-;
R1 represents a 6-membered heteroaryl group which is unsubstituted or mono- or di- substituted (preferably unsubstituted or mono-substituted), wherein the substituents are independently selected from the group consisting of halogen, hydroxy, (C1-C4)alkoxy, (C1-C4)alkylthio, (C1-C4)alkyl-sulfonyl, (C1-C4)alkyl-amino and di-[(C1-C4)alkyl]-amino (preferably halogen, hydroxy and (C1-C4)alkoxy);
R2 represents chloro;
R3 represents hydrogen and R4 represents hydroxy or hydroxy-(Ci-C4)alkyl (and preferably hydroxy or hydroxymethyl);
R5 represents hydrogen or fluoro;
R6 represents hydrogen or fluoro;
R7 and R8 represent independently from each other hydrogen or fluoro; or R7 and R8 together represent an oxo-group; and
R9 represents hydrogen, (Ci-C4)alkyl, (Ci-C2)alkoxy-(Ci-C4)alkyl, (C3-C6)cycloalkyl-(Ci- C4)alkyl, phenyl-(Ci-C4)alkyl, or phenyloxy-(Ci-C4)alkyl (and preferably hydrogen or (Ci- C4)alkyl);
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
7) A further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) or 2), wherein
n represents 1 , 2, 3 or 4 (and preferably 2, 3 or 4);
Y represents -C(R7R8)-, -N(R9)-, -0-, or -S- (preferably -N(R9)-); R1 represents a 6-membered heteroaryl group which is unsubstituted or mono- or di- substituted, wherein the substituents are independently selected from the group consisting of halogen, hydroxy, (Ci-C4)alkyl, (Ci-C4)alkoxy, (Ci-C4)alkylthio, (Ci-C4)alkyl-sulfonyl, (Ci-C4)alkyl-amino and di-[(Ci-C4)alkyl]-amino (preferably halogen, hydroxy and (Ci- C4)alkylthio);
R2 represents chloro;
R3 represents (Ci-C4)alkyl or hydroxy-(Ci-C4)alkyl (and preferably methyl or hydroxymethyl) and R4 represents hydrogen;
R5 represents hydrogen or fluoro (preferably hydrogen);
R6 represents hydrogen or fluoro (preferably hydrogen);
R7 and R8 represent independently from each other hydrogen or fluoro; or R7 and R8 together represent an oxo-group; and
R9 represents hydrogen, (d-C4)alkyl, (C1-C2)alkoxy-(C1-C4)alkyl, (C3-C6)cycloalkyl-(C1- C4)alkyl, phenyl-(d-C4)alkyl, or phenyloxy-(C1-C4)alkyl (preferably hydrogen or (d- C4)alkyl);
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
8) A further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) or 2), wherein
n represents 2;
Y represents -N(R9)-;
R1 represents a 6-membered heteroaryl group which is unsubstituted or mono- or di- substituted (preferably mono-substituted), wherein the substituents are independently selected from the group consisting of halogen, hydroxy and (Ci-C4)alkylthio (preferably halogen and hydroxy);
R2 represents chloro;
R3 represents (Ci-C4)alkyl or hydroxy-(Ci-C4)alkyl (and preferably methyl or hydroxymethyl) and R4 represents hydrogen;
R5 represents hydrogen;
R6 represents hydrogen; and R9 represents hydrogen or (Ci-C4)alkyl (and preferably hydrogen or methyl);
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
9) A further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 7), wherein
n represents 2, 3 or 4 (preferably 2 or 3 and most preferably 2);
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
10) A further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 7), wherein
n represents 3 or 4;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
1 1 ) A further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 7), 9) or 10), wherein
Y represents -C(R7R8)-, -N(R9)-, -0-, or -S-;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
12) A further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 7), 9) or 10), wherein
Y represents -C(R7R8)-, -0-, or -S-;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds. 13) A further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 7), 9) or 10), wherein
Y represents -C(R7R8)-;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
14) A further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 10), wherein
Y represents -N(R9)-;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
15) A further embodiment of the invention relates to benzamide derivatives accord any one of embodiments 1 ) to 7), 9) or 10), wherein Y represents -0-;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
16) A further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 7), 9) or 10), wherein
Y represents -S-, -S(O)-, or -S(0)2- (preferably -S-);
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
17) A further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ), 2), 5) or 9) to 16), wherein
R1 represents
· a 5-membered heteroaryl group which is unsubstituted or mono- or di-substituted (preferably mono-substituted) with (C1-C4)alkyl;
• a 6-membered heteroaryl group which is unsubstituted or mono- or di-substituted, wherein the substituents are independently selected from the group consisting of halogen, hydroxy, (Ci-C4)alkoxy, (Ci-C4)alkylthio, (Ci-C4)alkyl-sulfonyl, (Ci- C4)alkyl-amino and di-[(C-i-C4)alkyl]-amino (preferably from halogen, hydroxy and
(Ci-C4)alkoxy; and most preferably from halogen and hydroxy);
• a phenyl group which is unsubstituted or mono- or di-substituted with halogen; and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
18) A further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ), 2), 5) or 9) to 16), wherein
R1 represents
• a 5-membered heteroaryl group which is unsubstituted or mono- or di-substituted (preferably mono-substituted) with (C1-C4)alkyl (preferably methyl);
• a 6-membered heteroaryl group which is unsubstituted or mono- or di-substituted, wherein the substituents are independently selected from the group consisting of halogen, hydroxy, (Ci-C4)alkoxy, (Ci-C4)alkylthio, (Ci-C4)alkyl-sulfonyl, (Ci- C4)alkyl-amino and di-[(C-i-C4)alkyl]-amino (preferably from halogen, hydroxy and methoxy; and most preferably from halogen and hydroxy);
and to the salts (in particular pharmaceutically acceptable salts) of such compounds. 19) A further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ), 2), 5) or 9) to 16), wherein R1 represents a 5-membered heteroaryl group which is unsubstituted or mono- or di- substituted (preferably mono-substituted) with (Ci-C4)alkyl (preferably methyl);
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
20) A further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 16), wherein
R1 represents a 6-membered heteroaryl group which is unsubstituted or mono- or di- substituted, wherein the substituents are independently selected from the group consisting of halogen, hydroxy, (Ci-C4)alkyl, (Ci-C4)alkoxy, (Ci-C4)alkylthio, (Ci-C4)alkyl-sulfonyl, (Ci-C4)alkyl-amino and di-[(C-i-C4)alkyl]-amino (preferably from halogen, hydroxy and methoxy; and most preferably from halogen and hydroxy);
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
21 ) A further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 16), wherein
R1 represents a 6-membered heteroaryl group which is unsubstituted or mono-substituted (preferably mono-substituted), wherein the substituents are independently selected from the group consisting of halogen, hydroxy and (Ci-C4)alkoxy (preferably from fluoro, chloro, hydroxy and methoxy; and most preferably from fluoro, chloro and hydroxy);
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
22) A further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ), 2), 5) or 9) to 16), wherein
R1 represents a phenyl group which is unsubstituted or mono- or di-substituted with halogen (preferably fluoro);
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
23) A further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ), 2), 5) or 9) to 16), wherein
R1 represents a heterocyclyl group which is unsubstituted or mono- or di-substituted (preferably unsubstituted or mono-substituted) with (Ci-C4)alkyl or (d-C2)alkoxy-(Ci- C4)alkyl;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds. 24) A further embodiment of the invention relates to benzamide derivatives according to embodiment 23), wherein the heterocyclyl group is selected from groups G1 and/or G2;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
25) A further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 24), wherein
R2 represents chloro;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
26) A further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ), 2), 5) or 9) to 24), wherein
R2 represents methyl;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
27) A further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ), 2), 5) or 9) to 26), wherein
R3 represents hydrogen and R4 represents hydroxy, hydroxy-(C1-C4)alkyl, -CONH2 or (C1-C4)alkoxy (and preferably hydroxy, hydroxymethyl or methoxy);
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
28) A further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 6) or 9) to 26), wherein
R3 represents hydrogen and R4 represents hydroxy or hydroxy-(Ci-C4)alkyl (and preferably hydroxy or hydroxymethyl);
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
29) A further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 6) or 9) to 26), wherein
R3 represents hydrogen and R4 represents hydroxy;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds. 30) A further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 6) or 9) to 26), wherein
R3 represents hydrogen and R4 represents hydroxy-(Ci-C4)alkyl (preferably hydroxymethyl);
and to the salts (in particular pharmaceutically acceptable salts) of such compounds. 31 ) A further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 4) or 7) to 26), wherein
R3 represents (Ci-C4)alkyl or hydroxy-(Ci-C4)alkyl (and preferably methyl or hydroxymethyl) and R4 represents hydrogen;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
32) A further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 4) or 7) to 26), wherein
R3 represents (Ci-C4)alkyl (preferably methyl) and R4 represents hydrogen;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds. 33) A further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 4) or 7) to 26), wherein
R3 represents hydroxy-(C1-C4)alkyl (preferably hydroxymethyl) and R4 represents hydrogen;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds. 34) A further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 33), wherein
R5 and R6 both represent hydrogen;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
35) A further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 7) or 9) to 33), wherein
R5 and R6 both represent fluoro;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
36) A further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 7) or 9) to 33), wherein
R5 represents hydrogen and R6 represents fluoro;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
37) A further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ), 3) or 9) to 36), wherein R7 and R8 represent independently from each other hydrogen, fluoro, hydroxy or (Ci- C4)alkyl, with the proviso that R8 is different from fluoro or hydroxy if R7 represents hydroxy;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds. 38) A further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 7) or 9) to 36), wherein
R7 and R8 represent independently from each other hydrogen or fluoro;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
39) A further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 7) or 9) to 36), wherein
R7 and R8 both represent hydrogen;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
40) A further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 7) or 9) to 36), wherein
R7 and R8 both represent fluoro;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
41 ) A further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 7) or 9) to 36), wherein
R7 represents hydrogen and R8 represents fluoro;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
42) A further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ), 3) or 9) to 36), wherein
R7 represents hydrogen or (Ci-C4)alkyl (preferably (Ci-C4)alkyl) and R8 represents hydroxy;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
43) A further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 7) or 9) to 36), wherein
R7 and R8 together represent an oxo-group;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds. 44) A further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 7) or 9) to 43), wherein
R9 represents hydrogen, methyl, ethyl, n-propyl, /'so-propyl, /'so-butyl, 2-methoxy-ethyl, cyclopentyl-methyl, benzyl, or 2-phenyloxy-ethyl;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
45) A further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 43), wherein
R9 represents hydrogen or (d-C4)alkyl (preferably methyl, ethyl, n-propyl, /'so-propyl or /so-butyl);
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
46) A further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 7), 9) to 38), 41 ), 42) or 44) to 45), wherein,
in case R7 and R8 are different from each other, the carbon atom of the group -C(R7R8)- has (S)-configuration;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
47) A further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 7), 9) to 38), 41 ), 42) or 44) to 45), wherein,
in case R7 and R8 are different from each other, the carbon atom of the group -C(R7R8)- has (R)-configuration;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
48) A further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 4), 7) to 26) or 31 ) to 47), wherein
the carbon atom, which is attached to the group R3, has (S)-configuration;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds. 49) A further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 4), 7) to 26) or 31 ) to 47), wherein
the carbon atom, which is attached to the group R3, has (R)-configuration;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
50) A further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 7), 9) to 33) or 35) to 49), wherein, in case n is different from 2 and at least one of R5 and R6 is different from hydrogen, the carbon atom, which is attached to the group R4, has (S)-configuration;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
51 ) A further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 7), 9) to 33) or 35) to 49), wherein,
in case n is different from 2 and at least one of R5 and R6 is different from hydrogen, the carbon atom, which is attached to the group R4, has (R)-configuration;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
52) A further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 7), 9) to 33) or 35) to 51 ), wherein,
in case n is different from 2 and one of R5 or R6 represents fluoro, the carbon atom, which is attached to the groups R5 and R6, has (S)-configuration;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
53) A further embodiment of the invention relates to benzamide derivatives according to any one of embodiments 1 ) to 7), 9) to 33) or 35) to 51 ), wherein,
in case n is different from 2 and one of R5 or R6 represents fluoro, the carbon atom, which is attached to the groups R5 and R6, has (R)-configuration;
and to the salts (in particular pharmaceutically acceptable salts) of such compounds.
54) Preferred compounds of formula (I) as defined in embodiment 1 ) are selected from the group consisting of:
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-phenylamino-benzamide;
2-Chloro-N-((1 -hydroxycyclohexyl)methyl)-5-(methyl(phenyl)amino)benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[(2-methoxy-ethyl)-phenyl-amino]-benzamide; 2-Chloro-5-(2-fluoro-phenylamino)-N-(1-hydroxy-cyclohexylmethyl)-benzamide;
2-Chloro-5-[(2-fluoro-phenyl)-methyl-amino]-N-(1-hydroxy-cyclohexylmethyl)-benzamide; 2-Chloro-5-(2,4-difluoro-phenylamino)-N-(1-hydroxy-cyclohexylmethyl)-benzamide;
2-Chloro-5-[(2,4-difluoro-phenyl)-methyl-amino]-N-(1-hydroxy-cyclohexylmethyl)- benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(pyrimidin-4-ylamino)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(methyl-pyrimidin-4-yl-amino)-benzamide; 2-Chloro-5-(2-chloro-pyrimidin-4-ylamino)-N-(1-hydroxy-cyclohexylmethyl)-benzamide; 2-Chloro-5-[(2-chloro-pyrimidin-4-yl)-methyl-amino]-N-(1 -hydroxy-cyclohexylmethyl)- benzamide; 2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(2-methoxy-p^
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[(2-methoxy-pyrimidin-4-yl)-methyl-amino]- benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[methyl-(2-methylamino-pyrimidin-4-yl)- amino]-benzamide;
2-Chloro-5-[(2-dimethylamino-pyrimidin-4-yl)-methyl-amino]-N-(1 -hydroxy- cyclohexylmethyl)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(2-hydroxypyrimidin-4-ylamino)-benzamide; 2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[methyl-(2-oxo-1 ,2-dihydro-pyrimidin-4-yl)- amino]-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[methyl-(3-methyl-2-oxo-2,3-dihydro- pyrimidin-4-yl)-amino]-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[methyl-(1-methyl-2-oxo-1 ,2-dihydro- pyrimidin-4-yl)-amino]-benzamide;
2-Chloro-5-[(2-chloro-pyrimidin-4-yl)-ethyl-amino]-N-(1 -hydroxy-cyclohexylmethyl)- benzamide;
2-Chloro-5-[ethyl-(2-oxo-1 ,2-dihydro-pyrimidin-4-yl)-amino]-N-(1-hydroxy- cyclohexylmethyl)-benzamide;
2-Chloro-5-[(2-chloro-pyrimidin-4-yl)-propyl-amino]-N-(1 -hydroxy-cyclohexylmethyl)- benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[(2-oxo-1 ,2-dihydro-pyrimidin-4-yl)-propyl- amino]-benzamide;
2-Chloro-5-[(2-chloro-pyrimidin-4-yl)-isopropyl-amino]-N-(1-hydroxy-cyclohexylmethyl)- benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[isopropyl-(2-oxo-1 ,2-dihydro-pyrimidin-4-yl)- amino]-benzamide;
2-Chloro-5-[(2-chloro-pyrimidin-4-yl)-isobutyl-amino]-N-(1-hydroxy-cyclohexylmethyl)- benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[isobutyl-(2-oxo-1 ,2-dihydro-pyrimidin-4-yl)- amino]-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[isobutyl-(2-methoxy-pyrimidin-4-yl)-amino]- benzamide;
5-[Benzyl-(2-chloro-pyrimidin-4-yl)-amino]-2-chloro-N-(1-hydroxy-cyclohexylmethyl)- benzamide; 5-[Benzyl-(2-oxo-1 ,2-dihydro-pyrimidin-4-yl)-amino]-2-chloro-N-(1 -hydroxy- cyclohexylmethyl)-benzamide;
5-[Benzyl-(2-methoxy-pyrimidin-4-yl)-amino]-2-chloro-N-(1-hydroxy-cyclohexylmethyl)- benzamide;
2-Chloro-5-[(2-chloro-pyrimidin-4-yl)-(2-methoxy-ethyl)-amino]-N-(1-hydroxy- cyclohexylmethyl)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[(2-methoxy-ethyl)-(2-oxo-1 ,2-dihydro- pyrimidin-4-yl)-amino]-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[(2-methoxy-ethyl)-(2-methoxy-pyrimidin-4-yl)- amino]-benzamide;
2-Chloro-5-[(2-chloro-pyrimidin-4-yl)-cyclopentylmethyl-amino]-N-(1-hydroxy- cyclohexylmethyl)-benzamide;
2-Chloro-5-[cyclopentylmethyl-(2-oxo-1 ,2-dihydro-pyrimidin-4-yl)-amino]-N-(1-hydroxy- cyclohexylmethyl)-benzamide;
2-Chloro-5-[cyclopentylmethyl-(2-methoxy-pyrimidin-4-yl)-amino]-N-(1-hydroxy- cyclohexylmethyl)-benzamide;
2-Chloro-5-[(2-chloro-pyrimidin-4-yl)-(2-phenoxy-ethyl)-amino]-N-(1-hydroxy- cyclohexylmethyl)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[(2-oxo-1 ,2-dihydro-pyrimidin-4-yl)-(2- phenoxy-ethyl)-amino]-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[(2-methoxy-pyrimidin-4-yl)-(2-phenoxy-ethyl)- amino]-benzamide;
2-Chloro-5-[(2-chloro-pyrimidin-4-yl)-methyl-amino]-N-((R)-1 -cyclohexyl-ethyl)-benzamide; 2-Chloro-N-((R)-1-cyclohexyl-ethyl)-5-[methyl-(2-oxo-1 ,2-dihydro-pyrimidin-4-yl)-amino]- benzamide;
2-Chloro-5-[(2-chloro-pyrimidin-4-yl)-methyl-amino]-N-((S)-1-cyclohexyl-2-hydroxy-ethyl)- benzamide;
2-Chloro-N-((S)-1 -cyclohexyl-2-hydroxy-ethyl)-5-[methyl-(2-oxo-1 ,2-dihydro-pyrimidin-4- yl)-amino]-benzamide;
2-Chloro-5-[(2-chloro-pyrimidin-4-yl)-methyl-amino]-N-(1 -hydroxy-cycloheptylmethyl)- benzamide;
2-Chloro-N-(1-hydroxy-cycloheptylmethyl)-5-[methyl-(2-oxo-1 ,2-dihydro-pyrimidin-4-yl)- amino]-benzamide;
2-Chloro-5-[(2-chloro-pyrimidin-4-yl)-methyl-amino]-N-(1 -hydroxy-cyclooctylmethyl)- benzamide; 2-Chloro-N-(1-hydroxy-cyclooctylmethyl^^
amino]-benzamide;
2-Chloro-5-[(2-chloro-pyrimidin-4-yl)-methyl-amino]-N-(1 -hydroxy-cyclopentylmethyl)- benzamide;
2-Chloro-N-(1-hydroxy-cyclopentylmethyl)-5-[methyl-(2-oxo-2,3-dihydro-pyrimidin-4-yl)- amino]-benzamide;
2-Chloro-5-[(2-chloro-pyrimidin-4-yl)-methyl-amino]-N-(1 -methoxy-cyclohexylmethyl)- benzamide;
2-Chloro-N-(1-methoxy-cyclohexylmethyl)-5-[methyl-(2-oxo-2,3-dihydro-pyrimidin-4-yl)- amino]-benzamide;
N-(1-Carbamoyl-cyclohexylmethyl)-2-chloro-5-[(2-chloro-pyrimidin-4-yl)-methyl-amino]- benzamide;
N-(1-Carbamoyl-cyclohexylmethyl)-2-chloro-5-[methyl-(2-oxo-2,3-dihydro-pyrimidin-4-yl)- amino]-benzamide;
2-Chloro-5-[(2-chloro-pyrimidin-4-yl)-methyl-amino]-N-(1 -hydroxymethyl- cyclohexylmethyl)-benzamide;
2-Chloro-N-(1-hydroxymethyl-cyclohexylmethyl)-5-[methyl-(2-oxo-2,3-dihydro-pyrimidin-4- yl)-amino]-benzamide;
2-Chloro-5-[(2-chloro-pyrimidin-4-yl)-methyl-amino]-N-(4,4-difluoro-1-hydroxy- cyclohexylmethyl)-benzamide;
2-Chloro-N-(4,4-difluoro-1 -hydroxy-cyclohexylmethyl)-5-[methyl-(2-oxo-2,3-dihydro- pyrimidin-4-yl)-amino]-benzamide;
2-Chloro-N-((R)-1-cyclohexyl-ethyl)-5-(2-methylsulfanyl-pyrimidin-4-ylamino)-benzamide; 2-Chloro-N-((S)-1 -cyclohexyl-2-hydroxy-ethyl)-5-(2-methylsulfanyl-pyrimidin-4-ylamino)- benzamide;
2-Chloro-N-(1 -hydroxy-cycloheptylmethyl)-5-(2-methylsulfanyl-pyrimidin-4-ylamino)- benzamide;
2-Chloro-5-[(2,6-dichloro-pyrimidin-4-yl)-methyl-amino]-N-(1 -hydroxy-cyclohexylmethyl)- benzamide;
2-Chloro-5-[(6-chloro-2-methoxy-pyrimidin-4-yl)-methyl-amino]-N-(1 -hydroxy- cyclohexylmethyl)-benzamide;
2-Chloro-5-[(6-chloro-2-oxo-1 ,2-dihydro-pyrimidin-4-yl)-methyl-amino]-N-(1-hydroxy- cyclohexylmethyl)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[methyl-(6-methylsulfanyl-pyrimidin-4-yl)- amino]-benzamide; 2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[(6-methanesulfonyl-pyrimidin-4-yl)-m amino]-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[(6-methoxy-pyrimidin-4-yl)-methyl-amino]- benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[methyl-(6-oxo-1 ,6-dihydro-pyrimidin-4-yl)- amino]-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(pyrimidin-2-ylamino)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(methyl-pyrimidin-2-yl-amino)-benzamide; 2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[(2-methoxy-ethyl)-pyrimidin-2-yl-amino]- benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(4-methylsulfanyl-pyrimidin-2-ylamino)- benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[methyl-(4-methylsulfanyl-pyrimidin-2-yl)- amino]-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[(4-methoxy-pyrimidin-2-yl)-methyl-amino]- benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[methyl-(6-oxo-1 ,6-dihydro-pyrimidin-2-yl)- amino]-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(pyrimidin-5-ylamino)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[(2-methoxy-ethyl)-pyrimidin-5-yl-amino]- benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(pyrazin-2-ylamino)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(methyl-pyrazin-2-yl-amino)-benzamide; 2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[(2-methoxy-ethyl)-pyrazin-2-yl-amino]- benzamide;
2-Chloro-5-[(6-chloro-pyrazin-2-yl)-methyl-amino]-N-(1-hydroxy-cyclohexylmethyl)- benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[(6-methoxy-pyrazin-2-yl)-methyl-amino]- benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[methyl-(6-methylamino-pyrazin-2-yl)-amino] benzamide;
2-Chloro-5-[(6-dimethylamino-pyrazin-2-yl)-methyl-amino]-N-(1 -hydroxy- cyclohexylmethyl)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[methyl-(6-oxo-1 ,6-dihydro-pyrazin-2-yl)- amino]-benzamide; 2-Chloro-5-[(3-chloro-pyrazin-2-yl)-methyl-amino]-N-(1-hydroxy-cyclohexylmethyl)- benzamide;
2-Chloro-5-[(5-chloro-pyrazin-2-yl)-methyl-amino]-N-(1-hydroxy-cyclohexylmethyl)- benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[(5-methoxy-pyrazin-2-yl)-methyl-amino]- benzamide;
2-Chloro-5-[(6-chloro-pyridazin-3-yl)-methyl-amino]-N-(1 -hydroxy-cyclohexylmethyl)- benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[methyl-(6-oxo-1 ,6-dihydro-pyridazin-3-yl)- amino]-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[(6-methoxy-pyridazin-3-yl)-methyl-amino]- benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(pyridin-2-ylamino)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(methyl-pyridin-2-yl-amino)-benzamide; 2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(6-oxo-1 ,6-dihydro-pyridin-2-ylamino)- benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[methyl-(6-oxo-1 ,6-dihydro-pyridin-2-yl)- amino]-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(1-methyl-6-oxo-1 ,6-dihydro-pyridin-2- ylamino)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[1 -(2-methoxy-ethyl)-6-oxo-1 ,6-dihydro- pyridin-2-ylamino]-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-{[1 -(2-methoxy-ethyl)-6-oxo-1 ,6-dihydro- pyridin-2-yl]-methyl-amino}-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(1-methyl-2-oxo-1 ,2-dihydro-pyridin-3- ylamino)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(2-methyl-2H-pyrazol-3-ylamino)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[methyl-(2-methyl-2H-pyrazol-3-yl)-amino]- benzamide;
2-Chloro-5-(6-fluoro-pyridin-2-yloxy)-N-(1-hydroxy-cyclohexylmethyl)-benzamide;
2-Chloro-5-(4-fluoro-pyridin-2-yloxy)-N-(1-hydroxy-cyclohexylmethyl)-benzamide;
2-Chloro-5-(2-chloro-pyridin-4-yloxy)-N-(1-hydroxy-cyclohexylmethyl)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(pyridin-2-yloxy)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(pyridin-4-yloxy)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(pyridin-3-yloxy)-benzamide; 2-Chloro-5-(6-chloro-pyridin-2-yloxy)-N-(1-hydroxy-cyclohexylmethyl)-benzami
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(6-methylamino-pyridin-2-yloxy)-benzamid 2-Chloro-5-(6-dimethylamino-pyridin-2-yloxy)-N-(1 -hydroxy-cyclohexylmethyl)-benzami 2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(6-methoxy-pyridin-2-yloxy)-benzamide; 2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(6-oxo-1 ,6-dihydro-pyridin-2-yloxy)- benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(1 -methyl-6-oxo-1 ,6-dihydro-pyridin-2-yloxy)- benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(pyrimidin-4-yloxy)-benzamide;
2-Chloro-5-(2-chloro-pyrimidin-4-yloxy)-N-(1-hydroxy-cyclohexylmethyl)-benzamide; 2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(2-methylamino-pyrimidin-4-yloxy)- benzamide;
2-Chloro-5-(2-dimethylamino-pyrimidin-4-yloxy)-N-(1-hydroxy-cyclohexylmethyl)- benzamide;
2-Chloro-N-(4,4-difluoro-1 -hydroxy-cyclohexylmethyl)-5-(2-oxo-1 ,2-dihydro-pyrimidin-4- yloxy)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(2-oxo-2,3-dihydro-pyrimidin-4-yloxy)- benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(2-methoxy-pyrimidin-4-yloxy)-benzamide; 2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(pyrazin-2-yloxy)-benzamide;
2-Chloro-5-(6-chloro-pyrazin-2-yloxy)-N-(1-hydroxy-cyclohexylmethyl)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(6-methoxy-pyrazin-2-yloxy)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(6-methylamino-pyrazin-2-yloxy)-benzamide;
2-Chloro-5-(6-dimethylamino-pyrazin-2-yloxy)-N-(1 -hydroxy-cyclohexylmethyl)- benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(6-oxo-1 ,6-dihydro-pyrazin-2-yloxy)- benzamide;
2-Chloro-5-(6-chloro-pyridazin-3-yloxy)-N-(1-hydroxy-cyclohexylmethyl)-benzamide; 2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(6-methoxy-pyridazin-3-yloxy)-benzamide; 2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(6-oxo-1 ,6-dihydro-pyridazin-3-yloxy)- benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(pyridazin-3-yloxy)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(5-methoxy-pyridazin-3-yloxy)-benzamide; 2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(pyridin-2-ylsulfanyl)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(pyridine-2-sulfinyl)-benzamide; 2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(pyridine-2-sulfonyl)-benzamide;
2-Chloro-5-(2-chloro-pyrimidin-4-ylsulfanyl)-N-(1 -hydroxy-cyclohexylmethyl)-benzamide; 2-Chloro-5-(2-chloro-pyrimidine-4-sulfinyl)-N-(1 -hydroxy-cyclohexylmethyl)-benzamide; 2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(2-oxo-1 ,2-dihydro-pyrimidin-4-ylsulfanyl)- benzamide;
2-Chloro-N-(4,4-difluoro-1 -hydroxy-cyclohexylmethyl)-5-(2-oxo-1 ,2-dihydro-pyrimidin-4- ylsulfanyl)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(2-methoxy-pyrimidin-4-ylsulfanyl)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(2-methoxy-pyrimidine-4-sulfinyl)-benzamide; 2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(2-methoxy-pyrimidine-4-sulfonyl)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(2-oxo-2H-pyridin-1-ylmethyl)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(2-oxo-2H-pyrimidin-1-ylmethyl)-benzamide;
2-Chloro-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1 -ylmethyl)-N-(1-hydroxy- cyclohexylmethyl)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-pyridin-2-ylmethyl-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(2-methylsulfanyl-pyrimidin-4-ylmethyl)- benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(2-oxo-1 ,2-dihydro-pyrimidin-4-ylmethyl)- benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(2-methoxy-pyrimidin-4-ylmethyl)-benzamide; 2-Chloro-N-(4,4-difluoro-1 -hydroxy-cyclohexylmethyl)-5-(2-oxo-1 ,2-dihydro-pyrimidin-4- ylmethyl)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(2-oxo-1 ,2-dihydro-pyrimidine-4-carbonyl)- benzamide;
2-Chloro-5-[difluoro-(2-oxo-1 ,2-dihydro-pyrimidin-4-yl)-methyl]-N-(1 -hydroxy- cyclohexylmethyl)-benzamide;
2-Chloro-5-[fluoro-(2-oxo-1 ,2-dihydro-pyrimidin-4-yl)-methyl]-N-(1 -hydroxy- cyclohexylmethyl)-benzamide;
5-[(2-Chloro-pyrimidin-4-yl)-methyl-amino]-N-(1-hydroxy-cyclohexylmethyl)-2-methyl- benzamide;
N-(1 -Hydroxy-cyclohexylmethyl)-5-[(2-methoxy-pyrimidin-4-yl)-methyl-amino]-2-m benzamide; and
N-(1 -Hydroxy-cyclohexylmethyl)-2-methyl-5-[methyl-(2-oxo-1 ,2-dihydro-pyrimidin-4-yl)- amino]-benzamide;
or salts (in particular pharmaceutically acceptable salts) of such compounds; it is to be understood for any of the above listed compounds, that a stereogenic center, which is not specifically assigned, may be in absolute (R)- or absolute (S)-configuration.
55) Further preferred compounds of formula (I) as defined in embodiment 1 ) are selected from the group consisting of:
2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-[1-hydroxy-1 -(2-OXO-1 ,2-dihydro-pyrimidin-4- yl)-ethyl]-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[(1 S)-1 -hydroxy-1 -(2-0X0-1 ,2-dihydro- pyrimidin-4-yl)-ethyl]-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[(1 R)-1-hydroxy-1 -(2-oxo-1 ,2-dihydro- pyrimidin-4-yl)-ethyl]-benzamide; and
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[1 -hydroxy-1-(2-methoxy-pyrimidin-4-yl)- ethyl]-benzamide;
or salts (in particular pharmaceutically acceptable salts) of such compounds;
it is to be understood for any of the above listed compounds, that a stereogenic center, which is not specifically assigned, may be in absolute (R)- or absolute (S)-configuration.
The present invention also includes isotopically labelled, especially 2H (deuterium) labelled compounds of formula (I), which compounds are identical to the compounds of formula (I) except that one or more atoms have each been replaced by an atom having the same atomic number but an atomic mass different from the atomic mass usually found in nature. Isotopically labelled, especially 2H (deuterium) labelled compounds of formula (I) and salts thereof are within the scope of the present invention. Substitution of hydrogen with the heavier isotope 2H (deuterium) may lead to greater metabolic stability, resulting e.g. in increased in-vivo half-life or reduced dosage requirements, or may lead to reduced inhibition of cytochrome P450 enzymes, resulting e.g. in an improved safety profile. In one embodiment of the invention, the compounds of formula (I) are not isotopically labelled, or they are labelled only with one or more deuterium atoms. In a sub-embodiment, the compounds of formula (I) are not isotopically labelled at all. Isotopically labelled compounds of formula (I) may be prepared in analogy to the methods described hereinafter, but using the appropriate isotopic variation of suitable reagents or starting materials.
The term "pharmaceutically acceptable salts" refers to non-toxic, inorganic or organic acid and/or base addition salts, Lit. e.g. "Salt selection for basic drugs", Int. J. Pharm. (1986), 33, 201-217. Where the plural form is used for compounds, salts, pharmaceutical compositions, diseases and the like, this is intended to mean also a single compound, salt, or the like.
The compounds of formula (I) according to any one of embodiments 1 ) to 55), or pharmaceutically acceptable salts thereof, are suitable for use as medicaments. In particular, compounds of formula (I) modulate the P2X7 receptor, i.e. they act as P2X7 receptor antagonists, and are useful for the prevention or treatment of diseases which are associated with the activation of the P2X7 receptor such as pain; neurodegenerative and neuroinflammatory diseases; bone and joint diseases; obstructive diseases of the airways; cardiovascular diseases; eye diseases; skin diseases; abdominal and gastrointestinal tract diseases; genitourinary diseases; cancer; other auto-immune and allergic disorders; and other disorders with an inflammatory or immunological component.
In particular, the compounds of formula (I) according to any one of embodiments 1 ) to 55), or pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of pain. Pain refers to acute pain; chronic pain; pain associated with sprains and strains; chronic articular pain; pain associated with rheumatic fever; musculoskeletal pain; lower back and neck pain; inflammatory pain; neuropathic pain; visceral pain; pain associated with influenza or other viral infections; pain associated with cancer and tumor invasion; joint and bone pain; atypical facial pain; pain associated with migraine, toothache and dysmenorrhea; headache including tension headache and cluster headaches; pain associated with myocardial ischemia; pain associated with functional bowel disorders; sympathetically maintained pain; myositis; pain associated with cancer chemotherapy; and post operative pain.
Neuropathic pain includes especially diabetic neuropathy, sciatica, non-specific lower back pain, trigeminal neuralgia, multiple sclerosis pain, fibromyalgia, HIV-related neuropathy, post-herpetic neuralgia, trigeminal neuralgia, and pain resulting from physical trauma, amputation, phantom limb syndrome, spinal surgery, cancer, toxins or chronic inflammatory conditions. In addition, neuropathic pain conditions include pain associated with normally non-painful sensations such as "pins and needles" (paraesthesias and dysesthesias), increased sensitivity to touch (hyperesthesia), painful sensation following innocuous stimulation (dynamic, static, thermal or cold allodynia), increased sensitivity to noxious stimuli (thermal, cold, mechanical hyperalgesia), continuing pain sensation after removal of the stimulation (hyperpathia) or an absence of or deficit in selective sensory pathways (hypoalgesia).
Chronic articular pain conditions include especially rheumatoid arthritis, osteoarthritis, rheumatoid spondylitis, gouty arthritis and juvenile arthritis. Pain associated with functional bowel disorders includes especially non-ulcer dyspepsia, non-cardiac chest pain and irritable bowel syndrome.
Further, the compounds of formula (I) according to any one of embodiments 1 ) to 55), or pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of neurodegenerative and neuroinflammatory diseases. Neurodegenerative and neuro- inflammatory diseases include Alzheimer's disease and other dementing disorders including, but not limited to, Creutzfeldt-Jakob disease (CJD) and new variant Creutzfeldt-Jakob disease (nvCJD); Amyotrophic lateral sclerosis, amyloidosis; multiple sclerosis and other demyelinating syndromes; cerebral atherosclerosis and vasculitis; temporal arteritis; myasthenia gravis; Huntington's disease; Lewy Body dementia; and Parkinson's disease.
Further, the compounds of formula (I) according to any one of embodiments 1 ) to 55), or pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of bone and joint diseases. Bone and joint diseases include arthritides such as rheumatoid arthritis, osteoarthritis, gout or crystal arthropathy; intervertebral disc degeneration; temporomandibular joint degeneration; bone remodelling disease such as osteoporosis, Paget's disease or osteonecrosis; polychondritis; scleroderma; mixed connective tissue disorder; spondyloarthropathies; periodontal disease such as periodontitis; arthritides associated with or including osteoarthritis/osteoarthrosis, both primary and secondary to, for example, congenital hip dysplasia; cervical and lumbar spondylitis; Still's disease; seronegative spondyloarthropathies including ankylosing spondylitis, psoriatic arthritis, reactive arthritis and undifferentiated spondyloarthropathy; septic arthritis and other infection-related arthopathies and bone disorders such as tuberculosis, including Potts' disease and Poncet's syndrome; acute and chronic crystal-induced synovitis including urate gout, calcium pyrophosphate deposition disease, and calcium apatite related tendon, bursal and synovial inflammation; Behcet's disease; primary and secondary Sjogren's syndrome; systemic sclerosis and limited scleroderma; systemic lupus erythematosus, mixed connective tissue disease, and undifferentiated connective tissue disease; inflammatory myopathies including dermatomyositits and polymyositis; polymalgia rheumatica; juvenile arthritis including idiopathic inflammatory arthritides of whatever joint distribution and associated syndromes, and rheumatic fever and its systemic complications; vasculitides including giant cell arteritis, Takayasu's arteritis, Churg-Strauss syndrome, polyarteritis nodosa, microscopic polyarteritis, and vasculitides associated with viral infection, hypersensitivity reactions, cryoglobulins, and paraproteins; Familial Mediterranean fever, Muckle-Wells syndrome, and Familial Hibernian Fever, Kikuchi disease; and drug-induced arthalgias, tendonitis, and myopathies including dystrophies and other inflammatory myopathies.
Further, the compounds of formula (I) according to any one of embodiments 1 ) to 55), or pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of obstructive diseases of the airways. Obstructive diseases of the airways include asthma, including bronchial, allergic, intrinsic, and extrinsic asthma, exercise-induced, drug- induced (including aspirin and NSAID-induced) and dust- induced asthma, both intermittent and persistent and of all severities, and other causes of airway hyper- responsiveness; chronic obstructive pulmonary disease (COPD); bronchitis, including infectious and eosinophilic bronchitis; emphysema; bronchiectasis; cystic fibrosis; sarcoidosis; farmer's lung and related diseases; hypersensitivity pneumonitis; lung fibrosis, including cryptogenic fibrosing alveolitis, idiopathic interstitial pneumonias, fibrosis complicating anti-neoplastic therapy and chronic infection, including tuberculosis and aspergillosis and other fungal infections; complications of lung transplantation; vasculitic and thrombotic disorders of the lung vasculature, and pulmonary hypertension; antitussive activity including treatment of chronic cough associated with inflammatory and secretory conditions of the airways, and iatrogenic cough; acute and chronic rhinitis including rhinitis medicamentosa, and vasomotor rhinitis; perennial and seasonal allergic rhinitis including rhinitis nervosa (hay fever); nasal polyposis; and acute viral infection including the common cold, and infection due to respiratory syncytial virus, influenza, coronavirus (including SARS) and adenovirus.
Further, the compounds of formula (I) according to any one of embodiments 1 ) to 55), or pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of cardiovascular diseases. Cardiovascular diseases include atherosclerosis, affecting the coronary and peripheral circulation; pericarditis; myocarditis; inflammatory and autoimmune cardiomyopathies including myocardial sarcoid; ischaemic reperfusion injuries; endocarditis, valvulitis, and aortitis including infective (for example syphilitic); vasculitides; and disorders of the proximal and peripheral veins including phlebitis and thrombosis, including deep vein thrombosis and complications of varicose veins.
Further, the compounds of formula (I) according to any one of embodiments 1 ) to 55), or pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of eye diseases. Eye diseases include blepharitis; conjunctivitis, including perennial and vernal allergic conjunctivitis; iritis; anterior and posterior uveitis; choroiditis; autoimmune, degenerative or inflammatory disorders affecting the retina; ophthalmitis including sympathetic ophthalmitis; sarcoidosis; and infections of the eyes including viral , fungal, and bacterial infections.
Further, the compounds of formula (I) according to any one of embodiments 1 ) to 55), or pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of skin diseases. Skin diseases include psoriasis, skin burn, atopic dermatitis, contact dermatitis or other eczematous dermatoses, and delayed-type hypersensitivity reactions; phyto- and photodermatitis; seborrhoeic dermatitis, dermatitis herpetiformis, lichen planus, lichen sclerosus et atrophica, pyoderma gangrenosum, skin sarcoid, discoid lupus erythematosus, pemphigus, pemphigoid, epidermolysis bullosa, urticaria, angioedema, vasculitides, toxic erythemas, cutaneous eosinophilias, alopecia areata, male-pattern baldness, Sweet's syndrome, Weber-Christian syndrome, erythema multiforme; cellulitis, both infective and non-infective; panniculitis; cutaneous lymphomas, non-melanoma skin cancer and other dysplastic lesions; and drug-induced disorders including fixed drug eruptions.
Further, the compounds of formula (I) according to any one of embodiments 1 ) to 55), or pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of abdominal and gastrointestinal tract diseases. Abdominal and gastrointestinal tract diseases include hepatitis, including autoimmune, alcoholic and viral hepatitis; fibrosis and cirrhosis of the liver; cholecystitis; pancreatitis, both acute and chronic; non-inflammatory diarrhea; glossitis, gingivitis, periodontitis; oesophagitis, including reflux; eosinophilic gastro-enteritis, mastocytosis, Crohn's disease, colitis including ulcerative colitis, proctitis, pruritis ani; Coeliac disease, irritable bowel disease/syndrome, and food-related allergies which may have effects remote from the gut, for example migraine, rhinitis or eczema; allograft rejection including acute and chronic allograft rejection following, for example, transplantation of kidney, heart, liver, lung, bone marrow, skin or cornea or following blood transfusion; and chronic graft versus host disease;
Further, the compounds of formula (I) according to any one of embodiments 1 ) to 55), or pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of genitourinary diseases. Genitourinary diseases include nephritis including interstitial and glomerulonephritis; nephrotic syndrome; cystitis including acute and chronic (interstitial) cystitis and Hunner's ulcer; acute and chronic urethritis, prostatitis, epididymitis, oophoritis and salpingitis; vulvovaginitis; Peyronie's disease; and erectile dysfunction, both male and female. Further, the compounds of formula (I) according to any one of embodiments 1 ) to 55), or pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of cancer. The treatment of cancer includes the treatment of brain tumors, prostate, lung, breast, ovarian, bowel and colon, stomach, pancreatic, skin and bone marrow (including leukaemias) and lymphoproliferative systems, such as non-Hodgkin's and Hodgkin's lymphoma; including the prevention and treatment of metastatic disease and tumor recurrences, and paraneoplastic syndromes.
Further, the compounds of formula (I) according to any one of embodiments 1 ) to 55), or pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of other auto-immune and allergic disorders. Other auto-immune and allergic disorders include Hashimoto's thyroiditis, Graves' disease, Addison's disease, diabetes mellitus, idiopathic thrombocytopaenic purpura, eosinophilic fasciitis, hyper-lgE syndrome, and antiphospholipid syndrome.
Further, the compounds of formula (I) according to any one of embodiments 1 ) to 55), or pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of other disorders with an inflammatory or immunological component. Other disorders with an inflammatory or immunological component include acquired immune deficiency syndrome (AIDS), leprosy, Sezary syndrome, and paraneoplastic syndromes.
Further, the compounds of formula (I) according to any one of embodiments 1 ) to 55), or pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of mood, sleep and anxiety disorders.
Further, the compounds of formula (I) according to any one of embodiments 1 ) to 55), or pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of injury induced trauma and spinal cord injury.
Especially, compounds of formula (I) according to any one of embodiments 1 ) to 55), or pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of diseases selected from one, several or all of the following groups of diseases and disorders:
1 ) Pain, wherein pain refers to acute pain; chronic pain; pain associated with sprains and strains; chronic articular pain; pain associated with rheumatic fever; musculoskeletal pain; lower back and neck pain; inflammatory pain; neuropathic pain; visceral pain; pain associated with influenza or other viral infections; pain associated with cancer and tumor invasion; joint and bone pain; atypical facial pain; pain associated with migraine, toothache and dysmenorrhea; headache including tension headache and cluster headaches; pain associated with myocardial ischemia; pain associated with functional bowel disorders; sympathetically maintained pain; myositis; pain associated with cancer chemotherapy; and post operative pain;
Neuropathic pain includes especially diabetic neuropathy, sciatica, non-specific lower back pain, trigeminal neuralgia, multiple sclerosis pain, fibromyalgia, HIV- related neuropathy, post-herpetic neuralgia, trigeminal neuralgia, and pain resulting from physical trauma, amputation, phantom limb syndrome, spinal surgery, cancer, toxins or chronic inflammatory conditions. In addition, neuropathic pain conditions include pain associated with normally non-painful sensations such as "pins and needles" (paraesthesias and dysesthesias), increased sensitivity to touch (hyperesthesia), painful sensation following innocuous stimulation (dynamic, static, thermal or cold allodynia), increased sensitivity to noxious stimuli (thermal, cold, mechanical hyperalgesia), continuing pain sensation after removal of the stimulation (hyperpathia) or an absence of or deficit in selective sensory pathways
(hypoalgesia);
Chronic articular pain conditions include especially rheumatoid arthritis, osteoarthritis, rheumatoid spondylitis, gouty arthritis and juvenile arthritis;
Pain associated with functional bowel disorders includes especially non-ulcer dyspepsia, non-cardiac chest pain and irritable bowel syndrome;
) Neurodegenerative and neuro-inflammatory diseases such as Alzheimer's disease and other dementing disorders including, but not limited to, Creutzfeldt-Jakob disease (CJD) and new variant Creutzfeldt-Jakob disease (nvCJD); amyloidosis; Amyotrophic lateral sclerosis, multiple sclerosis and other demyelinating syndromes; cerebral atherosclerosis and vasculitis; temporal arteritis; myasthenia gravis; Huntington's disease; Lewy Body dementia; and Parkinson's disease;
) Bone and joint diseases such as arthritides such as rheumatoid arthritis, osteoarthritis, gout or crystal arthropathy; intervertebral disc degeneration; temporomandibular joint degeneration; bone remodelling disease such as osteoporosis, Paget's disease or osteonecrosis; polychondritis; scleroderma; mixed connective tissue disorder; spondyloarthropathies; periodontal disease such as periodontitis; Behcet's disease; primary and secondary Sjogren's syndrome; systemic sclerosis and limited scleroderma; systemic lupus erythematosus, mixed connective tissue disease, and undifferentiated connective tissue disease; inflammatory myopathies including dermatomyositits and polymyositis; polymalgia rheumatica; juvenile arthritis including idiopathic inflammatory arthritides of whatever joint distribution and associated syndromes, and rheumatic fever and its systemic complications; vasculitides including giant cell arteritis, Takayasu's arteritis, Churg-Strauss syndrome, polyarteritis nodosa, microscopic polyarteritis, and vasculitides associated with viral infection, hypersensitivity reactions, cryoglobulins, and paraproteins; Muckle-Wells syndrome, and Familial Hibernian Fever, Kikuchi disease; and drug-induced arthalgias, tendonitis, and myopathies;
4) Obstructive diseases of the airways such as chronic obstructive pulmonary disease (COPD); cystic fibrosis; lung emphysema; sarcoidosis; farmer's lung and related diseases; lung fibrosis, including fibrosis complicating tuberculosis; and chronic cough associated with inflammatory and secretory conditions of the airways;
5) Cardiovascular diseases such as inflammatory and auto-immune cardiomyopathies;
6) Eye diseases such as degenerative or inflammatory disorders affecting the retina;
7) Skin diseases such as psoriasis, skin burn, atopic dermatitis, contact dermatitis or other eczematous dermatoses; and discoid lupus erythematosus;
8) Abdominal and gastrointestinal tract diseases such as fibrosis and cirrhosis of the liver; cholecystitis; pancreatitis, both acute and chronic; Crohn's disease; colitis including ulcerative colitis; and irritable bowel disease/syndrome;
9) Genitourinary diseases such as nephritis including interstitial and glomerulonephritis; nephrotic syndrome; and cystitis including acute and chronic (interstitial) cystitis; and
10) Other auto-immune and allergic disorders such as Hashimoto's thyroiditis, Graves' disease, Addison's disease, diabetes mellitus, idiopathic thrombocytopaenic purpura, eosinophilic fasciitis, hyper-lgE syndrome, and antiphospholipid syndrome.
Most preferably, compounds of formula (I) according to any one of embodiments 1 ) to 55), or pharmaceutically acceptable salts thereof, are suitable for the prevention or treatment of diseases selected from one, several or all of the following groups of diseases and disorders:
1 ) Pain, wherein pain refers to acute pain; chronic pain; pain associated with sprains and strains; chronic articular pain; pain associated with rheumatic fever; musculoskeletal pain (preferred); lower back and neck pain; inflammatory pain; neuropathic pain (preferred); visceral pain; pain associated with influenza or other viral infections; pain associated with cancer and tumor invasion; joint and bone pain; atypical facial pain; pain associated with migraine, toothache and dysmenorrhea; headache including tension headache and cluster headaches; pain associated with myocardial ischemia; pain associated with functional bowel disorders; sympathetically maintained pain; myositis; pain associated with cancer chemotherapy; and post operative pain;
Neuropathic pain includes especially diabetic neuropathy, sciatica, non-specific lower back pain, trigeminal neuralgia, multiple sclerosis pain, fibromyalgia, HIV- related neuropathy, post-herpetic neuralgia, trigeminal neuralgia, and pain resulting from physical trauma, amputation, phantom limb syndrome, spinal surgery, cancer, toxins or chronic inflammatory conditions. In addition, neuropathic pain conditions include pain associated with normally non-painful sensations such as "pins and needles" (paraesthesias and dysesthesias), increased sensitivity to touch (hyperesthesia), painful sensation following innocuous stimulation (dynamic, static, thermal or cold allodynia), increased sensitivity to noxious stimuli (thermal, cold, mechanical hyperalgesia), continuing pain sensation after removal of the stimulation (hyperpathia) or an absence of or deficit in selective sensory pathways (hypoalgesia);
Chronic articular pain conditions include especially rheumatoid arthritis, osteoarthritis, rheumatoid spondylitis, gouty arthritis and juvenile arthritis;
Pain associated with functional bowel disorders includes especially non-ulcer dyspepsia, non-cardiac chest pain and irritable bowel syndrome;
2) Rheumatoid arthritis and osteoarthritis;
3) Chronic obstructive pulmonary disease (COPD); and
4) Crohn's disease.
The invention also relates to the use of a compound of formula (I) according to any one of embodiments 1 ) to 55) for the preparation of pharmaceutical compositions for the treatment and/or prophylaxis of the above-mentioned diseases.
The present invention also relates to pharmaceutically acceptable salts and to pharmaceutical compositions and formulations of compounds of formula (I) according to any one of embodiments 1 ) to 55).
A pharmaceutical composition according to the present invention contains at least one compound of formula (I) according to any one of embodiments 1 ) to 55) (or a pharmaceutically acceptable salt thereof) as the active agent and optionally carriers and/or diluents and/or adjuvants.
The compounds of formula (I) according to any one of embodiments 1 ) to 55) and their pharmaceutically acceptable salts can be used as medicaments, e.g. in the form of pharmaceutical compositions for enteral (such especially oral) or parenteral administration (including topical application or inhalation).
The production of the pharmaceutical compositions can be effected in a manner which will be familiar to any person skilled in the art (see for example Remington, The Science and Practice of Pharmacy, 21 st Edition (2005), Part 5, "Pharmaceutical Manufacturing" [published by Lippincott Williams & Wilkins]) by bringing the described compounds of formula (I) or their pharmaceutically acceptable salts, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, therapeutically compatible solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants.
The present invention also relates to a method for the prevention or treatment of a disease or disorder mentioned herein comprising administering to a subject a pharmaceutically active amount of a compound of formula (I) according to any one of embodiments 1 ) to 55), or a pharmaceutically acceptable salt thereof.
Any reference to a compound of formula (I) in this text is to be understood as referring also to the salts (and especially the pharmaceutically acceptable salts) of such compounds, as appropriate and expedient. The preferences indicated for the compounds of formula (I) of course apply mutatis mutandis to the salts and pharmaceutically acceptable salts of the compounds of formula (I). The same applies to these compounds as medicaments, to pharmaceutical compositions containing these compounds as active principles or to the uses of these compounds for the manufacture of a medicament for the treatment of the diseases according to this invention.
Unless used regarding temperatures, the term "about" (or alternatively "around") placed before a numerical value "X" refers in the current application to an interval extending from X minus 10% of X to X plus 10% of X, and preferably to an interval extending from X minus 5% of X to X plus 5% of X. In the particular case of temperatures, the term "about" (or alternatively "around") placed before a temperature "Y" refers in the current application to an interval extending from the temperature Y minus 10 °C to Y plus 10 °C, and preferably to an interval extending from Y minus 5 °C to Y plus 5 °C. Besides, the term "room temperature" (rt) as used herein refers to a temperature of about 25°C.
Whenever the word "between" is used to describe a numerical range, it is to be understood that the end points of the indicated range are explicitly included in the range. For example: if a temperature range is described to be between 40 °C and 80 °C, this means that the end points 40 °C and 80 °C are included in the range; or if a variable is defined as being an integer between 1 and 4, this means that the variable is the integer 1 , 2, 3, or 4.
The compounds of Formula (I) can be manufactured by the methods given below, by the methods given in the Examples or by analogous methods. Optimum reaction conditions may vary with the particular reactants or solvents used, but such conditions can be determined by a person skilled in the art by routine optimisation procedures.
If not indicated otherwise, the generic groups R1, R2, R3, R4, R5, R6, R7, R8, R9, n and Y are as defined for formula (I). Other abbreviations used are defined in the experimental section.
In some instances the generic groups R1, R2, R3, R4, R5, R6, R7, R8, R9, n and Y might be incompatible with the assembly illustrated in the schemes below and will therefore require the use of protecting groups (PG). The use of protecting groups is well known in the art (see for example "Protective Groups in Organic Synthesis", T.W. Greene, P.G.M. Wuts, Wiley-lnterscience, 1999). For the purposes of this discussion, it will be assumed that such protecting groups are as necessary in place.
A. Synthesis of final products
Compounds of formula la and lb wherein Y represents NR9 can be prepared following the procedures outlined in Scheme 1 below.
The compounds of formula V can be prepared (Scheme 1 ) by a Buchwald-Hartwig type of reaction, using a commercially available iodide of formula VII (or a commercially available aniline of formula VIII, respectively) and an aniline of formula R1-NH2 (or a halide, preferably an iodide of formula R1-X, respectively), in the presence of a suitable palladium catalyst such as palladium(ll) acetate or tris(dibenzylideneacetone) dipalladium, in the presence of a suitable ligand such as 2,2'-bis(diphenylphosphino)-1 , 1 '- binaphthalene or 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene, in the presence of a suitable base such as Cs2C03 or sodium phenoxide and heating in a suitable solvent such as dioxane at a temperature between 90°C and 120°C. The compounds of formula VI can be prepared (Scheme 1 ) by alkylation of a compound of formula V using an appropriate alkyl iodide or bromide of formula R9-X, in the presence of a suitable base such as Cs2C03 or potassium carbonate and in the presence of a suitable organic solvent such as DMF or THF, preferably at a temperature between RT and 60°C. The compounds of formula III (or IV, respectively) can be prepared (Scheme 1 ) by hydrolysis of a compound of formula V (or VI, respectively) using standard conditions such as NaOH or LiOH in a mixture of water and a suitable organic solvent such as THF, MeOH or EtOH, preferably at a temperature between RT and 45°C.
The compounds of formula la (or lb, respectively) can be prepared (Scheme 1 ) by coupling an acid of formula III (or IV, respectively) with an amine of formula II using standard amide coupling reagents such as TBTU, EDC.HCI / HOBT, HATU, PyBOP or PyCloP in the presence of a suitable base such as NEt3 or DIPEA and in a suitable solvent such as DCM, THF or DMF, preferably at a temperature between RT and 45°C.
Alternatively, the compounds of formula lb can be prepared (Scheme 1 ) by alkylation of a compound of formula la with an appropriate alkyl iodide or bromide of formula R9-X using standard conditions such as a suitable base (preferably Cs2C03) and a suitable organic solvent such as DMF or THF, preferably at a temperature between RT and 45°C.
Figure imgf000043_0001
Scheme 1 : Y represents NR9 Compounds of formula lc, wherein Y represents O or S, Id and le can be prepared following the procedures outlined in Scheme 2 below.
The compounds of formula IX can be prepared (Scheme 2) by an aromatic nucleophilic substitution of a commercially available phenol or thiophenol, respectively of formula XI with a halide (preferably a bromide or iodide) of formula R1-X, in the presence of a suitable base such as Cs2C03 and heating in a suitable sovent such as DMSO at a temperature between 60°C and 1 10°C.
The compounds of formula lc can be prepared (Scheme 2) by coupling an acid of formula IX with an amine of formula II using standard amide coupling conditions such as those already described for the synthesis of the compounds of formula la and lb (Scheme 1 ).
The compounds of formula Id can be prepared (Scheme 2) by oxidation of a compound of formula lc, wherein Y represents S, using a suitable oxidating reagent such as 3- chloroperbenzoic acid in a suitable solvent such as DCM at a temperature around 0°C.
The compounds of formula le can be prepared (Scheme 2) by oxidation of a compound of formula lc, wherein Y represents S, using a suitable oxidating reagent such as 3- chloroperbenzoic acid in a suitable solvent such as DCM at a temperature around RT.
Figure imgf000044_0001
Scheme 2: Y represents O or S Compounds of formula If and Ig, wherein Y represents C(R7R8), can be prepared following the procedures outlined in Scheme 3 below.
The compounds of formula XX can be prepared (Scheme 3) by bromination of a commercially available compound of formula XXI, wherein R2 represents chloro, using a suitable brominating reagent such as N-bromosuccinimide in the presence of a radical initiator such as 2,2'-azobis(2-methylpropionitrile) and heating in a suitable solvent such as chlorobenzene at a temperature between 90 and 120°C.
The compounds of formula XVIII can be prepared (Scheme 3) by coupling an acid of formula XX with an amine of formula II using standard amide coupling conditions such as EDC.HCI / HOBT, PyBOP in the presence of a suitable base such as DIPEA and in a suitable solvent such as DCM, preferably at a temperature between RT and 45°C. In such conditions, the consecutive substitution of the bromide atom in compound of formula XX with the 1 -oxy-benzotriazole group (-OBt) from HOBT is observed.
The compounds of formula If can be prepared (Scheme 3) by nucleophilic substitution of a heterocycle of formula XIX (wherein the letter codes a,b,c and d are selected as follows a=b=c=d=CH; or a=N and b=c=d=CH; or a=N, b=COH and c=d=CH) with a 1 -oxy- benzotriazole activated compound of formula XVIII, in the presence of a suitable base such as potassium carbonate or Cs2C03 and heating in a suitable solvent such as DMF or 1 ,2-dimethoxyethane at a temperature around 90°C.
The compounds of formula XVI can be prepared (Scheme 3) by esterification of compounds of formula XX using standard conditions such as heating in a suitable solvent such as MeOH in the presence of a suitable acid such as sulphuric acid at a temperature around 70°C.
The compounds of formula XVII, wherein Z represents -CH2CN, can be prepared (Scheme 3) by nucleophilic substitution of a compound of formula XVI with a cyanide precursor such as trimethylsilylcyanide in the presence of a suitable base such as potassium carbonate or Cs2C03 and heating in a suitable solvent such as CH3CN at a temperature between RT and 60°C.
The compounds of formula XVII, wherein Z represents -CHO, can be prepared (Scheme 3) by an oxidative cleavage of a compound of formula XVI with an oxidative reagent such as 4-methylmorpholine-N-oxide and heating in a suitable solvent such as dioxane at a temperature around 100°C. The compounds of formula XIII can be prepared (Scheme 3) by a Negishi type reaction. The compound of formula XVI can be transformed into an organozinc reagent in the presence of preactivated zinc dust in a suitable solvent such as THF. The cross coupling reaction proceeds by the reaction of the organozinc reagent with a halide of formula R1-X, in the presence of a suitable palladium catalyst such as tetrakis(triphenylphosphine)palladium (0) or tris(dibenzylideneacetone)dipalladium, in the optional presence of a suitable ligand such as tri-2-furylphosphine and in a suitable solvent such as THF at a temperature around RT.
The compounds of formula XIV can be prepared (Scheme 3) by deprotonation of a cyanomethyl derivative of formula XVII, wherein Z represents -CH2CN, at the ocarbon atom with a base such as NaH in a suitable solvent such as DMF at a temperature around RT and subsequent reaction of the obtained anion with a halide of formula R1-X wherein R1 is a 2-chloro-pyrimidin-4-yl or 2-(2-(trimethylsilyl)ethoxy)-pyrimidin-4-yl group. The consecutive oxidative cleavage of the carbon-cyanide bond proceeds in the presence of atmospheric air and additional amounts of a suitable base such as NaH in a suitable solvent such as DMF at a temperature around RT.
Alternatively, the compounds of formula XIV can be prepared (Scheme 3) by an aroylation of a halide of formula R1-X wherein R1 is a 2-methoxy-pyrimidin-4-yl group by an aromatic adehyde of formula XVII, wherein Z represents -CHO, in the presence of an azolium salt such as 1 ,3-dimethylimidazolium iodide and a base such as NaH in a suitable solvent such as dioxane at a temperature around 100°C.
The compounds of formula XV, wherein R7 and/or R8 represent fluoro, can be prepared (Scheme 3) by the fluorination of a ketone of formula XIV, in the presence of a fluorinating reagent such as bis(2-methoxyethyl)aminosulfur trifluoride at a temperature around 90°C. Alternatively, the compounds of formula XV, wherein one of R7 or R8 represents hydrogen and the other represents fluoro, can be prepared (Scheme 3) by a two-step procedure. The ketone of formula XIV can be reduced using standard conditions such as NaBH4 in the presence of a suitable solvent such as MeOH at a temperature around RT. The resulting alcohol can be fluorinated using a fluorinating reagent such as bis(2- methoxyethyl)aminosulfur trifluoride in the presence of a suitable solvent such as DCM at a temperature around RT.
Alternatively, the compounds of formula XV, wherein one of R7 or R8 represents (C C4)alkyl and the other represents hydroxy, can be prepared (Scheme 3) by the addition of a Grignard reagent of formula R7-MgX or R8-MgX (wherein X represents a bromine or a chlorine atom) to the ketone of formula XIV in the presence of a suitable solvent such as THF or Et20 at a temperature between -15°C and RT.
The compounds of formula XII can be prepared (Scheme 3) by hydrolysis of a compound of formula XIII, XIV or XV using standard conditions such as those already described for the synthesis of the compounds of formula III and IV (Scheme 1 ).
The compounds of formula Ig can be prepared (Scheme 3) by coupling an acid of formula XII with an amine of formula II using standard amide coupling conditions such as those already described for the synthesis of the compounds of formula la and lb (Scheme 1 ).
Figure imgf000047_0001
Scheme 3: Y represents C(R7R8) Alternatively, compounds of formula li, Ij, Ik, Im, In and lo can be prepared following the procedures outlined in Scheme 4 below. In all the structures of the scheme, one of the letter code, a,b,c or d represents a carbon atom, which is attached to the rest of the molecule via the substituent Y, and the other remaining letter codes are selected from N, CH and CR10, wherein R10 represents chloro, to form a 6-membered heteroaryl or a heterocyclyl group R1 as defined above.
The compounds of formula Ih and li, wherein X represents chloro, can be prepared (Scheme 4) as previously described in Schemes 1 (compounds of formula la and lb), 2 (compounds of formula lc) and 3 (compounds of formula Ig).
The compounds of formula li wherein X represents S02CH3 can be prepared (Scheme 4) by oxidation of a compound of formula Ih in the presence of a suitable oxidating reagent such as 3-chloroperbenzoic acid and in the presence of a suitable solvent such as DCM at a temperature between 0°C and RT.
The compounds of formula Ij can be prepared (Scheme 4) by an aromatic nucleophilic substitution of a compound of formula li with a commercially available or freshly prepared solution of sodium alkoxide of formula NaOR11, wherein R11 represents (Ci-C4)alkyl, in the corresponding alcohol of formula HOR11, the reaction being carried out in the presence of a solvent such as the corresponding alcohol of formula HOR11 or THF at a temperature between 0°C and 90°C.
The compounds of formula Ik can be prepared (Scheme 4) by an aromatic nucleophilic substitution of a compound of formula li with an amine of formula HNR11R12, wherein R11 represents (Ci-C4)alkyl and R12 represents hydrogen or (Ci-C4)alkyl, optionally in the presence of a suitable base such as NEt3 or DIPEA and heating in a suitable solvent such as H20, THF, CH3CN or DMF at a temperature between RT and 120°C.
The compound of formula Im can be prepared (Scheme 4) by aromatic nucleophilic substitution of a compound of formula li with an aqueous sodium hydroxide solution and heating in a suitable solvent such as dioxane or THF at a temperature between RT and 100°C.
The compound of formula In (or lo, respectively) can be prepared (Scheme 4) by alkylation of a compound of formula Im wherein Y represents NH (or Im wherein Y is different from NH, respectively) using a suitable alkylating reagent such as an alkyl iodide or bromide of formula R13-X, wherein R13 represents (C1-C4)alkyl, in the presence of a suitable base such as Cs2C03 or potassium carbonate and carrying out the reaction in a suitable solvent such as DMF or THF at a temperature between RT and 45°C.
Figure imgf000049_0001
Scheme 4: final modifications of R1
Alternatively compounds of formula Im can be prepared following the procedures outlined in Scheme 5 below. In all the structures of the scheme, one of the letter code, a,b,c or d represents a carbon atom, which is attached to the rest of the molecule via the substituent Y, and the other remaining letter codes are selected from N, CH and CR10, wherein R10 represents chloro, to form a 6-membered heteroaryl or a heterocyclyl group R1 as defined above. The intermediates of formula XXII and XXIII wherein PG represents a suitable protecting group can be prepared as previously described in Schemes 1 (compounds la and lb), 2 (compounds lc) and 3 (compounds Ig).
The compounds of formula Im can be prepared (Scheme 5) by cleavage of the protecting group (PG) in intermediates XXII or intermediates XXIII wherein PG represents a trimethylsilylethoxymethyl group by treatment with a tetrabutylammonium fluoride solution in THF and carrying out the reaction in a suitable solvent such as THF at a temperature between RT and 70°C.
Alternatively, the compounds of formula Im can be prepared (Scheme 5) by cleavage of the protecting group (PG) in intermediates XXIII wherein PG represents a trimethylsilylethyl group by treatment with a suitable acid such as TFA and carrying out the reaction in a suitable solvent such as DCM at a temperature around RT.
Figure imgf000050_0001
Scheme 5: final deprotection of R1
Alternatively compounds of formula Ir and Iq can be prepared following the procedures outlined in Scheme 6 below.
The compounds of formula XXIV can be prepared as previously described in Schemes 1 (compounds la and lb), 2 (compound lc) and 3 (compounds If and Ig) wherein R3 represents H and R4 represents COOMe.
The compounds of formula XXV can be prepared (Scheme 6) by hydrolysis of a compound of formula XXIV using standard conditions such as those already described for the synthesis of the compounds of formula III and IV (Scheme 1 ). The compounds of formula Iq can be prepared (Scheme 6) by coupling an acid of formula XXV with ammonia as an ethanolic solution using standard amide coupling conditions such as an activation with isobutylchloroformate in the presence of a base such as 4- methylmorpholine and a suitable solvent such as DCM at a temperature between -70°C to RT.
The compounds of formula Ir can be prepared (Scheme 6) by reduction of a compound of formula XXIV using a suitable reducing reagent such as diisobutylaluminum hydride, in the presence of a suitable solvent such as THF at a temperature around RT.
Figure imgf000051_0001
Scheme 6: final modification of R4
If not commercially available, intermediates of formula R1-X can be prepared following the procedures outlined in Scheme 7 below. In all the structures of the scheme, one of the letter code, a,b,c or d represents a carbon atom bearing the halogen atom X, and the other remaining letter codes are selected from N, CH and CR10, wherein R10 represents chloro, to form a 6-membered heteroaryl or a heterocyclyl group R1 as defined above.
The compounds of formula XXVII can be prepared (Scheme 7) by alkylation of a compound of formula XXVI using a suitable alkyl halide of formula R14-X wherein R14 represents a (CrC4)alkyl or a (Ci-C2)alkoxy-(CrC4)alkyl group (or of formula PG-X wherein PG represents a tnmethylsilylethoxymethyl protecting group, respectively), in the presence of a suitable base such as potassium carbonate and carrying out the reaction in a suitable solvent such as acetone, CH3CN or DMF at a temperature between RT and 45°C. When PG-X (wherein PG represents a tnmethylsilylethoxymethyl protecting group) is used as alkylating reagent, the O-alkylated by-product of formula XXVIII can also be isolated. Alternatively, the compounds of formula XXVIII, wherein PG represents a trimethylsilylethyl protecting group, can be prepared (Scheme 7) by an aromatic nucleophilic substitution of a compound of formula XXIX with a freshly prepared lithium 2- (trimethylsilyl)ethanolate (by treatment of 2-(trimethylsilyl)ethanol with n-butyllithium in THF at a temperature between -70°C and -30°C), the reaction being carried out in the presence of a suitable solvent such as THF at a temperature between -70°C and RT.
Figure imgf000052_0001
XXVI
XXVII XXVIII
Figure imgf000052_0002
XXIX
Scheme 7: synthesis of R1-X, wherein R14 represents a (C^-C^alkyl or (Ci-Cg)alkoxy-(Ci- C^alkyl group and PG represents a trimethylsilylethoxymethyl or a trimethylsilylethyl protecting group
If not commercially available, intermediates of formula II, wherein R3 represents hydrogen and R4 represents hydroxy or (d-C4)alkoxy, can be prepared following the procedures outlined in Scheme 8 below.
The compounds of formula XXXII wherein R15 represents trimethylsilyl or hydrogen can be prepared (Scheme 8) by cyanosilylation of a ketone of formula XXX using a suitable cyanation reagent such as trimethylsilylcyanide, in the presence of a lewis acid such as gold (III) chloride and carrying out the reaction in a suitable solvent such as DCM at a temperature around RT (Synthesis, 2008, 4, 507-510).
The compounds of formula XXXII wherein R15 represents (C1-C4)alkyl can be prepared (Scheme 8) by cyanation of a ketal of formula XXXI with a suitable cyanation reagent such as ferf-butyl isocyanide in the presence of a suitable lewis acid such as titanium tetrachloride and carrying out the reaction in a suitable solvent such as DCM at a temperature between -70°C and RT (Chemistry Lett., 1984, 937-940). The compounds of formula II, wherein R3 represents hydrogen and R4 represents hydroxy or (Ci-C4)alkoxy, can be prepared (Scheme 8) by reduction of a compound of formula XXXII using a suitable reducing reagent such as lithium aluminum hydride, in the presence of a suitable solvent such as Et20 or THF at a temperature between 0°C and RT. In those conditions, the consecutive hydrolysis of the possible trimethylsilyl group R15 is observed.
The compounds of formula II wherein, R3 represents hydrogen and R4 represents hydroxy or (Ci-C4)alkoxy, can be transformed into their corresponding hydrochloride salt using standard methods.
Figure imgf000053_0001
Scheme 8: synthesis of amines of formula II
Experimental Part
Abbreviations (as used herein and in the description above)
Ac acetyl
anh. anhydrous
CC column chromatography
DCM dichloromethane
DIPEA diisopropylethylamine
DMF dimethylformamide
DMSO dimethylsulfoxide
Et ethyl
EDC.HCI N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride
eq equivalent h hour(s)
Hept heptanes
HATU 2-(7-aza-1 H-benzotriazole-1-yl)-1 , 1 ,3,3-tetramethyluronium
hexafluorophosphate
HOBT 1 -hydroxybenzotriazole hydrate
HV high vacuum
LC-MS liquid chromatography - mass spectrometry
M molar(ity)
Me methyl
Min minute(s)
NMR nuclear magnetic resonance
ON overnight
PG protecting group
PyBOP benzotriazole-1 -yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate PyCloP chlorotripyrrolidinophosphonium hexafluorophosphate
RT room temperature
sat. saturated
TFA trifluoroacetic acid
THF tetrahydrofuran
TBTU 0-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate tR retention time
UV ultra-violet
Vis visible
EXAMPLES Characterization methods used
NMR: Brucker Avance 400, 400 MHz ; chemical shifts are given in ppm relative to the solvent used; multiplicities: s = singlet, d = doublet, t = triplet, q = quadruplet, m = multiplet, br = broad, coupling constants are given in Hz.
LC-MS: Thermo Finnigan MSQ Surveyor MS with Agilent 1 100 Binary Pump and DAD. Eluents (acidic conditions): A: H20 + 0.04% TFA; B: CH3CN; gradient: 5% B→ 95% B ; runtime: 1.5 min ; flow: 4.5 mL/min ; detection: UV/Vis + MS, tR is given in min.
LC-MS (A): column Zorbax SB-AQ, 5 μηι, 4.6x50 mm LC-MS (B): column Waters XBridge C18, 2.5μηι, 4.6x30 mm
LC-MS (C): column Waters Atlantis T3, 5μηι, 4.6x30 mm ;
Eluents (basic conditions): A: H20 + 13 mmol/L NH4OH; B: CH3CN ; gradient: 5% B→
95% B ; runtime: 1.5 min ; flow: 4.5 mL/min:
LC-MS (D): column Waters XBridge C18, 2.5μηι, 4.6x50 mm.
Purification methods used
Preparative LC-MS: flow: 75 mL/min. Detection: UV/Vis and/or MS.
Additional information for the purification are summerized in the table below using following explanations:
XBridge: column Waters XBridge C18, 10μηι, 30x75 mm
Atlantis: column Waters Atlantis T3, 10μηι, 30x75 mm
Acidic: eluant: A = H20 with 0.5% formic acid, B = CH3CN
Basic: eluant: A = H20 with 0.125% NH4OH, B = CH3CN
Normal gradient: 20% B→ 95% B over 4 min then 95%B over 2 min
Polar gradient: 10% B→ 95% B over 4 min then 95%B over 2 min
Very polar gradient: 5% B→ 50% B over 3 min then 50% B→ 95% B over 1 min and finally 95%B over 2 min
XBridge Atlantis acidic basic acidic
Normal gradient Method VI Method VII
Polar gradient Method III Method IV Method II Very polar gradient Method I Method V
Column chromatography (CC) was performed using silica gel 60 Merck (0.063-0.200mm) or using prepacked cartridges (SNAP KP-SIL™, SNAP KP-NH™, Isolute™ Silica II, Isolute™ NH2 or Isolute™ C18) from Biotage.
The following examples illustrate the invention but do not at all limit the scope thereof. Example 1 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-phenylamino-benzamide
1.1 2-Chloro-5-Dhenylamino-benzoic acid methyl ester
Cs2C03 (2.79 g), palladium(ll) acetate (82 mg), 2,2'-bis(diphenylphosphino)-1 ,1 '- binaphthalene (228 mg), iodobenzene (0.69 mL) and methyl-5-amino-2-chlorobenzoate (1.13 g) were placed in a flask and flushed with argon. Dioxane (18 mL) was added and the reaction mixture was heated to 100°C for 24h. After cooling to RT, it was diluted with Et20, filtered over a pad of celite and the filtrate was concentrated in vacuo. The crude material was purified by CC (Hept/EtOAc 1/0 to 8/2) to give 1.18 g of the titled compound as a light yellow solid.
LC-MS (A): tR = 1 .05 min; [M+H]+: 262.55.
1.2 2-Chloro-5-Dhenylamino-benzoic acid
A solution of intermediate 1 .1 (300 mg) in THF (3.44 mL) was treated with a solution of lithium hydroxide hydrate (144 mg) in H20 (1.15 mL). The reaction mixture was stirred ON at RT, diluted with H20 and extracted twice with EtOAc. The aqueous phase was acidified with a 1 M solution of HCI and extracted three times with EtOAc. The organic phases were dried over MgS04 and concentrated in vacuo to give 266 mg of the titled compound as a light yellow solid.
LC-MS (A): tR = 0.94 min; [M+CH3CN+H]+: 289.51 .
1.3 2-Chloro-N-(1-hvdroxy-cvclohexylmethyl)-5-phenylamino-benzamide
To a solution of intermediate 1.2 (200 mg) and DIPEA (0.55 mL) in DCM (1.6 mL) was added HOBT (131 mg) and EDC.HCI (186 mg) at RT. The solution was stirred for 10 min at RT and 1-aminomethyl-cyclohexanol hydrochloride (147 mg) was added. The reaction mixture was further stirred for 18h at RT and diluted with EtOAc. The organic phase was washed with a 5% solution of KHS04, a sat. solution of NaHC03 and brine, dried over MgS04 and concentrated in vacuo. The crude material was purified by CC (Hept/EtOAc 1/0 to 1/4) to give 244 mg of the titled compound as a light yellow solid.
LC-MS (A): tR = 0.94 min; [M+H]+: 359.01. Example 2 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-(methyl-phenyl-amino)- benzamide
2.1 Methyl 2-chloro-5-(methyl(Dhenyl)amino)benzoate
To a solution of intermediate 1.1 (150 mg) in anh. DMF (1.1 mL) was added Cs2C03 (467 mg) and methyl iodide (0.054 mL). The reaction mixture was stirred for 48h at 40°C, quenched with H20 and extracted with EtOAc. The organic phase was dried over MgS04 and concentrated in vacuo to give 153 mg of the crude titled compound as a yellow oil.
LC-MS (B): tR = 0.96 min; [M+H]+: 276.28.
2.2 2-Chloro-5-(methyl(Dhenyl)amino)benzoic acid
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.2), intermediate 2.1 replacing intermediate 1.1 .
LC-MS (B): tR = 0.81 min; [M+H]+: 262.21.
2.3 2-Chloro-N-((1-hvdroxycvclohexyl)methyl)-5-(methyl(Dhenyl)amino)benzamide
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.3), intermediate 2.2 replacing intermediate 1.2.
LC-MS (B): tR = 0.84 min; [M+H]+: 373.20.
Example 3 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-[(2-methoxy-ethyl)-phenyl- amino]-benzamide
This compound was prepared using a method analogous to that of Example 2 (intermediate 2.1 ), intermediate 1.3 replacing intermediate 1.1 and 2-bromoethyl methyl ether replacing methyl iodide except that the reaction mixture was stirred for 3 days at RT and for 3 days at 70°C and that the crude was purified by CC (Hept/EtOAc 9/1 to 3/7).
LC-MS (B): tR = 0.84 min; [M+H]+: 417.17. Example 4 2-Chloro-5-(2-fluoro-phenylamino)-N-(1 -hydroxy-cyclohexylmethyl)- benzamide
4.1 2-Chloro-5-(2-fluoro-Dhenylamino)-benzoic acid methyl ester
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.1 ), 1 -bromo-2-fluorobenzene replacing iodobenzene.
LC-MS (A): tR = 1 .01 min; [M+H]+: 279.93
4.2 2-Chloro-5-( 2-fluoro-phenylamino)-benzoic acid
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.2), intermediate 4.1 replacing intermediate 1.1 .
LC-MS (B): tR = 0.74 min; [M+CH3CN+H]+: 307.13
4.3 2-Chloro-5-( 2-fluoro-phen ylamino)-N-( 1 -h ydroxy-cvclohexylmeth yl)-benzamide
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.3), intermediate 4.2 replacing intermediate 1.2.
LC-MS (B): tR = 0.79 min; [M+H]+: 377.19
Example 5 2-Chloro-5-[(2-fluoro-phenyl)-methyl-amino]-N-(1 -hydroxy- cyclohexylmethyl)-benzamide
5.1 2-Chloro-5-f(2-fluoro-Dhenyl)-methyl-aminol-benzoic acid methyl ester
This compound was prepared using a method analogous to that of Example 2 (intermediate 2.1 ), intermediate 4.1 replacing intermediate 1.1 .
LC-MS (B): tR = 0.93 min; [M+H]+: 294.18
5.2 2-Chloro-5-[(2-fluoro-phenyl)-methyl-aminol-benzoic acid
This compound was prepared using a method analogous to that of Example 1 (intermediate 1 .2), intermediate 5.1 replacing intermediate 1 .1 except that a 1 M solution of NaOH was used instead of lithium hydroxide in H20.
LC-MS (B): tR = 0.79 min; [M+H]+: 280.22 5.3 2-Chloro-5-i(2-fluoro-Dhenyl)-methyl-aminol-N-(1-hvdroxy-cvclohexylmethyl)- benzamide
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.3), intermediate 5.2 replacing intermediate 1.2.
LC-MS (B): tR = 0.83 min; [M+H]+: 391 .21
Example 6 2-Chloro-5-(2,4-difluoro-phenylamino)-N-(1 -hydroxy- cyclohexylmethyl)-benzamide
6.1 2-Chloro-5-(2,4-difluoro-Dhenylamino)-benzoic acid methyl ester
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.1 ), 2,4-difluoroiodobenzene replacing iodobenzene.
LC-MS (B): tR = 0.88 min; [M+CH3CN+H]+: 339.14
6.2 2-Chloro-5-( 2.4-difluoro-Dhenylamino)-benzoic acid
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.2), intermediate 6.1 replacing intermediate 1.1 .
LC-MS (B): tR = 0.75 min; [M+CH3CN+H]+: 325.08
6.3 2-Chloro-5-(2,4-difluoro-Dhenylamino)-N-(1-hvdroxy-cvclohexylmethyl)-benzamide
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.3), intermediate 6.2 replacing intermediate 1.2.
LC-MS (B): tR = 0.79 min; [M+H]+: 395.15
Example 7 2-Chloro-5-[(2,4-difluoro-phenyl)-methyl-amino]-N-(1 -hydroxy- cyclohexylmethyl)-benzamide
7.1 2-Chloro-5-[(2A-difluoro-phenyl)-methyl-aminol-benzoic acid methyl ester
This compound was prepared using a method analogous to that of Example 2 (intermediate 2.1 ), intermediate 6.1 replacing intermediate 1.1 . LC-MS (B): tR = 0.94 min; [M+H]+: 312.16
7.2 2-Chloro-5-i(2,4-difluoro-Dhenyl)-methyl-amino]-benzoic acid
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.2), intermediate 7.1 replacing intermediate 1.1 .
LC-MS (B): tR = 0.81 min; [M+H]+: 298.12
7.3 2-Chloro-5-[( 2, 4-difluoro-phen yl)-meth yl-aminol-N-( 1 -h vdroxy-cvclohexylmethyl)- benzamide
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.3), intermediate 7.2 replacing intermediate 1.2.
LC-MS (B): tR = 0.85 min; [M+H]+: 409.16
Example 8 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-(pyrimidin-4-ylamino)- benzamide
8.1 2-Chloro-5-(Dyrimidin-4-ylamino)-benzoic acid methyl ester
Sodium phenoxide (810 mg), tris(dibenzylideneacetone)dipalladium (0) (102 mg), Xantphos (161 mg) and methyl-2-chloro-5-iodobenzoate (1379 mg) were placed in a flask and flushed with argon. 4-aminopyrimidine (486 mg) and dioxane (27.5 mL) were added and the reaction mixture was heated to 120°C for 18h. After cooling to RT, it was diluted with EtOAc and washed with a 1 M solution of NaOH. The organic phase was dried over MgS04 and concentrated in vacuo. The crude material was purified by CC (Hept/EtOAc 1/1 to 0/1 ) to give 718 mg of the titled compound as a yellowish powder.
LC-MS (B): tR = 0.48 min; [M+H]+: 264.21.
8.2 2-Chloro-5-(pyrimidin-4-ylamino)-benzoic acid
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.2), intermediate 8.1 replacing intermediate 1.1 .
LC-MS (B): tR = 0.36 min; [M+H]+: 249.95. 8.3 2-Chloro-N-(1-hvdroxy-cvclohexylmethyl)-5-(Dyrimidin-4-ylamino
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.3), intermediate 8.2 replacing intermediate 1 .2, except that the crude was purified by preparative LC-MS using conditions I.
LC-MS (B): tR = 0.49 min; [M+H]+: 361 .24.
Example 9 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-(methyl-pyrimidin-4-yl- amino)-benzamide
9.1 2-Chloro-5-(methyl-pyrimidin-4-yl-amino)-benzoic acid methyl ester
This compound was prepared using a method analogous to that of Example 2 (intermediate 2.1 ), intermediate 8.1 replacing intermediate 1.1 except that the crude was purified by CC (Hept/EtOAc 1/0 to 0/1 ).
LC-MS (B): tR = 0.48 min; [M+H]+: 278.22
9.2 2-Chloro-5-(methyl-Dyrimidin-4-yl-amino)-benzoic acid
This compound was prepared using a method analogous to that of Example 1 (intermediate 1 .2), intermediate 9.1 replacing intermediate 1 .1 except that a 1 M solution of NaOH was used instead of lithium hydroxide in H20.
LC-MS (B): tR = 0.37 min; [M+H]+: 264.24
9.3 2-Chloro-N-(1-hvdroxy-cvclohexylmethyl)-5-(methyl-Dyrimi
benzamide
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.3), intermediate 9.2 replacing intermediate 1.2.
LC-MS (B): tR = 0.49 min; [M+H]+: 375.10 Example 10 2-Chloro-5-(2-chloro-pyrimidin-4-ylamino)-N-(1 -hydroxy- cyclohexylmethyl)-benzamide
10.1 2-Chloro-5-(2-chloro-Dyrimidin-4-ylamino)-benzoic acid methyl ester
This compound was prepared using a method analogous to that of Example 1 , intermediate 1.1 , 2,4-dichloropyrimidine replacing iodobenzene.
LC-MS (A): tR = 0.97 min; [M+H]+: 300.06
10.2 2-Chloro-5-(2-chloro-pyrimidin-4-ylamino)-benzoic acid
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.2), intermediate 10.1 replacing intermediate 1.1.
LC-MS (B): tR = 0.86 min; [M+CH3CN+H]+: 325.20.
10.3 2-Chloro-5-(2-chloro-Dyrimidin-4-ylamino)-N-(1-hvdroxy-cvclohexylmethyl)- benzamide
To a solution of intermediate 10.2 (179 mg) and DIPEA (0.431 ml.) in DCM (3.2 ml.) was added PyCloP (345 mg) and 1 -aminomethyl-cyclohexanol hydrochloride (125 mg) at 0°C. The reaction mixture was stirred for 18h at RT and diluted with DCM. The organic phase was washed with H20, sat.-NaHC03 and brine, dried over MgS04 and concentrated in vacuo. The crude material was purified by CC (EtOAc) to give 122 mg of the titled compound as a white foam.
LC-MS (A): tR = 0.89 min; [M+H]+: 394.47.
Example 11 2-Chloro-5-[(2-chloro-pyrimidin-4-yl)-methyl-amino]-N-(1 -hydroxy- cyclohexylmethyl)-benzamide
11.1 2-Chloro-5-[(2-chloro-pyrimidin-4-yl)-methyl-aminol-benzoic acid methyl ester
To a solution of intermediate 10.1 (1523 mg) in anh. DMF (10.2 mL) was added Cs2C03 (3329 mg) and methyl iodide (0.350 mL). The reaction mixture was stirred for 1 h at RT, quenched with ice H20 and extracted with EtOAc. The organic phase was dried over MgS04 and concentrated in vacuo. The crude material was purified by CC (Hept/EtOAc 1/0 to 1/1 ) to give 1301 mg of the titled compound as a yellow waxy solid. LC-MS (A): tR = 1 .00 min; [M+H]+: 312.12.
77.2 2-Chloro-5-[(2-chloro-Dyrimidin-4-yl)-methyl-aminol-benzoic acid
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.2), intermediate 1 1 .1 replacing intermediate 1.1.
LC-MS (A): tR = 0.87 min; [M+H]+: 297.78.
77.3 2-Chloro-5-[( 2-chloro-p yrimidin-4-yl)-meth yl-aminol-N-( 1 -h ydroxy- cyclohexylmethvD-benzamide
This compound was prepared using a method analogous to that of Example 10 (intermediate 10.3), intermediate 1 1.2 replacing intermediate 10.2.
LC-MS (A): tR = 0.91 min; [M+H]+: 408.98.
Example 12 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-(2-methoxy-pyrimidin-4- ylamino)-benzamide
Intermediate 10.3 (1 18 mg) was mixed with a 5.4 M solution of NaOMe in MeOH (0.553 mL) and the reaction mixture was heated to 90°C for 2h. It was quenched with H20 and diluted with EtOAc. The organic phase was washed with a 5% solution of KHS04, a sat. solution of NaHC03 and brine, dried over MgS04 and concentrated in vacuo. The crude material was purified by CC (Hept/EtOAc 1/0 to 65/35) to give 62 mg of the titled compound as a white solid.
LC-MS (A): tR = 0.73 min; [M+H]+: 391 .15.
Example 13 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-[(2-methoxy-pyrimidin-4- yl)-methyl-amino]-benzamide
This compound was prepared using a method analogous to that of Example 1 1 (intermediate 1 1.1 ), example 12 replacing intermediate 10.1 and the reaction mixture was stirred ON at 40°C.
LC-MS (A): tR = 0.74 min; [M+H]+: 405.1 1. Example 14 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-[methyl-(2-methylamino- pyrimidin-4-yl)-amino]-benzamide
Intermediate 1 1 .3 (80 mg) was mixed with a 41 % solution of methylamine in H20 (0.165 mL) and the reaction mixture was heated to 80°C for 2h. It was quenched with a 1 M solution of NaOH and extracted with DCM. The organic phase was dried over MgS04 and concentrated in vacuo. The crude material was purified by CC (EtOAc/MeOH 1/0 to 9/1 ) to give 49 mg of the titled compound as a yellow foam.
LC-MS (A): tR = 0.76 min; [M+H]+: 404.1 1.
Example 15 2-Chloro-5-[(2-dimethylamino-pyrimidin-4-yl)-methyl-amino]-N-(1 - hydroxy-cyclohexylmethyl)-benzamide
A solution of intermediate 1 1.3 (80 mg) in 2-methoxy-ethanol (0.7 mL) was treated with a 40% solution of dimethylamine in H20 (0.247 mL) and the reaction mixture was heated to 1 10°C for 2h. It was quenched with a 1 M solution of NaOH and extracted with DCM. The organic phase was dried over MgS04 and concentrated in vacuo. The crude material was purified by CC (EtOAc/MeOH 1/0 to 9/1 ) to give 63 mg of the titled compound as a white foam.
LC-MS (A): tR = 0.78 min; [M+H]+: 417.94.
Example 16 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-(2-hydroxypyrimidin-4- ylamino)-benzamide
16.1 2-Chloro-5-((2-hvdroxyDyrimidin-4-yl)amino)benzoic acid
To a solution of intermediate 10.2 (89 mg) in dioxane (2 mL) was added a 2M solution of NaOH (3.2 mL) at RT and the reaction mixture was stirred for 18h at 95°C. It was concentrated to dryness and purified by preparative LC-MS using method II.
LC-MS (A): tR = 0.58 min; [M+H]+: 265.90. 16.2 2-Chloro-N-(1-hvdroxy-cvclohexylmethyl)-5-(2-hvdroxyDyrimidin-4-ylamino)- benzamide
This compound was prepared using a method analogous to that of Example 10 (intermediate 10.3), intermediate 16.1 replacing intermediate 10.2 except that it was purified by preparative LC-MS using method III.
LC-MS (A): tR = 0.68 min; [M+H]+: 377.00.
Example 17 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-[methyl-(2-oxo-1 ,2- dihydro-pyrimidin-4-yl)-amino]-benzamide
This compound was prepared using a method analogous to that of Example 16 (intermediate 16.1 ), intermediate 1 1 .3 replacing intermediate 10.2 except that it was purified by preparative LC-MS using method III.
LC-MS (A): tR = 0.69 min; [M+H]+: 391 .60.
Example 18 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-[methyl-(3-methyl-2-oxo- 2,3-dihydro-pyrimidin-4-yl)-amino]-benzamide
To a solution of intermediate 16.2 (17 mg) in anh. DMF (0.1 mL) was added Cs2C03 (29 mg) and methyl iodide (0.003 mL). The reaction mixture was stirred for 18h at RT, quenched with ice H20 and extracted with EtOAc. The organic phase was dried over MgS04 and concentrated in vacuo. The crude was purified by preparative LC-MS using method IV to give 7 mg of titled compound as a white powder.
LC-MS (A): tR = 0.72 min; [M+H]+: 405.18.
Example 19 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-[methyl-(1 -methyl-2-oxo- 1 ,2-dihydro-pyrimidin-4-yl)-amino]-benzamide
This compound was prepared using a method analogous to that of Example 18 and was isolated as second regioisomer.
LC-MS (A): tR = 0.68 min; [M+H]+: 405.04. Example 20 2-Chloro-5-[(2-chloro-pyrimidin-4-yl)-ethyl-amino]-N-(1 -hydroxy- cyclohexylmethyl)-benzamide
20.1 2-Chloro-5-f(2-chloro-Dyrimidin-4-yl)-ethyl-aminol-benzoic acid methyl ester
This compound was prepared using a method analogous to that of Example 1 1 (intermediate 1 1 .1 ), ethyl iodide replacing methyl iodide except that the reaction mixture was stirred for 18h at RT.
LC-MS (B): tR = 0.83 min; [M+H]+: 326.08
20.2 2-Chloro-5-[(2-chloro-pyrimidin-4-yl)-ethyl-aminol-benzoic acid
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.2), intermediate 20.1 replacing intermediate 1 .1.
LC-MS (B): tR = 0.68 min; [M+H]+: 312.09
20.3 2-Chloro-5-[( 2-chloro-p yrimidin-4-yl)-eth yl-aminol-N-( 1 -hydroxy-cvclohexylmeth yl)- benzamide
This compound was prepared using a method analogous to that of Example 10 (intermediate 10.3), intermediate 20.2 replacing intermediate 10.2.
LC-MS (B): tR = 0.73 min; [M+H]+: 423.14
Example 21 2-Chloro-5-[ethyl-(2-oxo-1 ,2-dihydro-pyrimidin-4-yl)-amino]-N-(1 - hydroxy-cyclohexylmethyl)-benzamide
This compound was prepared using a method analogous to that of Example 16 (intermediate 16.1 ), intermediate 20.3 replacing intermediate 10.2 except that it was purified by preparative LC-MS using method V.
LC-MS (B): tR = 0.50 min; [M+H]+: 405.28. Example 22 2-Chloro-5-[(2-chloro-pyrimidin-4-yl)-propyl-amino]-N-(1 -hydroxy- cyclohexylmethyl)-benzamide
22.7 2-Chloro-5-f(2-chloro-Dyrimidin-4-yl)-DroDyl-aminol-benzoic acid methyl ester
This compound was prepared using a method analogous to that of Example 1 1 (intermediate 1 1.1 ), propyl iodide replacing methyl iodide except that the reaction mixture was stirred for 18h at RT.
LC-MS (B): tR = 0.89 min; [M+H]+: 340.12
22.2 2-Chloro-5-[(2-chloro-pyrimidin-4-yl)-propyl-aminol-benzoic acid
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.2), intermediate 22.1 replacing intermediate 1 .1.
LC-MS (B): tR = 0.74 min; [M+H]+: 326.09
22.3 2-Chloro-5-i(2-chloro-Dyrimidin-4-yl)-DroDyl-aminol-N-(1-hvdroxy- cvclohexylmethvD-benzamide
This compound was prepared using a method analogous to that of Example 10 (intermediate 10.3), intermediate 22.2 replacing intermediate 10.2.
LC-MS (B): tR = 0.79 min; [M+H]+: 437.18.
Example 23 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-[(2-oxo-1 ,2-dihydro- pyrimidin-4-yl)-propyl-amino]-benzamide
This compound was prepared using a method analogous to that of Example 16 (intermediate 16.1 ), intermediate 22.3 replacing intermediate 10.2 except that it was purified by preparative LC-MS using method V.
LC-MS (B): tR = 0.55 min; [M+H]+: 419.29. Example 24 2-Chloro-5-[(2-chloro-pyrimidin-4-yl)-isopropyl-amino]-N-(1 -hydroxy- cyclohexylmethyl)-benzamide
24.1 2-Chloro-5-i(2-chloro-Dyrimidin-4-yl)-isoDroDyl-aminol-benzoic acid methyl ester
This compound was prepared using a method analogous to that of Example 1 1 (intermediate 1 1 .1 ), isopropyl iodide replacing methyl iodide except that the reaction mixture was stirred for 18h at RT.
LC-MS (B): tR = 0.87 min; [M+H]+: 340.21
24.2 2-Chloro-5-[(2-chloro-pyrimidin-4-yl)-isopropyl-aminol-benzoic acid
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.2), intermediate 24.1 replacing intermediate 1 .1.
LC-MS (B): tR = 0.73 min; [M+H]+: 326.09
24.3 2-Chloro-5-i(2-chloro-Dyrimidin-4-yl)-isoDroDyl-aminol-N-(1-hvdroxy- cvclohexylmethvD-benzamide
This compound was prepared using a method analogous to that of Example 10 (intermediate 10.3), intermediate 24.2 replacing intermediate 10.2.
LC-MS (B): tR = 0.78 min; [M+H]+: 437.24.
Example 25 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-[isopropyl-(2-oxo-1 ,2- dihydro-pyrimidin-4-yl)-amino]-benzamide
This compound was prepared using a method analogous to that of Example 16 (intermediate 16.1 ), intermediate 24.3 replacing intermediate 10.2 except that it was purified by preparative LC-MS using method V.
LC-MS (B): tR = 0.53 min; [M+H]+: 419.29. Example 26 2-Chloro-5-[(2-chloro-pyrimidin-4-yl)-isobutyl-amino]-N-(1 -hydroxy- cyclohexylmethyl)-benzamide
26.1 2-Chloro-5-i(2-chloro-Dyrimidin-4-yl)-isobutyl-aminol-benzoic acid methyl ester
This compound was prepared using a method analogous to that of Example 1 1 (intermediate 1 1.1 ), 1-iodo-2-methylpropane replacing methyl iodide except that the reaction mixture was stirred for 18h at RT and for 18h at 40°C.
LC-MS (B): tR = 0.93 min; [M+H]+: 353.98
26.2 2-Chloro-5-[(2-chloro-pyrimidin-4-yl)-isobutyl-aminol-benzoic acid
This compound was prepared using a method analogous to that of Example 1 (intermediate 1 .2), intermediate 26.1 replacing intermediate 1 .1 except that a 2M solution of NaOH was used instead of lithium hydroxide in H20.
LC-MS (B): tR = 0.79 min; [M+H]+: 340.13
26.3 2-Chloro-5-i(2-chloro-Dyrimidin-4-yl)-isobutyl-aminol-N-(1-hvdroxy- cvclohexylmethvD-benzamide
This compound was prepared using a method analogous to that of Example 10 (intermediate 10.3), intermediate 26.2 replacing intermediate 10.2.
LC-MS (B): tR = 0.83 min; [M+H]+: 451 .27.
Example 27 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-[isobutyl-(2-oxo-1 ,2- dihydro-pyrimidin-4-yl)-amino]-benzamide
This compound was prepared using a method analogous to that of Example 16 (intermediate 16.1 ), intermediate 26.3 replacing intermediate 10.2 except that it was purified by CC (EtOAc/MeOH 1/0 to 8/2).
LC-MS (B): tR = 0.58 min; [M+H]+: 433.18. Example 28 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-[isobutyl-(2-methoxy- pyrimidin-4-yl)-amino]-benzamide
This compound was prepared using a method analogous to that of Example 12, intermediate 26.3 replacing intermediate 10.3 except that the reaction mixture was stirred for 45 min at 50°C.
LC-MS (B): tR = 0.63 min; [M+H]+: 447.35.
Example 29 5-[Benzyl-(2-chloro-pyrimidin-4-yl)-amino]-2-chloro-N-(1 -hydroxy- cyclohexylmethyl)-benzamide
29.1 5-fBenzyl-(2-chloro-Dyrimidin-4-yl)-aminol-2-chloro-benzoic acid methyl ester
This compound was prepared using a method analogous to that of Example 1 1 (intermediate 1 1 .1 ), benzyl bromide replacing methyl iodide except that the reaction mixture was stirred for 18h at RT.
LC-MS (B): tR = 0.91 min; [M+H]+: 388.20
29.2 5-iBenzyl-(2-chloro-Dyrimidin-4-yl)-aminol-2-chloro-benzoic acid
This compound was prepared using a method analogous to that of Example 1 (intermediate 1 .2), intermediate 29.1 replacing intermediate 1 .1 except that a 2M solution of NaOH was used instead of lithium hydroxide in H20.
LC-MS (B): tR = 0.79 min; [M+H]+: 374.03
29.3 5-iBenzyl-(2-chloro-Dyrimidin-4-yl)-aminol-2-chloro-N-(1-hvdroxy- cvclohexylmethvD-benzamide
This compound was prepared using a method analogous to that of Example 10 (intermediate 10.3), intermediate 29.2 replacing intermediate 10.2.
LC-MS (B): tR = 0.83 min; [M+H]+: 485.26. Example 30 5-[Benzyl-(2-oxo-1 ,2-dihydro-pyrimidin-4-yl)-amino]-2-chloro-N-(1 - hydroxy -cyclohexylmethyl)-benzamide
This compound was prepared using a method analogous to that of Example 16 (intermediate 16.1 ), intermediate 29.3 replacing intermediate 10.2 except that it was purified by CC (EtOAc/MeOH 1/0 to 8/2).
LC-MS (B): tR = 0.62 min; [M+H]+: 467.33.
Example 31 5-[Benzyl-(2-methoxy-pyrimidin-4-yl)-amino]-2-chloro-N-(1 -hydroxy- cyclohexylmethyl)-benzamide
This compound was prepared using a method analogous to that of Example 12, intermediate 29.3 replacing intermediate 10.3 except that the reaction mixture was stirred for 45 min at 50°C.
LC-MS (B): tR = 0.64 min; [M+H]+: 481 .15.
Example 32 2-Chloro-5-[(2-chloro-pyrimidin-4-yl)-(2-methoxy-ethyl)-amino]-N-(1 - hydroxy-cyclohexylmethyl)-benzamide
32.1 2-Chloro-5-i(2-chloro-Dyrimidin-4-yl)-(2-methoxy-ethyl)-aminol-benzoi acid methyl ester
This compound was prepared using a method analogous to that of Example 1 1 (intermediate 1 1 .1 ), 2-bromoethyl methyl ether replacing methyl iodide except that the reaction mixture was stirred for 18h at 40°C.
LC-MS (B): tR = 0.79 min; [M+H]+: 356.22
32.2 2-Chloro-5-f(2-chloro-Dyrimidin-4-yl)-(2-methoxy-ethyl)-am acid
This compound was prepared using a method analogous to that of Example 1 (intermediate 1 .2), intermediate 32.1 replacing intermediate 1 .1 except that a 2M solution of NaOH was used instead of lithium hydroxide in H20.
LC-MS (B): tR = 0.65 min; [M+H]+: 342.12 32.3 2-Chloro-5-f(2-chloro-Dyrimidin-4-yl)-(2-methoxy-ethyl)-amino
cvclohexylmethvD-benzamide
This compound was prepared using a method analogous to that of Example 10 (intermediate 10.3), intermediate 32.2 replacing intermediate 10.2.
LC-MS (B): tR = 0.71 min; [M+H]+: 453.24
Example 33 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-[(2-methoxy-ethyl)-(2-oxo- 1 ,2-dihydro-pyrimidin-4-yl)-amino]-benzamide
This compound was prepared using a method analogous to that of Example 16 (intermediate 16.1 ), intermediate 32.3 replacing intermediate 10.2 except that it was purified by CC (EtOAc/MeOH 1/0 to 8/2).
LC-MS (B): tR = 0.52 min; [M+H]+: 435.27.
Example 34 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-[(2-methoxy-ethyl)-(2- methoxy-pyrimidin-4-yl)-amino]-benzamide
This compound was prepared using a method analogous to that of Example 12, intermediate 32.3 replacing intermediate 10.3 except that the reaction mixture was stirred for 18h at 30°C.
LC-MS (B): tR = 0.54 min; [M+H]+: 449.1 1.
Example 35 2-Chloro-5-[(2-chloro-pyrimidin-4-yl)-cyclopentylmethyl-amino]-N-(1 - hydroxy -cyclohexylmethyl)-benzamide
35.1 2-Chloro-5-f(2-chloro-Dyrimidin-4-yl)-cvcloDentylmethyl-amin acid methyl ester
This compound was prepared using a method analogous to that of Example 1 1 (intermediate 1 1.1 ), iodomethylcyclopentane replacing methyl iodide except that the reaction mixture was stirred for 4 days at 40°C.
LC-MS (B): tR = 1 .00 min; [M+H]+: 380.07 35.2 2-Chloro-5-i(2-chloro-Dyrimidin-4-yl)-cvcloDentylmethyl-aminol-benzoic acid
This compound was prepared using a method analogous to that of Example 1 (intermediate 1 .2), intermediate 35.1 replacing intermediate 1 .1 except that a 2M solution of NaOH was used instead of lithium hydroxide in H20.
LC-MS (B): tR = 0.86 min; [M+H]+: 366.08
35.3 2-Chloro-5-[(2-chloro-pyrimidin-4-yl)-cvclopentylmethyl-aminol-N-(1-hvd
cyclohexylmethvD-benzamide
This compound was prepared using a method analogous to that of Example 10 (intermediate 10.3), intermediate 35.2 replacing intermediate 10.2.
LC-MS (B): tR = 0.90 min; [M+H]+: 477.29
Example 36 2-Chloro-5-[cyclopentylmethyl-(2-oxo-1 ,2-dihydro-pyrimidin-4-yl)- amino]-N-(1 -hydroxy-cyclohexylmethyl)-benzamide
This compound was prepared using a method analogous to that of Example 16 (intermediate 16.1 ), intermediate 35.3 replacing intermediate 10.2 except that it was purified by CC (EtOAc/MeOH 1/0 to 8/2).
LC-MS (B): tR = 0.63 min; [M+H]+: 459.37.
Example 37 2-Chloro-5-[cyclopentylmethyl-(2-methoxy-pyrimidin-4-yl)-amino]-N- (1 -hydroxy -cyclohexylmethyl)-benzamide
This compound was prepared using a method analogous to that of Example 12, intermediate 35.3 replacing intermediate 10.3 except that the reaction mixture was stirred for 2h at 50°C.
LC-MS (B): tR = 0.68 min; [M+H]+: 473.36. Example 38 2-Chloro-5-[(2-chloro-pyrimidin-4-yl)-(2-phenoxy-ethyl)-amino]-N-(1 - hydroxy -cyclohexylmethyl)-benzamide
38.1 2-Chloro-5-i(2-chloro-Dyrimidin-4-yl)-(2-Dhenoxy-ethyl)-aminol-benzoic acid methyl ester
This compound was prepared using a method analogous to that of Example 1 1 (intermediate 1 1 .1 ), 2-bromoethyl phenyl ether replacing methyl iodide except that the reaction mixture was stirred for 3 days at RT.
LC-MS (B): tR = 0.94 min; [M+H]+: 417.86
38.2 2-Chloro-5-i(2-chloro-Dyrimidin-4-yl)-(2-Dhenoxy-ethyl)-amin acid
This compound was prepared using a method analogous to that of Example 1 (intermediate 1 .2), intermediate 38.1 replacing intermediate 1 .1 except that a 2M solution of NaOH was used instead of lithium hydroxide in H20.
LC-MS (B): tR = 0.82 min; [M+H]+: 404.04
38.3 2-Chloro-5-{(2-chloro-Dyrimidin-4-yl)-(2-Dhenoxy-ethyl)-am
cvclohexylmethvD-benzamide
This compound was prepared using a method analogous to that of Example 10 (intermediate 10.3), intermediate 38.2 replacing intermediate 10.2.
LC-MS (B): tR = 0.86 min; [M+H]+: 515.28
Example 39 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-[(2-oxo-1 ,2-dihydro- pyrimidin-4-yl)-(2-phenoxy-ethyl)-amino]-benzamide
This compound was prepared using a method analogous to that of Example 16 (intermediate 16.1 ), intermediate 38.3 replacing intermediate 10.2 except that it was purified by CC (EtOAc/MeOH 1/0 to 8/2).
LC-MS (B): tR = 0.65 min; [M+H]+: 497.15. Example 40 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-[(2-methoxy-pyrimidin-4- yl)-(2-phenoxy-ethyl)-amino]-benzamide
This compound was prepared using a method analogous to that of Example 12, intermediate 38.3 replacing intermediate 10.3 except that the reaction mixture was stirred for 18h at 30°C.
LC-MS (B): tR = 0.67 min; [M+H]+: 51 1 .31.
Example 41 2-Chloro-5-[(2-chloro-pyrimidin-4-yl)-methyl-amino]-N-((R)-1 - cyclohexyl-ethyl)-benzamide
This compound was prepared using a method analogous to that of Example 10 (intermediate 10.3), intermediate 1 1.2 replacing intermediate 10.2 and (R)-(-)-1- cyclohexylethylamine replacing 1 -aminomethyl-cyclohexanol hydrochloride.
LC-MS (B): tR = 0.88 min; [M+H]+: 407.18.
Example 42 2-Chloro-N-((R)-1 -cyclohexyl-ethyl)-5-[methyl-(2-oxo-1 ,2-dihydro- pyrimidin-4-yl)-amino]-benzamide
This compound was prepared using a method analogous to that of Example 16 (intermediate 16.1 ), example 41 replacing intermediate 10.2 except that it was purified by preparative LC-MS using method V.
LC-MS (B): tR = 0.64 min; [M+H]+: 389.22.
Example 43 2-Chloro-5-[(2-chloro-pyrimidin-4-yl)-methyl-amino]-N-((S)-1 - cyclohexyl-2 -hydroxy -ethyl)-benzamide
This compound was prepared using a method analogous to that of Example 10 (intermediate 10.3), intermediate 1 1 .2 replacing intermediate 10.2 and L- cyclohexylglycinol replacing 1-aminomethyl-cyclohexanol hydrochloride.
LC-MS (B): tR = 0.73 min; [M+H]+: 423.18. Example 44 2-Chloro-N-((S)-1 -cyclohexyl-2-hydroxy-ethyl)-5-[methyl-(2-oxo-1 ,2- dihydro-pyrimidin-4-yl)-amino]-benzamide
This compound was prepared using a method analogous to that of Example 16 (intermediate 16.1 ), example 43 replacing intermediate 10.2 except that it was purified by preparative LC-MS using method I.
LC-MS (D): tR = 0.69 min; [M+H]+: 405.19.
Example 45 2-Chloro-5-[(2-chloro-pyrimidin-4-yl)-methyl-amino]-N-(1 -hydroxy- cycloheptylmethyl)-benzamide
45.1 1-Trimethylsilanyloxy-cvcloheDtanecarbonitrile
To a solution of cycloheptanone (5 g) in anh. DCM (106 mL) were added trimethylsilyl cyanide (5.14 g) and gold (III) chloride (130 mg) at RT. The reaction mixture was stirred for 1 h at RT, quenched with a 10% solution of Na2C03 and extracted with DCM. The organic phases was dried over MgS04 and concentrated in vacuo. The crude was purified by CC (Hept/EtOAc 1/0 to 65/35) to give 4.93 g of titled compound as a colorless oil.
1H NMR (CDCIs) <5: 2.12 (dd, Ji = 14.1 Hz, J2 = 8.4 Hz, 2 H), 1 .95 (m, 2 H), 1 .65 (m, 8 H), 0.26 (s, 9 H)
45.2 l-Aminomethyl-cvcloheptanol hydrochloride
A 2M solution of lithium aluminum hydride (6.13 mL) in THF was diluted with anh. Et20 (6.5 mL) and a solution of 1 -trimethylsilanyloxy-cycloheptanecarbonitrile (1 .73 g) in anh. Et20 (3.3 mL) was added dropwise for 15 min at 0°C. The ice bath was removed and the reaction mixture was stirred for 2h at RT. It was cooled to 0°C and quenched successively with ice H20 (1 mL), a 1 M solution of NaOH (1 mL) and ice H20 (3.3 mL). The mixture was stirred for 10 min at RT, diluted with Et20 and filtered over a pad of celite. The filtrate was concentrated in vacuo and the residue was redissolved in Et20 (13 mL) and few drops of dioxane. A 4M solution of hydrogen chloride in dioxane (6.6 mL) was added at RT and the precipitate was filtered to give 1.05 g of the 1 -aminomethyl-cycloheptanol hydrochloride as a white solid.
1H NMR (CD3OD) δ: 2.90 (s, 2 H), 1.59 (m, 12 H)
13C NMR (CD3OD) δ: 72.1 , 47.7, 38.1 , 29.6, 21 .7 45.3 2-Chloro-5-[( 2-chloro-p yrimidin-4-yl)-meth yl-aminol-N-( 1 -h ydroxy- cvcloheptylmeth yl)-benzamide
This compound was prepared using a method analogous to that of Example 10 (intermediate 10.3), intermediate 1 1.2 replacing intermediate 10.2 and intermediate 45.2 replacing 1 -aminomethyl-cyclohexanol hydrochloride.
LC-MS (B): tR = 0.73 min; [M+H]+: 423.17.
Example 46 2-Chloro-N-(1 -hydroxy-cycloheptylmethyl)-5-[methyl-(2-oxo-1 ,2- dihydro-pyrimidin-4-yl)-amino]-benzamide
This compound was prepared using a method analogous to that of Example 16 (intermediate 16.1 ), intermediate 45.3 replacing intermediate 10.2 except that the reaction mixture was stirred for 72h at 80°C and the crude was purified by preparative LC-MS using method I and then by CC (EtOAc/MeOH 1/0 to 1/1 ).
LC-MS (B): tR = 0.52 min; [M+H]+: 405.27.
Example 47 2-Chloro-5-[(2-chloro-pyrimidin-4-yl)-methyl-amino]-N-(1 -hydroxy- cyclooctylmethyl)-benzamide
47.1 1 - Trimethylsilan yloxy-cvclooctanecarbonitrile
This compound was prepared using a method analogous to that of Example 45 (intermediate 45.1 ), cyclooctanone replacing cycloheptanone except that the reaction mixture was stirred for 2h at RT.
1H NMR (CDCIs) δ: 2.04 (t, J = 5.6 Hz, 4 H), 1.63 (m, 10 H), 0.26 (m, 9 H)
47.2 1-Aminomethyl-cvclooctanol hydrochloride
This compound was prepared using a method analogous to that of Example 45 (intermediate 45.2), intermediate 47.1 replacing intermediate 45.1 except that the reaction mixture was stirred for 2h at RT.
1H NMR ((CD3)2SO) δ: 7.87 (s, 3 H), 4.82 (s, 1 H), 2.70 (s, 2 H), 1 .54 (m, 14 H) 47.3 2-Chloro-5-f( 2-chloro-p yrimidin-4-yl)-meth yl-aminol-N-( 1 -h ydroxy- cvclooctylmeth yl)-benzamide
This compound was prepared using a method analogous to that of Example 10 (intermediate 10.3), intermediate 1 1.2 replacing intermediate 10.2 and intermediate 47.2 replacing 1 -aminomethyl-cyclohexanol hydrochloride.
LC-MS (B): tR = 0.77 min; [M+H]+: 437.22.
Example 48 2-Chloro-N-(1 -hydroxy-cyclooctylmethyl)-5-[methyl-(2-oxo-2,3- dihydro-pyrimidin-4-yl)-amino]-benzamide
This compound was prepared using a method analogous to that of Example 16 (intermediate 16.1 ), intermediate 47.3 replacing intermediate 10.2 except that the reaction mixture was stirred for 6h at 90°C and the crude was purified by preparative LC-MS using method I.
LC-MS (B): tR = 0.57 min; [M+H]+: 419.22.
Example 49 2-Chloro-5-[(2-chloro-pyrimidin-4-yl)-methyl-amino]-N-(1 -hydroxy- cyclopentylmethyl)-benzamide
49.1 1-Hvdroxy-cvcloDentanecarbonitrile
This compound was prepared using a method analogous to that of Example 45 (intermediate 45.1 ), cyclopentanone replacing cycloheptanone except that the reaction mixture was stirred for 2h at RT and the desilylated product was isolated.
1H NMR ((CD3)2SO) δ: 6.25 (s, 1 H), 1.93 (m, 4 H), 1.71 (m, 4 H)
13C NMR ((CD3)2SO) δ: 123.8, 72.3, 40.0, 23.1
49.2 1-Aminomethyl-cvclopentanol hydrochloride
This compound was prepared using a method analogous to that of Example 45 (intermediate 45.2), intermediate 49.1 replacing intermediate 45.1.
1H NMR ((CD3)2SO) δ: 7.99 (s, 3 H), 4.94 (s, 1 H), 2.83 (d, J = 4.9 Hz, 2 H), 1.63 (m, 8 H) 13C NMR ((CD3)2SO) δ: 78.7, 47.9, 37.7, 23.8 49.3 2-Chloro-5-f( 2-chloro-p yrimidin-4-yl)-meth yl-aminol-N-( 1 -h ydroxy- cvclopentylmeth yl)-benzamide
This compound was prepared using a method analogous to that of Example 10 (intermediate 10.3), intermediate 1 1.2 replacing intermediate 10.2 and intermediate 49.2 replacing 1 -aminomethyl-cyclohexanol hydrochloride.
LC-MS (B): tR = 0.63 min; [M+H]+: 395.04.
Example 50 2-Chloro-N-(1 -hydroxy-cyclopentylmethyl)-5-[methyl-(2-oxo-2,3- dihydro-pyrimidin-4-yl)-amino]-benzamide
This compound was prepared using a method analogous to that of Example 16 (intermediate 16.1 ), intermediate 49.3 replacing intermediate 10.2 except that the reaction mixture was stirred for 18h at 80°C and the crude was purified by preparative LC-MS using method IV.
LC-MS (B): tR = 0.43 min; [M+H]+: 377.10.
Example 51 2-Chloro-5-[(2-chloro-pyrimidin-4-yl)-methyl-amino]-N-(1 -methoxy- cyclohexylmethyl)-benzamide
51.1 1-me thoxycvclohexane carbon itrile
To a solution of 1 , 1-dimethoxycyclohexane (3 g) in DCM (62 mL) was added dropwise titanium tetrachloride (2.28 mL). The reaction mixture was cooled to -70°C and ferf-butyl isocyanide (2.35 mL) was added dropwise. The mixture was stirred for 5 min at -70°C then allowed to warm up ON to RT. It was quenched with a sat. solution of NaHC03 and extracted with DCM. The organic phase was washed with brine, dried over MgS04 and concentrated in vacuo. The crude was purified by CC (Hept/EtOAc 1/0 to 9/1 ) to give 1 g of the titled compound as an orange oil.
1H NMR ((CD3)2SO δ: 3.08 (s, 3 H), 1.58 (m, 10 H)
51.2 (l-methoxycvclohexyl)methanamine
This compound was prepared using a method analogous to that of Example 45 (intermediate 45.2), intermediate 51 .1 replacing intermediate 45.1 except that the compound was isolated as a free amine. 1H NMR ((CD3)2SO) δ: 3.04 (s, 3 H), 2.46 (d, J = 12.3 Hz, 2 H), 1.42 (m, 10 H)
51.3 2-Chloro-5-i(2-chloro-Dyrimidin-4-yl)-methyl-amino]-N-(1-methoxy- cvclohexylmethvD-benzamide
This compound was prepared using a method analogous to that of Example 10 (intermediate 10.3), intermediate 1 1.2 replacing intermediate 10.2 and intermediate 51 .2 replacing 1 -aminomethyl-cyclohexanol hydrochloride.
LC-MS (B): tR = 0.81 min; [M+H]+: 423.16.
Example 52 2-Chloro-N-(1 -methoxy-cyclohexylmethyl)-5-[methyl-(2-oxo-2,3- dihydro-pyrimidin-4-yl)-amino]-benzamide
This compound was prepared using a method analogous to that of Example 16 (intermediate 16.1 ), intermediate 51.3 replacing intermediate 10.2 except that the reaction mixture was stirred for 72h at 80°C and the crude was purified by preparative LC-MS using method VII.
LC-MS (B): tR = 0.57 min; [M+H]+: 405.22.
Example 53 N-(1 -Carbamoyl-cyclohexylmethyl)-2-chloro-5-[(2-chloro-pyrimidin-4- yl)-methyl-amino]-benzamide
53.1 1-({2-Chloro-5-f(2-chloro-Dyrimidin-4-yl)-methyl-aminol-benzo
cvclohexanecarboxylic acid methyl ester
This compound was prepared using a method analogous to that of Example 10 (intermediate 10.3), intermediate 1 1 .2 replacing intermediate 10.2 and methyl 1- aminomethyl-cyclohexanecarboxylate replacing 1-aminomethyl-cyclohexanol hydrochloride.
LC-MS (B): tR = 0.82 min; [M+H]+: 451 .22. 53.2 1-({2-Chloro-5-f(2-chloro-Dyrimidin-4-yl)-methyl-aminol-benzo
cvclohexanecarboxylic acid
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.2), intermediate 53.1 replacing intermediate 1.1.
LC-MS (B): tR = 0.71 min; [M+H]+: 437.19.
53.3 N-( 1 -Carbamoyl-cyclohexylmeth yl)-2-chloro-5-[( 2-chloro-p yrimidin-4-yl)-meth yl- aminol-benzamide
To a solution of intermediate 53.2 (70 mg) in DCM (1 mL) was added 4-methylmorpholine (0.020 mL) and isobutyl chloroformate (0.022 mL) at -70°C. The mixture was stirred for 10 min at -70°C and a 0.5M solution of ammonia in EtOH (0.320 mL) was added dropwise. The reaction mixture was allowed to warm up ON to RT, quenched with H20 and extracted with EtOAc. The organic phase was washed with a sat. solution of NaHC03, with brine, dried over MgS04 and concentrated in vacuo. The crude was purified by CC (Hept/EtOAc 1/0 to 0/1 ) to give 18 mg of the titled compound as a white solid.
LC-MS (B): tR = 0.63 min; [M+H]+: 436.22.
Example 54 N-(1 -Carbamoyl-cyclohexylmethyl)-2-chloro-5-[methyl-(2-oxo-2,3- dihydro-pyrimidin-4-yl)-amino]-benzamide
This compound was prepared using a method analogous to that of Example 16 (intermediate 16.1 ), intermediate 53.3 replacing intermediate 10.2 except that the reaction mixture was stirred for 72h at 80°C and the crude was purified by preparative LC-MS using method IV.
LC-MS (B): tR = 0.46 min; [M+H]+: 417.99.
Example 55 2-Chloro-5-[(2-chloro-pyrimidin-4-yl)-methyl-amino]-N-(1 - hydroxymethyl-cyclohexylmethyl)-benzamide
To a solution of intermediate 53.1 (150 mg) in THF (1 mL) was added a 1 M solution of diisobutylaluminum hydride (0.830 mL) at 0°C and the reaction mixture was stirred at RT. Additional amounts of a 1 M solution of diisobutylaluminum hydride (3 x 0.665 mL) were necessary until completion of the reaction. The reaction mixture was quenched with H20 and extracted with EtOAc. The organic phase was washed with sat. solution of NaHC03 and brine, dried over MgS04 and concentrated in vacuo. The crude was purified by CC (Hept/EtOAc 1/0 to 3/7) to give 56 mg of the titled compound as a white foam.
LC-MS (B): tR = 0.75 min; [M+H]+: 423.21.
Example 56 2-Chloro-N-(1 -hydroxymethyl-cyclohexylmethyl)-5-[methyl-(2-oxo-2,3- dihydro-pyrimidin-4-yl)-amino]-benzamide
This compound was prepared using a method analogous to that of Example 16 (intermediate 16.1 ), example 55 replacing intermediate 10.2 except that the reaction mixture was stirred for 18h at 90°C and the crude was purified by preparative LC-MS using method III.
LC-MS (B): tR = 0.54 min; [M+H]+: 405.16.
Example 57 2-Chloro-5-[(2-chloro-pyrimidin-4-yl)-methyl-amino]-N-(4,4-difluoro-1 - hydroxy-cyclohexylmethyl)-benzamide
57.1 4,4-Difluoro-1-trimethylsilanyloxy-cvclohexanecarbonitrile
To a solution of 4,4-difluorocyclohexanone (967 mg) in anh. DCM (18 mL) were added zinc iodide (23 mg) and trimethylsilyl cyanide (1 .1 mL) at 0°C. The reaction mixture was stirred for 1 h at RT, quenched with a 10% solution of Na2C03 and extracted with DCM. The organic phases was dried over MgS04 and concentrated in vacuo to give 1 .5 g of titled compound as a colorless oil.
1H NMR ((CD3)2SO) δ: 2.04 (m, 8 H), 0.25 (m, 9 H)
57.2 1-Aminomethyl-4A-difluoro-cvclohexanol hydrochloride
This compound was prepared using a method analogous to that of Example 45 (intermediate 45.2), intermediate 57.1 replacing intermediate 45.1.
1H NMR ((CD3)2SO) δ: 8.04 (s, 3 H), 5.21 (s, 1 H), 2.82 (s, 2 H), 1.98 (m, 4 H), 1.74 (m, 2 H), 1 .55 (td, = 13.2 Hz, J2 = 4.1 Hz, 2 H) 57.3 2-Chloro-5-{(2-chloro-Dyrimidin-4-yl)-methyl-amino]-N-(
cvclohexylmethvD-benzamide
This compound was prepared using a method analogous to that of Example 10 (intermediate 10.3), intermediate 1 1.2 replacing intermediate 10.2 and intermediate 57.2 replacing 1 -aminomethyl-cyclohexanol hydrochloride.
LC-MS (B): tR = 0.69 min; [M+H]+: 445.09.
Example 58 2-Chloro-N-(4,4-difluoro-1 -hydroxy-cyclohexylmethyl)-5-[methyl-(2- oxo-2,3-dihydro-pyrimidin-4-yl)-amino]-benzamide
This compound was prepared using a method analogous to that of Example 16 (intermediate 16.1 ), intermediate 57.3 replacing intermediate 10.2 except that the reaction mixture was stirred for 18h at 90°C and the crude was purified by preparative LC-MS using method IV.
LC-MS (B): tR = 0.49 min; [M+H]+: 427.05.
Example 59 2-Chloro-N-((R)-1 -cyclohexyl-ethyl)-5-(2-methylsulfanyl-pyrimidin-4- ylamino)-benzamide
59.1 2-Chloro-5-(2-methylsulfanyl-Dyrimidin-4-ylamino)-benzoic acid methyl ester
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.1 ), 4-chloro-2-methylthiopyrimidine replacing iodobenzene.
LC-MS (A): tR = 0.77 min; [M+H]+: 309.85
59.2 2-Chloro-5-(2-methylsulfanyl-Dyrimidin-4-ylamino)-benzoic acid
This compound was prepared using a method analogous to that of Example (intermediate 1.2), intermediate 59.1 replacing intermediate 1.1.
LC-MS (A): tR = 0.46 min; [M+H]+: 296.03. 59.3 2-Chloro-N-( (R)-1 -cvclohexyl-eth yl)-5-(2-methylsulfan yl-p yrimidin-4-ylamino)- benzamide
This compound was prepared using a method analogous to that of Example 1 (intermediate 1 .3), intermediate 59.2 replacing intermediate 1 .2 and (R)-(-)-1 - cyclohexylethylamine replacing 1 -aminomethyl-cyclohexanol hydrochloride.
LC-MS (A): tR = 0.90 min; [M+H]+: 405.64.
Example 60 2-Chloro-N-((S)-1 -cyclohexyl-2-hydroxy-ethyl)-5-(2-methylsulfanyl- pyrimidin-4-ylamino)-benzamide
This compound was prepared using a method analogous to that of Example 1 (intermediate 1 .3), intermediate 59.2 replacing intermediate 1.2 and L-cyclohexylglycinol replacing 1 -aminomethyl-cyclohexanol hydrochloride.
LC-MS (A): tR = 0.80 min; [M+H]+: 421 .56.
Example 61 2-Chloro-N-(1 -hydroxy-cycloheptylmethyl)-5-(2-methylsulfanyl- pyrimidin-4-ylamino)-benzamide
This compound was prepared using a method analogous to that of Example 1 (intermediate 1 .3), intermediate 59.2 replacing intermediate 1 .2 and intermediate 45.2 replacing 1 -aminomethyl-cyclohexanol hydrochloride.
LC-MS (B): tR = 0.59 min; [M+H]+: 421 .09.
Example 62 2-Chloro-5-[(2,6-dichloro-pyrimidin-4-yl)-methyl-amino]-N-(1 -hydroxy- cyclohexylmethyl)-benzamide
62.1 2-Chloro-5-(2,6-dichloro-pyrimidin-4-ylamino)-benzoic acid methyl ester
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.1 ), 2,4,6-trichloropyrimidine replacing iodobenzene.
LC-MS (B): tR = 0.86 min; [M+H]+: 333.99 62.2 2-Chloro-5-i(2,6-dichloro-Dyrimidin-4-yl)-methyl-aminol-benzoic acid methyl ester
This compound was prepared using a method analogous to that of Example 1 1 (intermediate 1 1 .1 ), intermediate 62.1 replacing intermediate 10.1.
LC-MS (B): tR = 0.89 min; [M+H]+: 345.96
62.3 2-Chloro-5-[(2,6-dichloro-pyrimidin-4-yl)-methyl-aminol-benzoic acid
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.2), intermediate 62.2 replacing intermediate 1 .1. This compound was contaminated with 2-chloro-5-[(6-chloro-2-methoxy-pyrimidin-4-yl)-methyl-amino]-benzoic acid.
LC-MS (B): tR = 0.75 min; [M+H]+: 331 .95
62.4 2-Chloro-5-i(2,6-dichloro-Dyrimidin-4-yl)-methyl-aminol-N-(1-hvdrox
cvclohexylmethvD-benzamide
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.3), intermediate 62.3 replacing intermediate 1 .2.
LC-MS (B): tR = 0.79 min; [M+H]+: 443.12
Example 63 2-Chloro-5-[(6-chloro-2-methoxy-pyrimidin-4-yl)-methyl-amino]-N-(1 - hydroxy-cyclohexylmethyl)-benzamide
This compound was isolated as a by-product in the preparation of intermediate 62.4.
LC-MS (B): tR = 0.76 min; [M+H]+: 439.18
Example 64 2-Chloro-5-[(6-chloro-2-oxo-1 ,2-dihydro-pyrimidin-4-yl)-methyl-amino]- N-(1 -hydroxy-cyclohexylmethyl)-benzamide
This compound was prepared using a method analogous to that of Example 16 (intermediate 16.1 ), intermediate 62.4 replacing intermediate 10.2 except that it was purified by preparative LC-MS using method V.
LC-MS (B): tR = 0.55 min; [M+H]+: 425.1 1 Example 65 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-[methyl-(6-methylsulfanyl- pyrimidin-4-yl)-amino]-benzamide
65.1 Methyl 2-chloro-5-(( 6-methylsulfanylDyrimidin-4-yl)amino)benzoate
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.1 ), 2,4,6-trichloropyrimidine replacing iodobenzene.
LC-MS (A): tR = 0.87 min; [M+H]+: 309.96
65.2 Methyl 2-chloro-5-(methyl(6-methylsulfanylpyrimidin-4-yl)amino)benzoate
This compound was prepared using a method analogous to that of Example 1 1 (intermediate 1 1 .1 ), intermediate 65.1 replacing intermediate 10.1
LC-MS (B): tR = 0.68 min; [M+H]+: 324.14
65.3 2-Chloro-5-(methyl(6-methylsulfanylDyrimidin-4-yl)amino)benzoic acid
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.2), intermediate 65.2 replacing intermediate 1 .1.
LC-MS (B): tR = 0.51 min; [M+H]+: 310.02
65.4 2-Chloro-N-(1-hvdroxy-cvclohexylmethyl)-5-[methyl-(6-methylsulfanyl-Dyrimidin^ yl)-aminol-benzamide
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.3), intermediate 65.3 replacing intermediate 1.2.
LC-MS (B): tR = 0.60 min; [M+H]+: 421 .15
Example 66 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-[(6-methanesulfonyl- pyrimidin-4-yl)-methyl-amino]-benzamide
To a solution of intermediate 65.4 (830 mg) in DCM (10 mL) was added 3- chloroperbenzoic acid (1021 mg) at 0°C. The reaction mixture was stirred for 1 h at 0°C then allowed to warm up ON to RT. The DCM was evaporated off and the residue taken up in EtOAc. The organic phase was washed with a 10% solution of Na2C03, dried over MgS04 and concentrated in vacuo. The crude was purified by CC (Hept/EtOAc 1/1 to 0/1 ) to give 231 mg of the titled compound as a white foam.
LC-MS (B): tR = 0.62 min; [M+H]+: 453.10
Example 67 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-[(6-methoxy-pyrimidin-4- yl)-methyl-amino]-benzamide
Example 66 (48 mg) was mixed with a 5.4 M solution of NaOMe in MeOH (0.196 ml.) and the reaction mixture was stirred ON at RT. It was quenched with H20 and extracted with EtOAc. The organic phase was washed with a sat. solution of NaHC03 and brine, dried over MgS04 and concentrated in vacuo. The crude material was purified by CC (Hept/EtOAc 1/1 to 0/1 ) to give 32 mg of the titled compound as a white foam.
LC-MS (B): tR = 0.60 min; [M+H]+: 405.20
Example 68 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-[methyl-(6-oxo-1 ,6- dihydro-pyrimidin-4-yl)-amino]-benzamide
This compound was prepared using a method analogous to that of Example 16 (intermediate 16.1 ), example 66 replacing intermediate 10.2 except that it was purified by preparative LC-MS using method V.
LC-MS (B): tR = 0.53 min; [M+H]+: 391 .18
Example 69 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-(pyrimidin-2-ylamino)- benzamide
69.1 2-Chloro-5-(pyrimidin-2-ylamino)-benzoic acid methyl ester
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.1 ), 2-chloropyrimidine replacing iodobenzene.
LC-MS (A): tR = 0.93 min; [M+H]+: 265.82 69.2 2-Chloro-5-(Dyrimidin-2-ylamino)-benzoic acid
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.2), intermediate 69.1 replacing intermediate 1.1.
LC-MS (A): tR = 0.80 min; [M+H]+: 250.54
69.3 2-Chloro-N-(1-hvdroxy-cvclohexylmethyl)-5-(pyrimidin-2-ylamino
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.3), intermediate 69.2 replacing intermediate 1.2.
LC-MS (A): tR = 0.85 min; [M+H]+: 361 .39
Example 70 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-(methyl-pyrimidin-2-yl- amino)-benzamide
This compound was prepared using a method analogous to that of Example 1 1 (intermediate 1 1 .1 ), intermediate 69.3 replacing intermediate 10.1.
LC-MS (A): tR = 0.83 min; [M+H]+: 375.70
Example 71 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-[(2-methoxy-ethyl)- pyrimidin-2-yl-amino]-benzamide
This compound was prepared using a method analogous to that of Example 1 1 (intermediate 1 1.1 ), intermediate 69.3 replacing intermediate 10.1 and 2-bromoethyl methyl ether replacing methyl iodide.
LC-MS (A): tR = 0.84 min; [M+H]+: 419.54
Example 72 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-(4-methylsulfanyl- pyrimidin-2-ylamino)-benzamide
72.1 2-Chloro-5-(4-methylsulfanyl-pyrimidin-2-ylamino)-benzoic acid methyl ester
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.1 ), 2-chloro-4-methylsulfanylpyrimidine replacing iodobenzene.
LC-MS (A): tR = 1 .00 min; [M+H]+: 310.60 72.2 2-Chloro-5-(4-methylsulfanyl-Dyrimidin-2-ylamino)-benzoic acid
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.2), intermediate 72.1 replacing intermediate 1.1.
LC-MS (A): tR = 0.86 min; [M+H]+: 296.36
72.3 2-Chloro-N-(1-hvdroxy-cvclohexylmethyl)-5-(4-methylsulfanyl-pyrimidin-2-yla benzamide
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.3), intermediate 72.2 replacing intermediate 1.2.
LC-MS (B): tR = 0.68 min; [M+H]+: 407.10
Example 73 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-[methyl-(4-methylsulfanyl- pyrimidin-2-yl)-amino]-benzamide
This compound was prepared using a method analogous to that of Example 1 1 (intermediate 1 1 .1 ), intermediate 72.3 replacing intermediate 10.1.
LC-MS (B): tR = 0.66 min; [M+H]+: 421 .14
Example 74 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-[(4-methoxy-pyrimidin-2- yl)-methyl-amino]-benzamide
74.1 2-Chloro-N-( 1 -hydroxy-cvclohexylmeth yl)-5-fmeth yl-(4-methanesulfon yl-p yrimidin- 2-yl)-aminol-benzamide
This compound was prepared using a method analogous to that of Example 66, example 73 replacing intermediate 65.4.
LC-MS (B): tR = 0.66 min; [M+H]+: 453.13 74.2 2-Chloro-N-(1-hvdroxy-cvclohexylmethyl)-5-f(4-methoxy-Dyrim
aminol-benzamide
This compound was prepared using a method analogous to that of Example 67, intermediate 74.1 replacing example 66.
LC-MS (B): tR = 0.55 min; [M+H]+: 405.18
Example 75 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-[methyl-(6-oxo-1 ,6- dihydro-pyrimidin-2-yl)-amino]-benzamide
This compound was prepared using a method analogous to that of Example 16 (intermediate 16.1 ), intermediate 74.1 replacing intermediate 10.2 except that the reaction mixture was stirred for 1 h at 45°C and that the crude was purified by preparative LC-MS using method V.
LC-MS (B): tR = 0.52 min; [M+H]+: 391 .20
Example 76 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-(pyrimidin-5-ylamino)- benzamide
76.1 2-Chloro-5-(Dyrimidin-5-ylamino)-benzoic acid methyl ester
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.1 ), 5-bromopyrimidine replacing iodobenzene.
LC-MS (A): tR = 0.92 min; [M+H]+: 265.17
76.2 2-Chloro-5-(Dyrimidin-5-ylamino)-benzoic acid
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.2), intermediate 76.1 replacing intermediate 1.1.
LC-MS (A): tR = 0.78 min; [M+H]+: 250.76
76.3 2-Chloro-N-(1-hvdroxy-cvclohexylmethyl)-5-(pyrimidin-5-yl^
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.3), intermediate 76.2 replacing intermediate 1.2. LC-MS (A): tR = 0.83 min; [M+H]+: 361 .45
Example 77 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-[(2-methoxy-ethyl)- pyrimidin-5-yl-amino]-benzamide
This compound was prepared using a method analogous to that of Example 1 1 (intermediate 1 1.1 ), intermediate 76.3 replacing intermediate 10.1 and 2-bromoethyl methyl ether replacing methyl iodide.
LC-MS (A): tR = 0.84 min; [M+H]+: 418.84
Example 78 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-(pyrazin-2-ylamino)- benzamide
78.1 2-Chloro-5-(Dyrazin-2-ylamino)-benzoic acid methyl ester
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.1 ), 2-chloropyrazine replacing iodobenzene.
LC-MS (A): tR = 0.93 min; [M+H]+: 264.47
78.2 2-Chloro-5-(Dyrazin-2-ylamino)-benzoic acid
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.2), intermediate 78.1 replacing intermediate 1.1.
LC-MS (A): tR = 0.81 min; [M+H]+: 250.74
78.3 2-Chloro-N-(1-hvdroxy-cvclohexylmethyl)-5-(Dyrazin-2-ylam
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.3), intermediate 78.2 replacing intermediate 1.2.
LC-MS (A): tR = 0.86 min; [M+H]+: 361 .53 Example 79 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-(methyl-pyrazin-2-yl- amino)-benzamide
79.1 2-Chloro-5-(methyl-Dyrazin-2-yl-amino)-benzoic acid methyl ester
This compound was prepared using a method analogous to that of Example 1 1 (intermediate 1 1 .1 ), intermediate 78.1 replacing intermediate 10.1.
LC-MS (A): tR = 0.97 min; [M+H]+: 279.13
79.2 2-Chloro-5-(methyl-pyrazin-2-yl-amino)-benzoic acid
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.2), intermediate 79.1 replacing intermediate 1.1.
LC-MS (A): tR = 0.78 min; [M+H]+: 263.95
79.3 2-Chloro-N-(1-hvdroxy-cvclohexylmethyl)-5-(methyl-Dyrazin-2-yl-amin
benzamide
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.3), intermediate 79.2 replacing intermediate 1 .2.
LC-MS (A): tR = 0.82 min; [M+H]+: 375.01
Example 80 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-[(2-methoxy-ethyl)- pyrazin-2-yl-amino]-benzamide
This compound was prepared using a method analogous to that of Example 1 1 (intermediate 1 1.1 ), intermediate 78.3 replacing intermediate 10.1 and 2-bromoethyl methyl ether replacing methyl iodide.
LC-MS (A): tR = 0.88 min; [M+H]+: 419.66 Example 81 2-Chloro-5-[(6-chloro-pyrazin-2-yl)-methyl-amino]-N-(1 -hydroxy- cyclohexylmethyl)-benzamide
81.1 2-Chloro-5-(6-chloro-Dyrazin-2-ylamino)-benzoic acid methyl ester
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.1 ), 2,6-dichloropyrazine replacing iodobenzene.
LC-MS (B): tR = 0.82 min; [M+CH3CN+H]+: 339.09
81.2 2-Chloro-5-[(6-chloro-pyrazin-2-yl)-methyl-aminol-benzoic acid methyl ester
This compound was prepared using a method analogous to that of Example 1 1 (intermediate 1 1 .1 ), intermediate 81.1 replacing intermediate 10.1.
LC-MS (C): tR = 0.92 min; [M+CH3CN+H]+: 353.08
81.3 2-Chloro-5-f(6-chloro-Dyrazin-2-yl)-methyl-aminol-benzoic acid
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.2), intermediate 81 .2 replacing intermediate 1.1.
LC-MS (B): tR = 0.71 min; [M+ CH3CN+H]+: 339.08
81.4 2-Chloro-5-i(6-chloro-Dyrazin-2-yl)-methyl-aminol-N-(1-hvdroxy-cvclohexylmethyl)- benzamide
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.3), intermediate 81 .3 replacing intermediate 1 .2.
LC-MS (B): tR = 0.76 min; [M+H]+: 409.13
Example 82 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-[(6-methoxy-pyrazin-2-yl)- methyl-amino]-benzamide
This compound was prepared using a method analogous to that of Example 12, intermediate 81 .4 replacing intermediate 10.3 except that the reaction mixture was stirred for 1 h at 40°C then for 18h at RT and that the crude was purified by preparative LC-MS using method VI. LC-MS (B): tR = 0.70 min; [M+H]+: 405.19
Example 83 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-[methyl-(6-methylamino- pyrazin-2-yl)-amino]-benzamide
This compound was prepared using a method analogous to that of Example 14, intermediate 81 .4 replacing intermediate 1 1.3 except that the reaction mixture was stirred for 5 days at 100°C and additional amounts of the 41 % aqueous solution of methylamine are necessary for completion of the reaction.
LC-MS (B): tR = 0.57 min; [M+H]+: 404.30
Example 84 2-Chloro-5-[(6-dimethylamino-pyrazin-2-yl)-methyl-amino]-N-(1 - hydroxy -cyclohexylmethyl)-benzamide
This compound was prepared using a method analogous to that of Example 15, intermediate 81 .4 replacing intermediate 1 1.3 except that the reaction mixture was stirred for 8 days at 100°C and additional amounts of the 40% aqueous solution of dimethylamine are necessary for completion of the reaction.
LC-MS (B): tR = 0.60 min; [M+H]+: 418.02
Example 85 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-[methyl-(6-oxo-1 ,6- dihydro-pyrazin-2-yl)-amino]-benzamide
To a solution of intermediate 81.4 (40 mg) in dimethylsufoxide (0.090 mL) was added a 32% aqueous solution of NaOH (0.090 mL) at RT and the reaction mixture was stirred for 1 h at 150°C. It was concentrated to dryness and purified by preparative LC-MS using method IV.
LC-MS (B): tR = 0.57 min; [M+H]+: 390.97 Example 86 2-Chloro-5-[(3-chloro-pyrazin-2-yl)-methyl-amino]-N-(1 -hydroxy- cyclohexylmethyl)-benzamide
86.1 2-Chloro-5-(3-chloro-Dyrazin-2-ylamino)-benzoic acid methyl ester
This compound was prepared using a method analogous to that of Example 8 (intermediate 8.1 ), 2-amino-3-chloropyrazine replacing 4-aminopyrimidine.
LC-MS (B): tR = 0.81 min; [M+H]+: 298.22
86.2 2-Chloro-5-((3-chloropyrazin-2-yl)-methyl-amino)benzoic acid methyl ester
This compound was prepared using a method analogous to that of Example 1 1 (intermediate 1 1 .1 ), intermediate 86.1 replacing intermediate 10.1.
LC-MS (B): tR = 0.83 min; [M+H]+: 312.09
86.3 2-Chloro-5-( ( 3-chlorop yrazin-2-yl)-meth yl-amino)benzoic acid
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.2), intermediate 86.2 replacing intermediate 1.1.
LC-MS (B): tR = 0.67 min; [M+ H]+: 298.22
86.4 2-Chloro-5-i(3-chloro-Dyrazin-2-yl)-methyl-aminol-N-(1-hvdroxy-cvclohexylmethyl)- benzamide
This compound was prepared using a method analogous to that of Example 10 (intermediate 10.3), intermediate 86.3 replacing intermediate 10.2
LC-MS (B): tR = 0.72 min; [M+H]+: 409.1 1
Example 87 2-Chloro-5-[(5-chloro-pyrazin-2-yl)-methyl-amino]-N-(1 -hydroxy- cyclohexylmethyl)-benzamide
87.1 2-Chloro-5-(5-chloro-pyrazin-2-ylamino)-benzoic acid methyl ester
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.1 ), 2,5-dichloropyrazine replacing iodobenzene.
LC-MS (B): tR = 0.84 min; [M+H]+: 298.06 87.2 2-Chloro-5-f(5-chloro-Dyrazin-2-yl)-methyl-aminol-benzoic acid methyl ester
This compound was prepared using a method analogous to that of Example 1 1 (intermediate 1 1 .1 ), intermediate 87.1 replacing intermediate 10.1.
LC-MS (B): tR = 0.87 min; [M+H]+: 312.10
87.3 2-Chloro-5-[(5-chloro-pyrazin-2-yl)-methyl-aminol-benzoic acid
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.2), intermediate 87.2 replacing intermediate 1.1.
LC-MS (B): tR = 0.72 min; [M+ H]+: 298.07.
87.4 2-Chloro-5-i(5-chloro-Dyrazin-2-yl)-methyl-aminol-N-(1-hvdroxy-cvcloh
benzamide
This compound was prepared using a method analogous to that of Example 10 (intermediate 10.3), intermediate 87.3 replacing intermediate 10.2
LC-MS (B): tR = 0.76 min; [M+H]+: 409.27
Example 88 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-[(5-methoxy-pyrazin-2-yl)- methyl-amino]-benzamide
This compound was prepared using a method analogous to that of Example 12, intermediate 87.4 replacing intermediate 10.3 except that the reaction mixture was stirred for 18h at 40°C and that the crude was purified by preparative LC-MS using method VI.
LC-MS (B): tR = 0.73 min; [M+H]+: 405.16
Example 89 2-Chloro-5-[(6-chloro-pyridazin-3-yl)-methyl-amino]-N-(1 -hydroxy- cyclohexylmethyl)-benzamide
89.1 2-Chloro-5-(6-chloro-pyridazin-3-ylamino)-benzoic acid methyl ester
A solution of 3,6-dichloropyridazine (240 mg) and methyl-5-amino-2-chlorobenzoate (299 mg) in EtOH (9 mL) was heated in the microwave for 30 min at 150°C. The reaction was concentrated in vacuo and the crude was purified by CC (Hept/EtOAc 1/0 to 4/6) to give 203 mg of the titled compound as a light yellow solid.
LC-MS (B): tR = 0.72 min; [M+H]+: 298.06
89.2 2-Chloro-5-f(6-chloro-Dyridazin-3-yl)-methyl-aminol-benzoic acid methyl ester
This compound was prepared using a method analogous to that of Example 1 1 (intermediate 1 1 .1 ), intermediate 89.1 replacing intermediate 10.1.
LC-MS (B): tR = 0.74 min; [M+H]+: 312.09
89.3 2-Chloro-5-i(6-chloro-Dyridazin-3-yl)-methyl-aminol-benzoic acid
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.2), intermediate 89.2 replacing intermediate 1.1
LC-MS (B): tR = 0.59 min; [M+ H]+: 298.06.
89.4 2-Chloro-5-i(6-chloro-Dyridazin-3-yl)-methyl-aminol-N-(1-hvdroxy- cvclohexylmethvD-benzamide
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.3), intermediate 89.3 replacing intermediate 1.2
LC-MS (B): tR = 0.66 min; [M+H]+: 409.10
Example 90 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-[methyl-(6-oxo-1 ,6- dihydro-pyridazin-3-yl)-amino]-benzamide
This compound was prepared using a method analogous to that of Example 16 (intermediate 16.1 ), intermediate 89.4 replacing intermediate 10.2 except that the reaction mixture was stirred for 5 days at 1 10°C and that the crude was purified by preparative LC- MS using method V.
LC-MS (B): tR = 0.56 min; [M+H]+: 391 .09 Example 91 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-[(6-methoxy-pyridazin-3- yl)-methyl-amino]-benzamide
This compound was prepared using a method analogous to that of Example 12, intermediate 89.4 replacing intermediate 10.3.
LC-MS (B): tR = 0.52 min; [M+H]+: 405.16
Example 92 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-(pyridin-2-ylamino)- benzamide
92.1 2-Chloro-5-(pyridin-2-ylamino)-benzoic acid methyl ester
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.1 ), 2-bromopyridine replacing iodobenzene.
LC-MS (A): tR = 0.71 min; [M+H]+: 263.05
92.2 2-Chloro-5-(Dyridin-2-ylamino)-benzoic acid hydrochloride salt
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.2), intermediate 92.1 replacing intermediate 1 .1 except that the product precipitated from the aqueous phase after acidification and was isolated as a hydrochloride salt.
LC-MS (A): tR = 0.60 min; [M+ H]+: 249.27
92.3 2-Chloro-N-(1-hvdroxy-cvclohexylmethyl)-5-(Dyridin-2-ylamino)-benzamide
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.3), intermediate 92.2 replacing intermediate 1.2.
LC-MS (A): tR = 0.70 min; [M+H]+: 360.78 Example 93 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-(methyl-pyridin-2-yl- amino)-benzamide
93.1 2-Chloro-5-(methyl-Dyridin-2-yl-amino)-benzoic acid methyl ester
This compound was prepared using a method analogous to that of Example 1 1 (intermediate 1 1 .1 ), intermediate 92.2 replacing intermediate 10.1 except that additional amounts of methyl iodide (2 x 1 eq) were used for completion of the reaction and the reaction was stirred for 24h at 40°C.
LC-MS (A): tR = 0.67 min; [M+H]+: 276.98
93.2 2-Chloro-5-(methyl-Dyridin-2-yl-amino)-benzoic acid
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.2), intermediate 93.1 replacing intermediate 1.1 except that a 1 M aqueous solution of NaOH was used instead of lithium hydroxide in H20.
LC-MS (A): tR = 0.57 min; [M+ H]+: 262.89
93.3 2-Chloro-N-(1-hvdroxy-cvclohexylmethyl)-5-(methyl-Dyridin
This compound was prepared using a method analogous to that of Example 10 (intermediate 10.3), intermediate 93.2 replacing intermediate 10.2
LC-MS (C): tR = 0.52 min; [M+H]+: 374.12
Example 94 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-(6-oxo-1 ,6-dihydro- pyridin-2-ylamino)-benzamide
94.1 2-Chloro-6-(2-trimethylsilanyl-ethoxymethoxy)-Dyridine
To a suspension of 6-chloro-2-pyridinol (2.00 g) in acetone (77 mL) was added potassium carbonate (7.47 g) and (2-chloromethoxyethyl)-trimethylsilane (3.28 mL) and the mixture was stirred for 1 h at RT. It was filtered off and the filtrate was concentrated in vacuo. The crude was purified by CC (Hept/EtOAc 1/0 to 1/1 ) to give 2.5 g of the titled compound as a yellowish oil in addition to 1.35 g of the N-protected product as a colorless oil (see intermediate 94.2).
LC-MS (A): tR = 1 .13 min; [M+H]+: 260.76 94.2 6-Chloro-1 -(2-trimethylsilanyl-ethoxymethyl)-1 H-Dyridin-2-one
This compound was isolated as by-product in the preparation of intermediate 94.1 LC-MS (A): tR = 1 .01 min; [M+H]+: 260.74
94.3 2-Chloro-5-[6-(2-trimethylsilanyl-ethoxymethoxy)-pyridin-2-ylam acid methyl ester
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.1 ), intermediate 94.1 replacing iodobenzene.
LC-MS (A): tR = 1 .17 min; [M+H]+: 409.71
94.4 2-Chloro-N-(1-hvdroxy-cvclohexylmethyl)-5-(6-oxo-1.6-dihvdro-Dyridin-2-yla benzamide
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.2), intermediate 94.3 replacing intermediate 1.1 except that a 1 M aqueous solution of NaOH was used instead of lithium hydroxide in H20.
LC-MS (A): tR = 1 .08 min; [M+ H]+: 395.31
94.5 2-Chloro-N-(1-hvdroxy-cvclohexylmethyl)-5-f6-(2-trimethylsila
Dyridin-2-ylaminol-benzamide
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.3), intermediate 94.4 replacing intermediate 1.2.
LC-MS (B): tR = 1 .00 min; [M+H]+: 506.13
94.6 2-Chloro-N-(1-hvdroxy-cvclohexylmethyl)-5-(6-oxo-1,6-dihvdro-py
benzamide
This compound was isolated as by-product in the previous step 94.5 where the cleavage of the silylated protecting group partially occurred.
LC-MS (B): tR = 0.56 min; [M+H]+: 376.12 Example 95 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-[methyl-(6-oxo-1 ,6- dihydro-pyridin-2-yl)-amino]-benzamide
95.1 2-Chloro-5-{methyl-[6-(2-trimethylsilanyl-ethoxymethoxy)-Dyridin^
benzoic acid methyl ester
This compound was prepared using a method analogous to that of Example 1 1 (intermediate 1 1 .1 ), intermediate 94.2 replacing intermediate 10.1 except that the reaction was stirred for 24h at RT.
LC-MS (B): tR = 1 .13 min; [M+H]+: 423.12
95.2 2-Chloro-5-{methyl-[6-(2-trimethylsilanyl-ethoxymethoxy)-Dyri^
benzoic acid
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.2), intermediate 95.1 replacing intermediate 1.1 except that a 1 M aqueous solution of NaOH was used instead of lithium hydroxide in H20.
LC-MS (B): tR = 1 .02 min; [M+ H]+: 409.15
95.3 2-Chloro-N-(1-hvdroxy-cvclohexylmethyl)-5-[methyl-(6-oxo-1 ,6-dihvdro-Dyridin-2- yl)-aminol-benzamide
To a solution of intermediate 95.2 (130 mg) and DIPEA (0.218 ml.) in DCM (2 ml.) was added HOBT (52 mg) and EDC.HCI (73 mg) at RT. The solution was stirred for 5 min at RT and 1-aminomethyl-cyclohexanol hydrochloride (63 mg) was added. The reaction mixture was further stirred for 18h at 35°C and diluted with DCM. The organic phase was washed with a sat. solution of NaHC03 and brine, dried over MgS04 and concentrated in vacuo. The crude material was dissolved in DCM (0.5 ml.) and treated with TFA (0.5 ml_). The solution was stirred for 30 min at 0°C, quenched with a sat. solution of NaHC03 at 0°C and extracted with DCM. The organic phase was washed with brine, dried over MgS04 and concentrated in vacuo. The crude was purified by CC (EtOAc/MeOH 1/0 to 7/3) to give the titled compound as a white solid
LC-MS (B): tR = 0.56 min; [M+H]+: 390.16 Example 96 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-(1 -methyl -6-oxo-1 ,6- dihydro-pyridin-2-ylamino)-benzamide
96.1 6-Chloro- 1-meth yl- 1 H-p yridin-2-one
To a suspension of 6-chloro-2-pyridinol (3 g) in acetone (1 16 mL) was added potassium carbonate (1 1.2 g) and methyl iodide (4.92 mL) and the mixture was stirred for 5h at RT. It was filtered off and the filtrate was concentrated in vacuo. The crude was purified by CC (Hept/EtOAc 8/2 to 0/1 ) to give 1 .96 g of the titled compound as a white solid.
LC-MS (B): tR = 0.39 min; [M+H]+: 144.14
96.2 2-Chloro-5-( 1-methyl-6-oxo-1 ,6-dihvdro-Dyridin-2-ylamino)-benzoic acid methyl ester
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.1 ), intermediate 96.1 replacing iodobenzene.
LC-MS (A): tR = 0.61 min; [M+H]+: 293.23
96.3 2-Chloro-5-( 1-methyl-6-oxo-1,6-dihvdro-Dyridin-2-ylamino)-benzoic acid
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.2), intermediate 96.2 replacing intermediate 1.1 except that a 1 M aqueous solution of NaOH was used instead of lithium hydroxide in H20.
LC-MS (B): tR = 0.49 min; [M+ H]+: 279.20
96.4 2-Chloro-N-(1 -hydroxy-cvclohexylmethyl)-5-(1 -methyl-6-oxo-1 ,6-dihvdro-Dyridin-2- ylamino)-benzamide
This compound was prepared using a method analogous to that of Example 1 (intermediate 1 .3), intermediate 96.3 replacing intermediate 1.2 except that the compound was further purified by preparative LC-MS using method IV.
LC-MS (B): tR = 0.58 min; [M+ H]+: 389.93 Example 97 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-[1 -(2-methoxy-ethyl)-6- oxo-1 ,6-dihydro-pyridin-2-ylamino]-benzamide
97.1 6-Chloro- 1-(2-methoxy-ethyl)- 1H-Dyridin-2-one
This compound was prepared using a method analogous to that of Example 96 (intermediate 96.1 ), 2-bromoethyl methyl ether replacing methyl iodide except that the reaction mixture was stirred for 17h at 70°C.
LC-MS (A): tR = 0.89 min; [M+ H]+: 188.52
97.2 2-Chloro-5-[1-(2-methoxy-ethyl)-6-oxo-1 -dihydro-pyridin-2-ylami acid methyl ester
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.1 ), intermediate 97.1 replacing iodobenzene.
LC-MS (A): tR = 1 .04 min; [M+H]+: 337.30
97.3 2-Chloro-5-{1-(2-methoxy-ethyl)-6-oxo-1.6-dihvdro-Dyridin-2-ylam acid
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.2), intermediate 97.2 replacing intermediate 1.1 except that a 1 M aqueous solution of NaOH was used instead of lithium hydroxide in H20.
LC-MS (A): tR = 0.92 min; [M+ H]+: 323.32
97.4 2-Chloro-N-(1 -hvdroxy-cvclohexylmethyl)-5-[1 -(2-methoxy-ethyl)-6-oxo-1 ,6- dihvdro-Dyridin-2-ylaminol-benzamide
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.3), intermediate 97.3 replacing intermediate 1.2.
LC-MS (A): tR = 0.96 min; [M+ H]+: 433.78 Example 98 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-{[1 -(2-methoxy-ethyl)-6- oxo-1 ,6-dihydro-pyridin-2-yl]-methyl-amino}-benzamide
This compound was prepared using a method analogous to that of Example 1 1 (intermediate 1 1 .1 ), intermediate 97.3 replacing intermediate 10.1 except that the reaction was stirred for 17h at RT.
LC-MS (C): tR = 1.1 1 min; [M+H]+: 447.83
Example 99 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-(1 -methyl -2-oxo-1 ,2- dihydro-pyridin-3-ylamino)-benzamide
99.1 3-Bromo-1-me th yl- 1 H-p yridin-2-one
This compound was prepared using a method analogous to that of Example 96 (intermediate 96.1 ), 3-bromo-2-hydroxypyridine replacing 6-chloropyridinol except that the reaction mixture was stirred for 18h at RT.
LC-MS (B): tR = 0.34 min; [M+ H]+: 188.10
99.2 2-Chloro-5-( 1-methyl-2-oxo-1,2-dihvdro-Dyridin-3-ylamino)-benzoic acid methyl ester
This compound was prepared using a method analogous to that of Example 1 (intermediate 1 .1 ), intermediate 99.1 replacing iodobenzene except that the reaction mixture was stirred for 6 days at 80°C.
LC-MS (B): tR = 0.68 min; [M+H]+: 293.12
99.3 2-Chloro-5-(1-methyl-2-oxo-1 ,2-dihvdro-Dyridin-3-ylamino)-benzoic acid
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.2), intermediate 99.2 replacing intermediate 1 .1 except that it precipitated out the aqueous phase after acidification and was filtered.
LC-MS (B): tR = 0.55 min; [M+ H]+: 279.09 99.4 2-Chloro-N-( 1 -h vdroxy-cvclohexylmethyl)-5-( 1 -meth yl-2-oxo- 1 , 2-dih ydro-p yridin-3- ylamino)-benzamide
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.3), intermediate 99.3 replacing intermediate 1.2.
LC-MS (B): tR = 0.62 min; [M+ H]+: 390.1 1
Example 100 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-(2-methyl-2H-pyrazol-3- ylamino)-benzamide
100.1 2-Chloro-5-(2-methyl-2H-pyrazol-3-ylamino)-benzoic acid methyl ester
This compound was prepared using a method analogous to that of Example 8 (intermediate 8.1 ), 2-methyl-2H-pyrazol-3-ylamine replacing 4-aminopyrimidine except that the reaction mixture was stirred for 2 days at 80°C.
LC-MS (B): tR = 0.64 min; [M+ H]+: 266.02
(ELN163-0329)
100.2 2-Chloro-5-(2-methyl-2H-Dyrazol-3-ylamino)-benzoic acid
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.2), intermediate 100.1 replacing intermediate 1.1 .
LC-MS (B): tR = 0.50 min; [M+ H]+: 251 .96
100.3 2-Chloro-N-(1-hvdroxy-cvclohexylmethyl)-5-(2-methyl-2H-Dyrazo
benzamide
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.3), intermediate 100.2 replacing intermediate 1.2.
LC-MS (B): tR = 0.59 min; [M+ H]+: 363.10
Example 101 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-[methyl-(2-methyl-2H- pyrazol-3-yl)-amino]-benzamide
This compound was prepared using a method analogous to that of Example 1 1 (intermediate 1 1 .1 ), intermediate 100.3 replacing intermediate 10.1 except that the reaction was stirred for 18h at RT. LC-MS (B): tR = 0.66 min; [M+H]+: 377.1 1
Example 102 2-Chloro-5-(6-fluoro-pyridin-2-yloxy)-N-(1 -hydroxy-cyclohexylmethyl)- benzamide
102.1 2-chloro-5-( ( 6-fluorop yridin-2-yl)oxy)benzoic acid
To a solution of 2-chloro-5-hydroxybenzoic acid (282 mg) in anh. DMSO (3.3 mL) was added Cs2C03 (1600 mg) and the suspension was stirred for 20 min at RT. 2,6- difluoropyridine (0.150 mL) was added and the reaction mixture was stirred for 18h at 80°C. It was quenched with H20 and extracted with EtOAc. The aqueous phase was acidified with a 25% aqueous solution of hydrochloric acid and extracted with EtOAc. The organic phase was dried over MgS04 and concentrated in vacuo to give 438 mg of the titled crude compound as a beige solid.
LC-MS (B): tR = 0.70 min; [M+ H]+: 267.94
102.2 2-Chloro-5-(6-fluoro-Dyridin-2-yloxy)-N-(1-hvdroxy-cvclohexylmethyl)-benzamide
This compound was prepared using a method analogous to that of Example 10 (intermediate 10.3), intermediate 102.1 replacing intermediate 10.2
LC-MS (B): tR = 0.75 min; [M+H]+: 379.06
Example 103 2-Chloro-5-(4-fluoro-pyridin-2-yloxy)-N-(1 -hydroxy-cyclohexylmethyl)- benzamide
103.1 2-chloro-5-( (4-fluoroDyridin-2-yl)oxy)benzoic acid
This compound was prepared using a method analogous to that of Example 102 (intermediate 102.1 ), 2,4-difluoropyridine replacing 2,6-difluoropyridine.
LC-MS (B): tR = 0.65 min; [M+H]+: 268.01
103.2 2-Chloro-5-(4-fluoro-pyridin-2-yloxy)-N-(1-hydroxy-cvcloh
This compound was prepared using a method analogous to that of Example 10 (intermediate 10.3), intermediate 103.1 replacing intermediate 10.2
LC-MS (B): tR = 0.71 min; [M+H]+: 379.08 Example 104 2-Chloro-5-(2-chloro-pyridin-4-yloxy)-N-(1 -hydroxy-cyclohexylmethyl)- benzamide
104.1 2-chloro-5-((2-chloroDyridin-4-yl)oxy)benzoic acid
This compound was prepared using a method analogous to that of Example 102 (intermediate 102.1 ), 2-chloro-4-fluoropyridine replacing 2,6-difluoropyridine.
LC-MS (B): tR = 0.68 min; [M+H]+: 284.02
104.2 2-Chloro-5-(2-chloro-pyridin-4-yloxy)-N-(1-hvdroxy-cvclohexylmethyl)-benzamide This compound was prepared using a method analogous to that of Example 10 (intermediate 10.3), intermediate 104.1 replacing intermediate 10.2
LC-MS (C): tR = 0.78 min; [M+H]+: 395.02
Example 105 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-(pyridin-2-yloxy)- benzamide
105.1 2-chloro-5-(Dyridin-2-yloxy)benzoic acid
This compound was prepared using a method analogous to that of Example 102
(intermediate 102.1 ), 2-chloropyridine replacing 2,6-difluoropyridine except that the reaction mixture was stirred for 4 days at 120°C.
LC-MS (B): tR = 0.64 min; [M+H]+: 249.93
105.2 2-Chloro-N-(1-hvdroxy-cvclohexylmethyl)-5-(Dyridin-2-yloxy)-benzamide
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.3), intermediate 105.1 replacing intermediate 1.2
LC-MS (B): tR = 0.69 min; [M+H]+: 361 .06 Example 106 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-(pyridin-4-yloxy)- benzamide
106.1 Sodium 2-chloro-5-(Dyridin-4-yloxy)benzoate
A microwave vial was charged with copper (I) bromide (23 mg), Cs2C03 (2055 mg), 4- hydroxypyridine (300 mg) and methyl-2-chloro-5-iodobenzoate (1 122 mg) and flushed with argon. DMSO (4.7 mL) was added followed by 2-pyridyl acetone (0.043 mL) and the reaction mixture was heated to 100°C for 3h in the microwave. It was diluted with EtOAc, filtered and the filtrate was washed with H20. The aqueous phase was basified with a 1 M solution of NaOH and extracted with EtOAc. The crude was purified by CC (RP C18, H20/CH3CN 1/0 to 8/2) to give 1 .2 g of the titled compound as a white powder.
LC-MS (B): tR = 0.34 min; [M+H]+: 249.98
106.2 2-Chloro-N-(1-hvdroxy-cvclohexylmethyl)-5-(Dyridin-4-yloxy)-benzamide
This compound was prepared using a method analogous to that of Example 10 (intermediate 10.3), intermediate 106.1 replacing intermediate 10.2
LC-MS (B): tR = 0.49 min; [M+H]+: 361 .26
Example 107 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-(pyridin-3-yloxy)- benzamide
107.1 2-chloro-5-(Dyridin-3-yloxy)benzoic acid methyl ester
A microwave vial was charged with copper (I) bromide (7.7 mg), Cs2C03 (685 mg), 3- hydroxypyridine (100 mg) and methyl-2-chloro-5-iodobenzoate (374 mg) and flushed with argon. DMSO (1.6 mL) was added followed by 2-pyridyl acetone (0.014 mL) and the reaction mixture was heated to 100°C for 3h in the microwave. It was diluted with EtOAc, filtered and the filtrate was washed with H20. The organic phase was dried over MgS04 and concentrated in vacuo. The crude was purified by CC (Hept/EtOAc 1/0 to 1/1 ) to give 58 mg of the titled compound as a yellowish waxy solid.
LC-MS (B): tR = 0.59 min; [M+H]+: 264.26 107.2 2-Chloro-5-(Dyridin-3-yloxy)-benzoic acid
This compound was prepared using a method analogous to that of Example 1 (intermediate 1 .2), intermediate 107.1 replacing intermediate 1 .1 except that a 2M solution of NaOH was used intead of LiOH in H20.
LC-MS (B): tR = 0.43 min; [M+ H]+: 249.94
107.3 2-Chloro-N-(1-hvdroxy-cvclohexylmethyl)-5-(pyridin-3-yloxy)-benzamide
This compound was prepared using a method analogous to that of Example 10 (intermediate 10.3), intermediate 107.2 replacing intermediate 10.2
LC-MS (B): tR = 0.53 min; [M+H]+: 361 .14
Example 108 2-Chloro-5-(6-chloro-pyridin-2-yloxy)-N-(1 -hydroxy-cyclohexylmethyl)- benzamide
108.1 2-Chloro-5-( 6-chloro-Dyridin-2-yloxy)-benzoic acid
This compound was prepared using a method analogous to that of Example 102 (intermediate 102.1 ), 2,6-dichloropyridine replacing 2,6-difluoropyridine.
LC-MS (B): tR = 0.74 min; [M+H]+: 284.02
108.2 2-Chloro-5-(6-chloro-Dyridin-2-yloxy)-N-(1-hvdroxy-cvclohexylmethyl)-benzamide This compound was prepared using a method analogous to that of Example 1 (intermediate 1.3), intermediate 108.1 replacing intermediate 1.2.
LC-MS (B): tR = 0.78 min; [M+ H]+: 394.97
Example 109 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-(6-methylamino-pyridin-2- yloxy)-benzamide
This compound was prepared using a method analogous to that of Example 14, intermediate 108.2 replacing intermediate 1 1.3 except that the reaction was stirred for 5 days at 100°C and additional amounts of the 41 % solution of methylamine in H20 (10 eq) were necessary for the completion of the reaction. LC-MS (B): tR = 0.68 min; [M+ H]+: 390.1 1
Example 110 2-Chloro-5-(6-dimethylamino-pyridin-2-yloxy)-N-(1 -hydroxy- cyclohexylmethyl)-benzamide
This compound was prepared using a method analogous to that of Example 15, intermediate 108.2 replacing intermediate 1 1 .3 except that the reaction was stirred for 5 days at 100°C and additional amounts of the 40% solution of dimethylamine in H20 (5 eq) were necessary for the completion of the reaction.
LC-MS (B): tR = 0.82 min; [M+ H]+: 404.13
Example 111 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-(6-methoxy-pyridin-2- yloxy)-benzamide
111.1 2-Chloro-5-hvdroxy-N-(1-hvdroxy-cvclohexylmethyl)-benzamide
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.3), 2-chloro-5-hydroxybenzoic acid replacing intermediate 1 .2.
LC-MS (B): tR = 0.56 min; [M+ H]+: 284.18
111.2 2-Chloro-N-(1-hvdroxy-cvclohexylmethyl)-5-(6-methoxy-Dyridin-2-yloxy)- benzamide
This compound was prepared using a method analogous to that of Example 102 (intermediate 102.1 ), 2-chloro-6-methoxypyridine replacing 2,6-difluoropyridine and intermediate 1 1 1.1 replacing 2-chloro-5-hydroxybenzoic acid except that the reaction mixture was stirred for 7 days at 100°C.
LC-MS (B): tR = 0.79 min; [M+H]+: 391 .13 Example 112 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-(6-oxo-1 ,6-dihydro- pyridin-2-yloxy)-benzamide
112.1 2-chloro-5-((6-oxo-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihvdroDyridin vDoxy) benzoic acid
This compound was prepared using a method analogous to that of Example 102 (intermediate 102.1 ), intermediate 94.2 replacing 2,6-difluoropyridine except that the reaction mixture was stirred for 4 days at 80°C.
LC-MS (B): tR = 0.80 min; [M+H]+: 396.22
112.2 2-Chloro-N-(1-hvdroxy-cvclohexylmethyl)-5-[6-oxo-1-(2-trimethylsilanyl- ethoxymethyl)-1,6-dihvdro-Dyridin-2-yloxyl-benzamide
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.3), intermediate 1 12.1 replacing intermediate 1.2.
LC-MS (B): tR = 0.85 min; [M+ H]+: 507.29
112.3 2-Chloro-N-(1-hvdroxy-cvclohexylmethyl)-5-(6-oxo-1.6-dihvdro-Dyridin-2-yloxy)- benzamide
To a solution of intermediate 1 12.2 (68 mg) in THF (1 .18 mL) was added a 1 M solution of tetrabutyl ammonium fluoride (0.496 mL) and the reaction mixture was stirred for 2 days at 60°C. Two additional amounts of a 1 M solution of tetrabutyl ammonium fluoride (2 x 0.5 mL) were necessary for the completion of the reaction. The reaction mixture was diluted with DCM and washed with a sat. solution of NaHC03. The organic phase was dried over MgS04 and concentrated in vacuo. The crude was purified by CC (Hept/EtOAc 1/1 to 0/1 ) then by preparative LC-MS using method IV to give the titled compound as a white powder.
LC-MS (B): tR = 0.61 min; [M+ H]+: 377.30 Example 113 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-(1 -methyl -6-oxo-1 ,6- dihydro-pyridin-2-yloxy)-benzamide
113.1 2-Chloro-5-( 1-methyl-6-oxo-1,6-dihvdro-Dyridin-2-yloxy)-benzoic acid
This compound was prepared using a method analogous to that of Example 102 (intermediate 102.1 ), intermediate 96.1 replacing 2,6-difluoropyridine except that the reaction mixture was stirred for 2 days at 85°C.
LC-MS (B): tR = 0.52 min; [M+H]+: 280.30
113.2 2-Chloro-N-(1 -hydroxy-cvclohexylmethyl)-5-(1 -methyl-6-oxo-1 ,6-dihydro-pyridin-2- yloxy)-benzamide
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.3), intermediate 1 13.1 replacing intermediate 1.2.
LC-MS (B): tR = 0.59 min; [M+ H]+: 391 .25
Example 114 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-(pyrimidin-4-yloxy)- benzamide
114.1 2-Chloro-5-(Dyrimidin-4-yloxy)-benzoic acid
This compound was prepared using a method analogous to that of Example 102 (intermediate 102.1 ), 4-chloropyrimidine dihydrochloride replacing 2,6-difluoropyridine except that the reaction mixture was stirred for 3 days at 80°C.
LC-MS (B): tR = 0.51 min; [M+H]+: 251 .24
114.2 2-Chloro-N-(1-hvdroxy-cvclohexylmethyl)-5-(Dyrimidin-4-yloxy)-benzamide
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.3), intermediate 1 14.1 replacing intermediate 1.2.
LC-MS (B): tR = 0.58 min; [M+ H]+: 362.24 Example 115 2-Chloro-5-(2-chloro-pyrimidin-4-yloxy)-N-(1 -hydroxy- cyclohexylmethyl)-benzamide
115.1 2-chloro-5-((2-chloroDyrimidin-4-yl)oxy)benzoic acid
This compound was prepared using a method analogous to that of Example 102 (intermediate 102.1 ), 2,4-dichloropyrimidine replacing 2,6-difluoropyridine except that the product precipitated out off the aqueous phase after acidification and was isolated by filtration.
LC-MS (B): tR = 0.63 min; [M+H]+: 285.16
115.2 2-Chloro-5-(2-chloro-Dyrimidin-4-yloxy)-N-(1-hvdroxy-cvclohexylmethyl)- benzamide
This compound was prepared using a method analogous to that of Example 10 (intermediate 10.3), intermediate 1 15.1 replacing intermediate 10.2
LC-MS (B): tR = 0.69 min; [M+H]+: 396.18
Example 116 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-(2-methylamino-pyrimidin- 4-yloxy)-benzamide
This compound was prepared using a method analogous to that of Example 14, intermediate 1 15.2 replacing intermediate 1 1 .3 except that a 2M solution of methylamine in THF (2 eq) was used instead of a 41 % solution in H20 and that the reaction was stirred for 18h at RT.
LC-MS (B): tR = 0.53 min; [M+ H]+: 391 .24
Example 117 2-Chloro-5-(2-dimethylamino-pyrimidin-4-yloxy)-N-(1 -hydroxy- cyclohexylmethyl)-benzamide
This compound was prepared using a method analogous to that of Example 15, intermediate 1 15.2 replacing intermediate 1 1.3 except that a 2M solution of dimethylamine in THF (2 eq) was used instead of a 40% solution in H20 and that the reaction was stirred for 2h at RT.
LC-MS (B): tR = 0.55 min; [M+ H]+: 405.29 Example 118 2-Chloro-N-(4,4-difluoro-1 -hydroxy-cyclohexylmethyl)-5-(2-oxo-1 ,2- dihydro-pyrimidin-4-yloxy)-benzamide
118.1 4-Chloro-2-(2-trimethylsilanyl-ethoxy)-Dyrimidine
To a solution of 2-(trimethylsilyl)-ethanol (0.962 mL) in THF (10 mL) was added dropwise a 2.5 M solution of n-butyllithium in hexanes at -70°C. The reaction mixture was allowed to warm up to -30°C and cannulated in a solution of 2,4-dichloropyrimidine (1 g) in THF (10 mL) at -70°C. The reaction mixture was allowed to warm up to RT and stirred for 1 h at RT. It was quenched with ice H20 and diluted with Et20. The organic phase was washed with a sat. solution of NaHC03, dried over MgS04 and concentrated in vacuo. The crude was purified by CC (Hept/EtOAc 1/0 to 9/1 ) to give 1 .13 g of the titled compound as a light yellow oil.
1H NMR ((CD3)2SO) δ: 8.58 (d, J = 5.2 Hz, 1 H), 7.29 (d, J = 5.2 Hz, 1 H), 4.43 (m, 2 H), 1.12 (m, 2 H), 0.06 (s, 9 H)
118.2 2-Chloro-5-i2-(2-trimethylsilanyl-ethoxy)-Dyrimidin-4-yloxyl-benzoic acid
This compound was prepared using a method analogous to that of Example 102 (intermediate 102.1 ), intermediate 1 18.1 replacing 2,6-difluoropyridine except that the reaction mixture was stirred for 1 h at 80°C.
LC-MS (B): tR = 0.87 min; [M-2Me+H]+: 339.03
118.3 2-C loro-N-(4A-difluoro-1- vdroxy-cvclo exylmet yl)-5-[2-(2-trimet ylsilanyl- ethoxy)-Dyrimidin-4-yloxyl-benzamide
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.3), intermediate 1 18.2 replacing intermediate 1.2 and intermediate 57.2 replacing 1 -aminomethyl-cyclohexanol hydrochloride.
LC-MS (B): tR = 0.91 min; [M-2Me+H]+: 486.14 118.4 2-Chloro-N-(4.4-difluoro-1-hvdroxy-cvclohexylmethyl)-5-(2-oxo-1.2-dihvdro- Dyrimidin-4-yloxy)-benzamide
To a solution of intermediate 1 18.3 (1 10 mg) in DCM (4.8 mL) was added TFA (1 .9 mL) and the reaction mixture was stirred for 30 min at RT. It was neutralized with a sat. solution of NaHC03 and concentrated in vacuo. The crude was purified by preparative LC- MS using method I to give 18 mg of the titled compound as a white powder.
LC-MS (B): tR = 0.54 min; [M+H]+: 413.98
Example 119 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-(2-oxo-2,3-dihydro- pyrimidin-4-yloxy)-benzamide
This compound was prepared using a method analogous to that of Example 1 (intermediate 1 .3), intermediate 1 18.2 replacing intermediate 1.2. The product was directly engaged in the next deprotection step using a method analogous to that of Example 1 18 (intermediate 1 18.4).
LC-MS (B): tR = 0.51 min; [M+H]+: 378.15
Example 120 2-Chloro-5-(2-chloro-pyrimidin-4-yloxy)-N-(1 -hydroxy- cyclohexylmethyl)-benzamide
120.1 2-Chloro-5-( 2-methoxy-Dyrimidin-4-yloxy)-benzoic acid
This compound was prepared using a method analogous to that of Example 102 (intermediate 102.1 ), 4-chloro-2-methoxypyrimidine replacing 2,6-difluoropyridine except that the reaction mixture was stirred for 1 h at 80°C then for 18h at RT and that the product precipitated out off the aqueous phase after acidification and was isolated by filtration.
LC-MS (B): tR = 0.60 min; [M+H]+: 281 .07
120.2 2-Chloro-N-(1-hvdroxy-cvclohexylmethyl)-5-(2-methoxy-pyrimidin-4-yloxy)- benzamide
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.3), intermediate 120.1 replacing intermediate 1.2
LC-MS (B): tR = 0.66 min; [M+H]+: 392.06 Example 121 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-(pyrazin-2-yloxy)- benzamide
121.1 2-Chloro-5-(Dyrazin-2-yloxy)-benzoic acid
This compound was prepared using a method analogous to that of Example 102 (intermediate 102.1 ), 2-chloropyrazine replacing 2,6-difluoropyridine.
LC-MS (B): tR = 0.56 min; [M+CH3CN+H]+: 292.26
121.2 2-Chloro-N-(1-hvdroxy-cvclohexylmethyl)-5-(pyrazin-2-yloxy)-benzamide
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.3), intermediate 121.1 replacing intermediate 1.2
LC-MS (B): tR = 0.63 min; [M+H]+: 362.10
Example 122 2-Chloro-5-(6-chloro-pyrazin-2-yloxy)-N-(1 -hydroxy-cyclohexylmethyl)- benzamide
122.1 2-Chloro-5-( 6-chloro-Dyrazin-2-yloxy)-benzoic acid
This compound was prepared using a method analogous to that of Example 102 (intermediate 102.1 ), 2,6-dichloropyrazine replacing 2,6-difluoropyridine.
LC-MS (B): tR = 0.68 min; [M+CH3CN+H]+: 325.97
122.2 2-Chloro-5-( 6-chloro-p yrazin-2-yloxy)-N-( 1 -h ydroxy-cvclohexylmeth yl)-benzamide
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.3), intermediate 122.1 replacing intermediate 1.2
LC-MS (B): tR = 0.74 min; [M+H]+: 396.01 Example 123 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-(6-methoxy-pyrazin-2- yloxy)-benzamide
This compound was prepared using a method analogous to that of Example 102 (intermediate 102.1 ), 2-chloro-6-methoxypyrazine replacing 2,6-difluoropyridine and intermediate 1 1 1.1 replacing 2-chloro-5-hydroxybenzoic acid.
LC-MS (B): tR = 0.71 min; [M+H]+: 392.08
Example 124 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-(6-methylamino-pyrazin-2- yloxy)-benzamide
This compound was prepared using a method analogous to that of Example 14, intermediate 122.2 replacing intermediate 1 1 .3 except that the reaction mixture was stirred for 18h at 70°C.
LC-MS (B): tR = 0.64 min; [M+ H]+: 391 .07
Example 125 2-Chloro-5-(6-dimethylamino-pyrazin-2-yloxy)-N-(1 -hydroxy- cyclohexylmethyl)-benzamide
This compound was prepared using a method analogous to that of Example 15, intermediate 122.2 replacing intermediate 1 1 .3 except that a 2M solution of dimethylamine in THF (10 eq) was used instead of a 40% solution in H20 and that the reaction mixture was stirred for 18h at 70°C.
LC-MS (B): tR = 0.70 min; [M+ H]+: 405.12
Example 126 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-(6-oxo-1 ,6-dihydro- pyrazin-2-yloxy)-benzamide
This compound was prepared using a method analogous to that of Example 16 (intermediate 16.1 ), intermediate 122.2 replacing intermediate 10.2 except that the reaction mixture was stirred for 15 min at 120°C in a sealed vial and that the crude was purified by preparative LC-MS using method I.
LC-MS (B): tR = 0.61 min; [M+ H]+: 378.08 Example 127 2-Chloro-5-(6-chloro-pyridazin-3-yloxy)-N-(1 -hydroxy- cyclohexylmethyl)-benzamide
This compound was prepared using a method analogous to that of Example 102 (intermediate 102.1 ), 3,6-dichloropyridazine replacing 2,6-difluoropyridine and intermediate 1 1 1.1 replacing 2-chloro-5-hydroxybenzoic acid.
LC-MS (B): tR = 0.67 min; [M+H]+: 396.03
Example 128 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-(6-methoxy-pyridazin-3- yloxy)-benzamide
128.1 2-chloro-5-((6-methoxyDyridazin-3-yl)oxy)benzoic acid
This compound was prepared using a method analogous to that of Example 102 (intermediate 102.1 ), 3-chloro-6-methoxypyridazine replacing 2,6-difluoropyridine except that the reaction mixture was stirred for 18h at 120°C.
LC-MS (B): tR = 0.60 min; [M+H]+: 281 .06
128.2 2-Chloro-N-(1-hvdroxy-cvclohexylmethyl)-5-(6-methoxy-Dyridazin-3-yloxy)- benzamide
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.3), intermediate 128.1 replacing intermediate 1.2
LC-MS (B): tR = 0.66 min; [M+H]+: 392.1 1
Example 129 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-(6-oxo-1 ,6-dihydro- pyridazin-3-yloxy)-benzamide
129.1 3-Chloro-6-(2-trimethylsilanyl-ethoxy)-pyridazine
To a solution of 2-(trimethylsilyl)-ethanol (0.505 mL) in THF (5 mL) was added portionwise a 60% dispersion of sodium hydride in mineral oil (148 mg) at 0°C. The suspension was stirred for 15 min at 0°C then added to a solution of 3,6-dichloropyridazine (500 mg) in THF (5 mL) at 0°C. The reaction mixture was stirred for 30 min at 0°C then for 18h at RT. It was quenched with H20 and a sat. solution of ammonium chloride and extracted with EtOAc. The organic phase was washed with brine, dried over MgS04 and concentrated. The crude was purified by CC (Hept/EtOAc 1/0 to 8/2) to give 497 mg of titled compound as a white solid.
1H NMR ((CD3)2SO) δ: 7.77 (d, J = 9.2 Hz, 1 H), 7.29 (d, J = 9.2 Hz, 1 H), 4.52 (m, 2 H), 1.15 (m, 2 H), 0.07 (s, 9 H).
129.2 2-Chloro-N-(1-hvdroxy-cvclohexylmethyl)-5-[6-(2-trimethylsilanyl-ethoxy)-py 3-yloxyl-benzamide
This compound was prepared using a method analogous to that of Example 102 (intermediate 102.1 ), intermediate 129.1 replacing 2,6-difluoropyridine and intermediate 1 1 1 .1 replacing 2-chloro-5-hydroxybenzoic acid except that the reaction mixture was stirred for 8 days at 80°C.
LC-MS (B): tR = 0.95 min; [M+H]+: 478.28
129.3 2-Chloro-N-(1-hvdroxy-cvclohexylmethyl)-5-(6-oxo-1,6-dihvdro-DV
benzamide
To a solution of intermediate 129.2 (20 mg) in THF (0.2 mL) was added a 1 M solution of tetrabutyl ammonium fluoride (0.126 mL) and the reaction mixture was stirred for 1 h at RT. It was concentrated in vacuo and purified by preparative LC-MS using method IV to give 2 mg of titled compound as a white powder.
LC-MS (B): tR = 0.55 min; [M+ H]+: 378.07
Example 130 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-(pyridazin-3-yloxy)- benzamide
130.1 3-Chloro-pyridazine
A suspension of 3(2H)-pyridazinone (1 g) in phosphorus oxychloride (0.970 mL) was heated to 80°C for 18h. The reaction mixture was evaporated off and the residue was treated with ice 2M solution of NaOH and extracted with EtOAc. The organic phase was washed with brine, dried over MgS04 and concentrated in vacuo to give 857 mg of the crude titled compound as a purple solid.
1H NMR ((CD3)2SO) δ: 9.27 (d, J = 4.7 Hz, 1 H), 7.95 (d, J = 8.7 Hz, 1 H), 7.82 (dd, 4 = 8.7 Hz, J2 = 4.7 Hz, 1 H) 130.2 2-Chloro-N-(1-hvdroxy-cvclohexylmethyl)-5-(Dyridazin-3-yloxy)-benzamide
This compound was prepared using a method analogous to that of Example 102 (intermediate 102.1 ), intermediate 130.1 replacing 2,6-difluoropyridine and intermediate 1 1 1 .1 replacing 2-chloro-5-hydroxybenzoic acid.
LC-MS (B): tR = 0.58 min; [M+H]+: 362.14
Example 131 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-(5-methoxy-pyridazin-3- yloxy)-benzamide
131.1 3-chloro-5-methoxyDyridazine
To a solution of 3,5-dichloropyridazine (300 mg) in MeOH (2 mL) was added a 5.4 M solution of sodium methoxide in MeOH (0.410 mL) and the reaction mixture was stirred for 1 h at 90°C. It was quenched with H20 and extracted with EtOAc. The organic phase was washed with a 5% solution of KHS04, a sat. solution of NaHC03 and brine, dried over MgS04 and concentrated in vacuo to give the crude titled compound as an orange solid.
1H NMR ((CD3)2SO) δ: 9.01 (d, J = 2.4 Hz, 1 H), 7.55 (d, J = 2.4 Hz, 1 H), 3.96 (s, 3 H)
131.2 2-Chloro-N-(1-hvdroxy-cvclohexylmethyl)-5-(5-methoxy-Dyridazin-3-yloxy)- benzamide
This compound was prepared using a method analogous to that of Example 102 (intermediate 102.1 ), intermediate 131.1 replacing 2,6-difluoropyridine and intermediate 1 1 1 .1 replacing 2-chloro-5-hydroxybenzoic acid.
LC-MS (B): tR = 0.61 min; [M+H]+: 392.24
Example 132 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-(pyridin-2-ylsulfanyl)- benzamide
132.1 2-Chloro-5-hydroxy-benzoic acid methyl ester
To a solution of 2-chloro-5-hydroxy-benzoic acid (3 g) in anh. MeOH (22.6 mL) was added a concentrated solution of sulfuric acid (0.870 mL) at RT and the reaction mixture was stirred for 18h at 75°C. The solvent was evaporated off and the residue was diluted with H20 and extracted with EtOAc. The organic phase was washed with a sat. solution of NaHC03, dried over MgS04 and concentrated in vacuo to give 3.15 g of the titled compound as a white solid.
1H NMR (CDCIs) δ: 7.36 (d, J = 3.0 Hz, 1 H), 7.29 (d, J = 8.7 Hz, 1 H), 6.96 (dd, Ji = 8.7 Hz, J2 = 3.0 Hz, 1 H), 6.55 (s, 1 H), 3.95 (s, 3 H)
132.2 2-Chloro-5-dimethylthiocarbamoyloxy-benzoic acid methyl ester
To a solution of intermediate 132.1 (10 g) in 1-methyl-2-pyrrolidinone (8 ml.) was added 1 ,4-diazabicyclo[2.2.2]octane (7.51 g) and the reaction mixture was heated to 50°C. A solution of dimethylthiocarbamoyl chloride (6.96 g) in 1-methyl-2-pyrrolidinone (2 ml.) was added dropwise and the reaction mixture was stirred for 3h at 50°C. It was quenched with H20 (85 ml.) over 10 min, heated to 50°C and cooled to RT. It was extracted with EtOAc, the organic phase was dried over MgS04 and concentrated in vacuo. A light yellow solid precipitated out the oily residue and was filtered to give 10 g of the crude titled compound. LC-MS (B): tR = 0.79 min; [M+H]+: 273.90
132.3 2-Chloro-5-dimethylcarbamoylsulfanyl-benzoic acid methyl ester
Intermediate 132.2 was heated to 220°C and the melted solid was stirred for 24h at 220°C. The cooled reaction mixture was purified by CC (Hept/EtOAc 1/0 to 7/3) to give 5.6 g of the titled compound as a yellow oil.
LC-MS (B): tR = 0.77 min; [M+H]+: 273.87
(ELN163-0487)
132.4 2-Chloro-5-mercaDto-benzoic acid
To a solution of KOH (4.5 g) in THF (24 ml.) was added a solution of intermediate 132.3 (5.5 g) in THF (2 ml.) and the reaction mixture was stirred for 20h at 70°C. The solvent was evaporated off and the residue was suspended in H20. The aqueous phase was acidified with a 2M solution of hydrochloric acid and extracted with DCM. The organic phase was dried over MgS04 and concentrated in vacuo to give 3.3 g of the crude titled compound as a light yellow oil.
1H NMR (CDCI3) δ: 7.95 (s, 1 H), 7.39 (s, 2 H), 3.59 (s, 1 H) 132.5 2-chloro-5-(Dyridin-2-ylsulfan vDbenzoic acid
This compound was prepared using a method analogous to that of Example 102 (intermediate 102.1 ), 2-chloropyridine replacing 2,6-difluoropyridine and intermediate 132.4 replacing 2-chloro-5-hydroxybenzoic acid except that the reaction mixture was stirred for 6 days at 80°C.
LC-MS (B): tR = 0.63 min; [M+H]+: 265.98
132.6 2-Chloro-N-(1-hvdroxy-cvclohexylmethyl)-5-(pyridin-2-ylsulfanyl)-benzamide
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.3), intermediate 132.5 replacing intermediate 1.2
LC-MS (B): tR = 0.69 min; [M+H]+: 377.07
Example 133 rac-2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-(pyridine-2-sulfinyl)- benzamide
To a solution of intermediate 132.6 (80 mg) in DCM (13 mL) was added dropwise a solution of 3-chloroperbenzoic acid (44 mg) in DCM (5 mL) at 0°C for 20 min. The reaction mixture was stirred for 15 min at 0°C and quenched with a sat. solution of KHS04. The organic phase was washed with a sat. solution of sodium carbonate and brine, dried over MgS04 and concentrated in vacuo. The crude was purified by CC (Hept/EtOAc 7/3 to 0/1 ) to give 59 mg of the titled compound as a white foam.
LC-MS (B): tR = 0.59 min; [M+H]+: 393.06
Example 134 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-(pyridine-2-sulfonyl)- benzamide
To a solution of intermediate 132.6 (80 mg) in DCM (5 mL) was added 3-chloroperbenzoic acid (1 10 mg) and the reaction mixture was stirred for 1 h at RT. It was quenched with a sat. solution of NaHS04. The organic phase was washed with a sat. solution of sodium carbonate and brine, dried over MgS04 and concentrated in vacuo. The crude was purified by CC (Hept/EtOAc 0/1 to 2/8) to give 68 mg of the titled compound as a white foam.
LC-MS (B): tR = 0.64 min; [M+H]+: 409.06 Example 135 2-Chloro-5-(2-chloro-pyrimidin-4-ylsulfanyl)-N-(1 -hydroxy- cyclohexylmethyl)-benzamide
135.1 2-chloro-5-(2-chloroDyrimidin-4-ylsulfanyl)benzoic acid
This compound was prepared using a method analogous to that of Example 102 (intermediate 102.1 ), 2,4-dichloropyrimidine replacing 2,6-difluoropyridine and intermediate 132.4 replacing 2-chloro-5-hydroxybenzoic acid except that the reaction mixture was stirred for 1 h at RT.
LC-MS (B): tR = 0.69 min; [M+H]+: 301 .00
135.2 2-Chloro-5-(2-chloro-Dyrimidin-4-ylsulfanyl)-N-(1-hvdroxy-cvclohexylmethyl)- benzamide
This compound was prepared using a method analogous to that of Example 10 (intermediate 10.3), intermediate 135.1 replacing intermediate 10.2
LC-MS (B): tR = 0.74 min; [M+H]+: 41 1 .91
Example 136 rac-2-Chloro-5-(2-chloro-pyrimidine-4-sulfinyl)-N-(1 -hydroxy- cyclohexylmethyl)-benzamide
This compound was prepared using a method analogous to that of Example 133, intermediate 135.2 replacing intermediate intermediate 132.6
LC-MS (B): tR = 0.64 min; [M+H]+: 428.22
Example 137 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-(2-oxo-1 ,2-dihydro- pyrimidin-4-ylsulfanyl)-benzamide
This compound was prepared using a method analogous to that of Example 16 (intermediate 16.1 ), intermediate 135.2 replacing intermediate 10.2 except that the reaction mixture was stirred for 10 min at 90°C and that the crude was purified by preparative LC-MS using method III.
LC-MS (B): tR = 0.55 min; [M+ H]+: 394.01 Example 138 2-Chloro-N-(4,4-difluoro-1 -hydroxy-cyclohexylmethyl)-5-(2-oxo-1 ,2- dihydro-pyrimidin-4-ylsulfanyl)-benzamide
138.1 2-Chloro-5-[2-(2-trimethylsilanyl-ethoxy)-Dyrimidin-4-ylsulfanyll-benz acid
This compound was prepared using a method analogous to that of Example 102 (intermediate 102.1 ), intermediate 1 18.1 replacing 2,6-difluoropyridine and intermediate 132.4 replacing 2-chloro-5-hydroxybenzoic acid except that the reaction mixture was stirred for 30 min at RT.
LC-MS (B): tR = 0.93 min; [M-2Me+H]+: 354.96
138.2 2-Chloro-N-(4A-difluoro-1-hvdroxy-cvclohexylmethyl)-5-f2-(2-trimethv^
ethoxy)-Dyrimidin-4-ylsulfanyll-benzamide
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.3), intermediate 138.1 replacing intermediate 1.2 and intermediate 57.2 replacing 1 -aminomethyl-cyclohexanol hydrochloride.
LC-MS (B): tR = 0.95 min; [M-2Me+H]+: 502.12
138.3 2-C loro-N-(4A-difluoro-1- vdroxy-cvclo exylmet yl)-5-(2-oxo-1.2-di vdro- Dyrimidin-4-ylsulfanyl)-benzamide
This compound was prepared using a method analogous to that of Example 1 18 (intermediate 1 18.4), intermediate 138.2 replacing intermediate 1 18.3.
LC-MS (B): tR = 0.55 min; [M+H]+: 429.94
Example 139 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-(2-methoxy-pyrimidin-4- ylsulfanyl)-benzamide
139.1 2-Chloro-5-(2-methoxy-pyrimidin-4-ylsulfanyl)-benzoic acid
This compound was prepared using a method analogous to that of Example 102 (intermediate 102.1 ), 4-chloro-2-methoxypyrimidine replacing 2,6-difluoropyridine and intermediate 132.4 replacing 2-chloro-5-hydroxybenzoic acid except that the reaction mixture was stirred for 30 min at 80°C.
LC-MS (B): tR = 0.65 min; [M+H]+: 297.04 139.2 2-Chloro-N-(1-hvdroxy-cvclohexylmethyl)-5-(2-methoxy-Dyrimidin-4-ylsulfanvi benzamide
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.3), intermediate 139.1 replacing intermediate 1.2
LC-MS (B): tR = 0.71 min; [M+H]+: 407.98
Example 140 rac-2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-(2-methoxy- pyrimidine-4-sulfinyl)-benzamide
This compound was prepared using a method analogous to that of Example 133, intermediate 139.2 replacing intermediate 132.6 except that the reaction mixture was stirred for 3h at 0°C and an additional amount of 3-chloroperbenzoic acid (0.3 eq) was necessary for the completion of the reaction.
LC-MS (B): tR = 0.61 min; [M+H]+: 424.07
Example 141 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-(2-methoxy-pyrimidine-4- sulfonyl)-benzamide
This compound was prepared using a method analogous to that of Example 134, intermediate 139.2 replacing intermediate 132.6 except that the reaction mixture was stirred for 18h at RT and an additional amount of 3-chloroperbenzoic acid (2 eq) was necessary for the completion of the reaction.
LC-MS (B): tR = 0.67 min; [M+H]+: 440.07
Example 142 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-(2-oxo-2H-pyridin-1 - ylmethyl)-benzamide
142.1 5-Bromomethyl-2-chloro-benzoic acid
A suspension of 2-chloro-5-methylbenzoic acid (10 g) in chlorobenzene (200 mL) was heated to 50°C and N-bromosuccinimide (10.95 g) was added. The reaction mixture was flushed with argon and 2,2'-azobis(2-methylpropionitrile) (98 mg) was added. The reaction mixture was refluxed for 4h and 2,2'-azobis(2-methylpropionitrile) (98 mg) was added. The reaction mixture was refluxed for 1 h and stirred for 18h at RT. The solvent was evaporated off and the residue taken up in Et20 and filtered. The filtrate was washed with a 2M solution of hydrochloric acid and brine, dried over MgS04 and concentrated in vacuo. The crude was recrystallised from Et20/Hept to give 8 g of the titled compound as a beige solid.
1H NMR ((CD3)2SO) δ: 13.51 (bs, 1 H), 7.88 (d, J = 2.2 Hz, 1 H), 7.61 (dd, Ji = 8.3 Hz, J2 = 2.2 Hz, 1 H), 7.55 (d, J = 8.3 Hz ,1 H), 4.76 (s, 2 H)
142.2 5-(Benzotriazol-1-yloxymethyl)-2-chloro-N-(1-hvdroxy-cvclohexylmethyl)- benzamide
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.3), intermediate 142.1 replacing intermediate 1.2
LC-MS (B): tR = 0.72 min; [M+H]+: 415.28
142.3 2-Chloro-N-( 1 -hydroxy-cvclohexylmeth VI)-5-(2-OXO-2H-D yridin- 1 -ylmeth vQ- benzamide
To a solution of 2-hydroxypyridine (28 mg) in anh. 1 ,2-dimethoxyethane (1 .6 mL) was added potassium carbonate (85 mg) and the suspension was refluxed for 1 h. Intermediate 142.2 (100 mg) was added in one portion and the reaction mixture was stirred for 20h at 90°C. It was quenched with H20 and extracted with EtOAc. The organic phase was washed with a sat. solution of NaHC03, a 5% solution of KHS04 and brine, dried over MgS04 and concentrated in vacuo. The crude was purified by CC (EtOAc/MeOH 1/0 to 8/2) to give 42 mg of titled compound as a white solid.
LC-MS (B): tR = 0.57 min; [M+H]+: 375.1 1
Example 143 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-(2-oxo-2H-pyrimidin-1 - ylmethyl)-benzamide
To a solution of 2-hydroxypyrimidine hydrochloride (58 mg) in anh. DMF (2 mL) was added potassium carbonate (127 mg) and sodium iodide (60 mg) and the suspension was refluxed for 1 h. Intermediate 142.2 (150 mg) was added in one portion and the reaction mixture was stirred for 20h at 90°C. It was quenched with H20 and extracted with DCM. The organic phase was washed with a sat. solution of NaHC03 dried over MgS04 and concentrated in vacuo. The crude was purified by CC (EtOAc/MeOH 1/0 to 8/2) to give 82 mg of titled compound as a white solid.
LC-MS (B): tR = 0.50 min; [M+H]+: 376.07
Example 144 2-Chloro-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1 -ylmethyl)-N-(1 - hydroxy-cyclohexylmethyl)-benzamide
This compound was prepared using a method analogous to that of Example 143, uracil replacing 2-hydroxypyrimidine hydrochloride except that the reaction mixture was stirred for 4 days at 90°C and an additional purification by preparative LC-MS using method IV was necessary.
LC-MS (B): tR = 0.57 min; [M+H]+: 392.26
Example 145 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-pyridin-2-ylmethyl- benzamide
145.1 5-Bromomethyl-2-chloro-benzoic acid methyl ester
This compound was prepared using a method analogous to that of Example 132.1 , intermediate 142.1 replacing 2-chloro-5-hydroxybenzoic acid except that the crude was purified by CC (Hept/EtOAc 1/0 to 85/15).
1H NMR ((CD3)2SO) δ: 7.91 (d, J = 2.2 Hz, 1 H), 7.66 (dd, Ji = 8.3 Hz, J2 = 2.2 Hz, 1 H), 7.59 (d, J = 8.3 Hz, 1 H), 4.77 (s, 2 H), 3.88 (s, 3 H)
145.2 2-chloro-5-(Dyridin-2-ylmethyl)benzoic acid methyl ester
Preactivated zinc dust (500 mg) was suspended in THF (1 mL) and 3 drops of trimethylsilylchlonde were added at RT followed by a solution of intermediate 145.1 (1 g) in THF (2 mL). The mixture was stirred for 10 min and added to a solution of 2- bromopyridine (0.453 mL) and tetrakis(triphenylphosphine)palladium(0) (27 mg) in THF (4 ml). The reaction mixture was stirred for 1 h at RT and the solvent was evaporated off. The residue was triturated in acetone and filtered. The filtrate was concentrated in vacuo and the crude was purified by CC (Hept/EtOAc 75/25 to 0/1 ) to give 197 mg of the titled compound as a yellowish oil. LC-MS (B): tR = 0.49 min; [M+H]+: 262.05
145.3 2-chloro-5-(Dyridin-2-ylmethyl)benzoic acid
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.2), intermediate 145.2 replacing intermediate 1.1 .
LC-MS (B): tR = 0.37 min; [M+ H]+: 247.96
145.4 2-Chloro-N-(1-hvdroxy-cvclohexylmethyl)-5-pyridin-2-ylmethyl-benzamide
This compound was prepared using a method analogous to that of Example 10 (intermediate 10.3), intermediate 145.3 replacing intermediate 10.2
LC-MS (B): tR = 0.49 min; [M+H]+: 359.12
Example 146 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-(2-methylsulfanyl- pyrimidin-4-ylmethyl)-benzamide
146.1 2-chloro-5-((2-methylsulfanylDyrimidin-4-yl)methyl)benzoic acid methyl ester
Dry lithium chloride (256 mg) and zinc dust (395 mg) were suspended in THF (0.8 mL) and 1 ,2-dibromoethane (0.013 mL) was added at RT. The reaction mixture was heated until ebullition and cooled to RT. Trimethylsilylchloride (0.004 mL) was added and the reaction mixture was heated until ebullition and cooled to 0°C. A solution of intermediate 145.1 (1 .12 g) in THF (0.8 mL) was added and the reaction mixture was stirred for 30 min at RT. It was added dropwise to a solution of 4-iodo-2-methylsulfanylpyrimidine (747 mg), bis(dibenzylideneacetone)palladium (0) (43 mg) and tri-2-furylphosphine (34 mg) in THF (3 mL). The reaction mixture was stirred for 30 min at RT, quenched with a sat. solution of sodium carbonate and extracted with EtOAc. The organic phase was dried over MgS04 and concentrated in vacuo. The crude was purified by CC (Hept/EtOAc 9/1 to 6/4) to give 409 mg of the titled compound as a yellow oil.
LC-MS (B): tR = 0.83 min; [M+H]+: 309.10 146.2 2-chloro-5-((2-methylsulfanylDyrimidin-4-yl)methyl)benzoic acid
This compound was prepared using a method analogous to that of Example 1 (intermediate 1 .2), intermediate 146.1 replacing intermediate 1.1 except that a 2M aqueous solution of NaOH was used instead of lithium hydroxide in H20.
LC-MS (B): tR = 0.68 min; [M+ H]+: 295.09
146.3 2-Chloro-N-(1-hvdroxy-cvclohexylmethyl)-5-(2-methylsulfanyl-pyrimidin-4- ylmethvD-benzamide
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.3), intermediate 146.2 replacing intermediate 1.2
LC-MS (B): tR = 0.73 min; [M+H]+: 406.30
Example 147 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-(2-oxo-1 ,2-dihydro- pyrimidin-4-ylmethyl)-benzamide
147.1 2-chloro-N-(1-hvdroxy-cvclohexylmethyl)-5-((2-methylsulfonylDyrimidin-4- vDmethvDbenzamide
To a solution of 3-chloroperbenzoic acid (395 mg) in THF (4 mL) was added dropwise at 0°C a solution of intermediate 146.3 (310 mg) in DCM (0.8 mL). The reaction mixture was allowed to warm up to RT and stirred for 1 h at RT. The solvent was evaporated off and the residue was taken up in EtOAc. The organic phase was washed with a 10% solution of sodium carbonate, dried over MgS04 and concentrated in vacuo to give 475 mg of crude titled compound as a yellow waxy solid.
LC-MS (B): tR = 0.61 min; [M+H]+: 438.29
147.2 2-Chloro-N-( 1 -h ydroxy-cyclohexylme th yl) -5-( 2-oxo- 1 , 2-dih ydro-p yrimidin-4- ylmethvD-benzamide
This compound was prepared using a method analogous to that of Example 16 (intermediate 16.1 ), intermediate 147.1 replacing intermediate 10.2 except that the reaction mixture was stirred for 1 h at RT and that the crude was purified first by CC (EtOAc/MeOH 1/0 to 8/2) and by preparative LC-MS using method V. LC-MS (B): tR = 0.50 min; [M+ H]+: 376.12
Example 148 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-(2-methoxy-pyrimidin-4- ylmethyl)-benzamide
This compound was prepared using a method analogous to that of Example 12, intermediate 147.1 replacing intermediate 10.3 except that the reaction mixture was stirred for 6h at RT and that the crude was purified by preparative LC-MS using method VI.
LC-MS (B): tR = 0.65 min; [M+H]+: 390.10
Example 149 2-Chloro-N-(4,4-difluoro-1 -hydroxy-cyclohexylmethyl)-5-(2-oxo-1 ,2- dihydro-pyrimidin-4-ylmethyl)-benzamide
149.1 2-Chloro-5-[2-(2-trimethylsilanyl-ethoxy)-Dyrimidin-4-ylmethyll-be acid methyl ester
This compound was prepared using a method analogous to that of Example 146 (intermediate 146.1 ), intermediate 1 18.1 replacing 4-iodo-2-methylsulfanylpyrimidine except that the reaction mixture was stirred for 20 h at RT.
LC-MS (B): tR = 1 .02 min; [M-2Me+H]+: 351.06
149.2 2-Chloro-5-f2-(2-trimethylsilanyl-ethoxy)-Dyrimidin-4-v^ acid
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.2), intermediate 149.1 replacing intermediate 1.1 .
LC-MS (B): tR = 0.89 min; [M-2Me+H]+: 337.07
149.3 2-Chloro-N-(4A-difluoro-1-hvdroxy-cvclohexylmethyl)-5-[2-(2-tri
ethoxy)-pyrimidin-4-ylmethyll-benzamide
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.3), intermediate 149.2 replacing intermediate 1.2 and intermediate 57.2 replacing 1 -aminomethyl-cyclohexanol hydrochloride.
LC-MS (B): tR = 0.92 min; [M-2Me+H]+: 484.14 149.4 2-Chloro-N-(4.4-difluoro-1-hvdroxy-cvclohexylmethyl)-5-(2-oxo-1.2-dihvdro- Dyrimidin-4-ylmethyl)-benzamide
This compound was prepared using a method analogous to that of Example 1 18 (intermediate 1 18.4), intermediate 149.3 replacing intermediate 1 18.3 except that the reaction mixture was neutralised with Et3N instead of a sat. solution of NaHC03.
LC-MS (B): tR = 0.50 min; [M+H]+: 412.26
Example 150 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-(2-oxo-1 ,2-dihydro- pyrimidine-4-carbonyl)-benzamide
150.1 2-Chloro-5-cvanomethyl-benzoic acid methyl ester
To a suspension of intermediate 145.1 (2.5 g) and potassium carbonate (1 .49 g) in CH3CN (17 ml.) was added trimethylsilylcyanide (1.72 ml.) and the reaction mixture was stirred for 7h at 60°C and for 18h at RT. Additional amount of trimethylsilylcyanide (0.86 ml.) was added and the reaction mixture was stirred for 7h at 60°C and for 18h at RT. It was quenched with a 1 M solution of NaOH and extracted with toluene. The organic phase was washed with a 1 M solution of NaOH and brine, dried over MgS04 and concentrated in vacuo. The crude was purified by CC (Hept/EtOAc 1/0 to 8/2) to give 1.59 g of the titled compound as a white solid.
1H NMR ((CD3)2SO) δ: 7.82 (d, J = 2.1 Hz, 1 H), 7.64 (d, J = 8.3 Hz, 1 H), 7.57 (dd, J1 = 8.3 Hz, J2 = 2.1 Hz, 1 H), 4.14 (s, 2 H), 3.89 (s, 3 H)
150.2 2-chloro-5-(2-(2-(trimethylsilyl)ethoxy)Dyrimidine-4-carbonyl)benzo acid sodium salt
To a solution of intermediate 150.1 (621 mg) and intermediate 1 18.1 (751 mg) in DMF (7.4 ml.) was added at 0°C under argon a 60% dispersion of sodium hydride in mineral oil (178 mg). The reaction mixture was allowed to warm up to RT and stirred for 20 min at RT. Additional amount of a 60% dispersion of sodium hydride in mineral oil (59 mg) was added at 0°C under argon and the reaction mixture was stirred for 15 min at RT. It was diluted with DMF (5 ml.) and additional amount of a 60% dispersion of sodium hydride in mineral oil (178 mg) was added. Compressed air was bubbled into the reaction mixture for 30 min and the reaction mixture was stirred for 5 days under air atmosphere. Additional amount of a 60% dispersion of sodium hydride in mineral oil (60 mg) was added at 0°C and the reaction mixture was stirred for 18h at RT under air atmosphere. It was quenched with a 20% aqueous solution of acetic acid, diluted with H20 and extracted with EtOAc. The organic phase was washed with brine, dried over MgS04 and concentrated in vacuo. The crude was diluted with H20 and a 2M solution of NaOH was added at RT. An ochre solid precipitated out of the aqueous phase and was filtered to give 792 mg of titled compound.
LC-MS (B): tR = 0.89 min; [M-2Me+H]+: 350.90
150.3 2-Chloro-N-(1-hvdroxy-cvclohexylmethyl)-5-i2-(2-trimethylsilanyl-ethoxy)- Dyrimidine-4-carbonyll-benzamide
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.3), intermediate 150.2 replacing intermediate 1.2.
LC-MS (B): tR = 0.94 min; [M+H]+: 489.92
150.4 2-Chloro-N-(1-hvdroxy-cvclohexylmethyl)-5-(2-oxo-1,2-dihvdro-Dyrimidine-4- carbonvD-benzamide
This compound was prepared using a method analogous to that of Example 1 18 (intermediate 1 18.4), intermediate 150.3 replacing intermediate 1 18.3 except that the reaction mixture was neutralised with Et3N at 0°C instead of a sat. solution of NaHC03.
LC-MS (B): tR = 0.52 min; [M+H]+: 389.91
Example 151 2-Chloro-5-[difluoro-(2-oxo-1 ,2-dihydro-pyrimidin-4-yl)-methyl]-N-(1 - hydroxy-cyclohexylmethyl)-benzamide
151.1 2-chloro-5-(2-(2-(trimethylsilyl)ethoxy)pyrimidine-4-carbonyl)benzoic acid methyl ester
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.3), intermediate 150.2 replacing intermediate 1.2 and MeOH replacing 1 - aminomethyl-cyclohexanol hydrochloride and DCM except that a catalytic amount of 4- dimethylaminopyridine (0.2 eq) was used.
LC-MS (B): tR = 1 .04 min; [M-2Me+H]+: 364.93 151.2 2-Chloro-5-{difluoro-[2-(2-trimethylsilanyl-ethoxy)-Dyrimidin-4-yll-m acid methyl ester
A solution of intermediate 151.1 (63 mg) in bis(2-methoxyethyl)aminosulfur trifluoride (0.174 ml.) was stirred for 20h at 90°C in a sealed vial. The reaction mixture was diluted with DCM and washed with H20, a sat. solution of NaHC03 and brine. The organic phase was dried over MgS04 and concentrated in vacuo. The crude was purified by CC (Hept/EtOAc 1/0 to 8/2) to give 16 mg of titled compound as a colorless oil.
LC-MS (B): tR = 1 .07 min; [M-2Me+H]+: 386.93
151.3 2-Chloro-5-{difluoro-[2-(2-trimethylsilanyl-ethoxy)-Dyri
acid
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.2), intermediate 151.2 replacing intermediate 1.1 .
LC-MS (B): tR = 0.95 min; [M-2Me+H]+: 372.99
151.4 2-Chloro-5-{difluoro-[2-(2-trimethylsilanyl-ethoxy)-Dyri
hvdroxy-cvclohexylmethvD-benzamide
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.3), intermediate 151.3 replacing intermediate 1.2.
LC-MS (B): tR = 0.99 min; [M-2Me+H]+: 484.14
151.5 2-Chloro-5-fdifluoro-(2-oxo- 1 , 2-dihydro-p yrimidin-4-yl)-meth yll-N-( 1-h ydroxy- cyclohexylmethvD-benzamide
This compound was prepared using a method analogous to that of Example 1 18 (intermediate 1 18.4), intermediate 151.4 replacing intermediate 1 18.3 except that the reaction mixture was neutralised with Et3N at 0°C instead of a sat. solution of NaHC03.
LC-MS (B): tR = 0.57 min; [M+H]+: 41 1 .93 Example 152 rac-2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-[1 -hydroxy-1 -(2-oxo- 1 ,2-dihydro-pyrimidin-4-yl)-ethyl]-benzamide
152.1 rac-2-Chloro-5-{hvdroxy-[2-(2-trimethylsilanyl-ethoxy)-Dyrimidin
benzoic acid methyl ester
To a solution of intermediate 151.1 (196 mg) in MeOH (5 mL) was added sodium borohydride (23 mg) and the reaction mixture was stirred for 30 min at RT. It was quenched with H20 and extracted with EtOAc. The organic phase was washed with brine, dried over MgS04 and concentrated in vacuo to give 192 mg of the crude titled compound as a colorless oil.
LC-MS (B): tR = 0.93 min; [M-2Me+H]+: 366.79
152.2 rac-2-Chloro-5-{fluoro-[2-(2-trimethylsilanyl-ethoxy)-Dyri
acid methyl ester
To a solution of intermediate 152.1 (184 mg) in DCM (1 mL) was added at 0°C a solution of bis(2-methoxyethyl)aminosulfur trifluoride (0.152 mL) in DCM (0.5 mL). The reaction mixture was stirred for 2h at RT, quenched with a 5% solution of NaHC03, diluted with H20 and extracted with DCM. The organic phase was dried over MgS04 and concentrated in vacuo. The crude was purified by CC (Hept/EtOAc 1/0 to 9/1 ) to give 48 mg of the titled compound as a colorless oil.
LC-MS (B): tR = 1 .04 min; [M-2Me+H]+: 368.92
152.3 rac-2-Chloro-5-{fluoro-[2-(2-trimethylsilanyl-ethoxy)-Dyrimidin-4-yll-methyl}-ben acid
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.2), intermediate 152.2 replacing intermediate 1.1 .
LC-MS (B): tR = 0.91 min; [M-2Me+H]+: 354.91
152.4 rac-2-Chloro-5-{fluoro-[2-(2-trimethylsilanyl-ethoxy)-Dyrimidin-4-yll-methyl}-N-(1^ hydroxy-cvclohexylmethvD-benzamide
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.3), intermediate 152.3 replacing intermediate 1.2. LC-MS (B): tR = 0.95 min; [M-2Me+H]+: 465.72
152.5 rac-2-Chloro-5-ifluoro-(2-oxo-1,2-dihvdro-Dyrimidin-4-yl)-methyll-N-(1-hvdroxy- cvclohexylmethvD-benzamide
This compound was prepared using a method analogous to that of Example 1 18 (intermediate 1 18.4), intermediate 152.4 replacing intermediate 1 18.3 except that the reaction mixture was neutralised with Et3N at 0°C instead of a sat. solution of NaHC03.
LC-MS (B): tR = 0.53 min; [M+H]+: 393.76
Example 153 5-[(2-Chloro-pyrimidin-4-yl)-methyl-amino]-N-(1 -hydroxy- cyclohexylmethyl)-2-methyl-benzamide
153.1 5-Amino-2-methyl-benzoic acid methyl ester
To a solution of 2-methyl-5-nitrobenzoic acid methyl ester (1015 mg) in EtOH (33 mL) was added 10% palladium on charcoal (175 mg) and the reaction mixture was stirred under an atmospheric pressure of hydrogen for 3h at RT. It was filtered over a pad of celite and the filtrate was concentrated in vacuo to give 860 mg of the titled compound as an orange oil.
1H NMR (CDCIs) δ: 7.27 (d, J = 2.6 Hz, 1 H), 7.05 (d, J = 8.1 Hz, 1 H), 6.77 (dd, Ji = 8.1 Hz, J2 = 2.6 Hz, 1 H), 3.89 (s, 3 H), 3.64 (s, 2 H), 2.49 (s, 3 H)
153.2 5-((2-chloroDyrimidin-4-yl)amino)-2-methylbenzoic acid methyl ester
This compound was prepared using a method analogous to that of Example 1 , intermediate 1.1 , 2,4-dichloropyrimidine replacing iodobenzene and intermediate 153.1 replacing methyl-5-amino-2-chlorobenzoate.
LC-MS (B): tR = 0.72 min; [M+H]+: 278.16
153.3 5-[(2-Chloro-pyrimidin-4-yl)-methyl-aminol-2-methyl-benzoic acid methyl ester
This compound was prepared using a method analogous to that of Example 1 1 (intermediate 1 1 .1 ), intermediate 153.2 replacing intermediate 10.1.
LC-MS (B): tR = 0.78 min; [M+H]+: 292.16. 153.4 5-f(2-Chloro-Dyrimidin-4-yl)-methyl-aminol-2-methyl-benzoic acid
This compound was prepared using a method analogous to that of Example 1 (intermediate 1 .2), intermediate 153.3 replacing intermediate 1.1 except that a 2M aqueous solution of NaOH was used instead of lithium hydroxide in H20.
LC-MS (B): tR = 0.64 min; [M+ H]+: 278.12
153.5 5-[(2-Chloro-pyrimidin-4-yl)-methyl-aminol-N-(1-hvdroxy-cvclo^
methyl-benzamide
This compound was prepared using a method analogous to that of Example 10 (intermediate 10.3), intermediate 153.4 replacing intermediate 10.2.
LC-MS (B): tR = 0.67 min; [M+H]+: 389.33.
Example 154 N-(1 -Hydroxy-cyclohexylmethyl)-5-[(2-methoxy-pyrimidin-4-yl)-methyl- amino]-2 -methyl-benzamide
This compound was prepared using a method analogous to that of Example 12, intermediate 153.5 replacing intermediate 10.3 except that the reaction mixture was stirred for 5h at 40°C.
LC-MS (B): tR = 0.51 min; [M+H]+: 385.22.
Example 155 N-(1 -Hydroxy-cyclohexylmethyl)-2-methyl-5-[methyl-(2-oxo-1 ,2- dihydro-pyrimidin-4-yl)-amino]-benzamide
This compound was prepared using a method analogous to that of Example 16 (intermediate 16.1 ), intermediate 153.5 replacing intermediate 10.2 except that it was purified by CC (EtOAc/MeOH 1/0 to 8/2).
LC-MS (B): tR = 0.45 min; [M+H]+: 371 .37. Example 156 rac-2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-[1 -hydroxy-1 -(2-oxo- 1 ,2-dihydro-pyrimidin-4-yl)-ethyl]-benzamide
156.1 rac-2-Chloro-5-{1-hvdroxy-1-[2-(2-trimethylsilanyl-ethoxy)-Dyrimid
benzoic acid methyl ester
To a solution of intermediate 151 .1 (100 mg) in anh. THF (5 mL) was added dropwise at -10°C a 3M solution of MeMgBr in Et20 (0.17 mL). The reaction mixture was allowed to warm to RT and stirred for 30 min. It was cooled to 0°C, quenched with a sat. solution of NH4CI and extracted with EtOAc. The organic phase was washed with brine, dried over MgS04 and concentrated in vacuo to give 106 mg of the titled compound as a light yellow oil.
LC-MS (B): tR = 0.97 min; [M-2Me+H]+: 380.85
156.2 rac-2-Chloro-5-{1-hvdroxy-1-f2-(2-trimethylsilanyl-ethoxy)-Dyrim
benzoic acid
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.2), intermediate 156.1 replacing intermediate 1.1 .
LC-MS (B): tR = 0.85 min; [M-2Me+H]+: 366.96
156.3 rac-2-Chloro-N-( 1 -hydroxy-cvclohexylmeth yl)-5-{ 1 -h ydroxy-1-[2-(2-trimeth ylsilanyl- ethoxy)-Dyrimidin-4-yll-ethyl}-benzamide
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.3), intermediate 156.2 replacing intermediate 1.2.
LC-MS (B): tR = 0.90 min; [M-2Me+H]+: 477.94 156.4 rac-2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(1-hydroxy-1 -(2-OXO-1, 2-dihydro- pyrimidin-4-yl)-ethyll-benzamide
This compound was prepared using a method analogous to that of Example 1 18 (intermediate 1 18.4), intermediate 156.3 replacing intermediate 1 18.3 except that the neutralization was performed using Et3N.
LC-MS (B): tR = 0.50 min; [M+H]+: 406.29 Example 157 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-[1 -hydroxy-1 -(2-oxo-1 ,2- dihydro-pyrimidin-4-yl)-ethyl]-benzamide (enantiomer A) and
Example 158 2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-[(1 -hydroxy-1 -(2-oxo-1 ,2- dihydro-pyrimidin-4-yl)-ethyl]-benzamide (enantiomer B)
Intermediate 156.4 was separated into the respective enantiomers using preparative chiral HPLC (Daicel, ChiralPak AD-H, 5 μπι, 30x250 mm; Hept/EtOH 70/30, flow 34 mL/min), detection: UV 210 nm).
Both enantiomers were characterized by analytical chiral HPLC (Daicel, ChiralPak AD-H, 5 μπι, 4.6x250 mm, Hept/EtOH 70/30, flow 0.8 mL/min), detection: UV 210 to 280 nm: Enantiomer A: tR = 6.76 min (example 157)
Enantiomer B: tR = 9.50 min (example 158)
Example 159 rac-2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-[1 -hydroxy-1 -(2- methoxy-pyrimidin-4-yl)-ethyl]-benzamide
159.1 2-Chloro-5-formyl-benzoic acid methyl ester
A mixture of intermediate 145.1 (250 mg) and methylmorpholine-4-oxide (315 mg) was suspended in dioxane (3 mL) and heated to reflux for 2h. After cooling to RT, the reaction mixture was diluted with EtOAc and washed with an aqueous NH4CI solution, water and brine. The organic phase was dried over MgS04 and concentrated in vacuo to give 178 mg of the titled compound as an orange solid.
1H NMR ((CD3)2SO) δ: 10.06 (s, 1 H), 8.34 (d, J = 2.0 Hz, 1 H), 8.08 (dd, Ji = 8.3 Hz, J2 = 2.0 Hz, 1 H), 7.85 (d, J = 8.3 Hz, 1 H), 3.92 (s, 3 H)
159.2 2-Chloro-5-(2-methoxyDyrimidine-4-carbonyl)benzoic acid methyl ester
A 60% suspension of NaH in mineral oil (51 mg) was added to a solution of 4-chloro-2- methoxypyrimidine (123 mg), intermediate 159.1 (170 mg) and dimethylimidazolium iodide (96 mg) in dioxane (35 mL). The reaction mixture was heated to reflux for 4h30 and ON at RT. It was diluted with water and extracted with EtOAc. The organic phase was dried over MgS04 and concentrated in vacuo. The crude was purified by CC (Hept/EtOAc 1/0 to 7/3) to give 49 mg of the titled compound as a light yellow solid.
LC-MS (B): tR = 0.77 min; [M+H]+: 307.19 159.3 2-Chloro-5-(1-hvdroxy-1-(2-methoxyDyrimidin-4-yl)ethyl)benzoic acid methyl ester
This compound was prepared using a method analogous to that of Example 156 (intermediate 156.1 ), intermediate 159.2 replacing intermediate 151.1.
LC-MS (B): tR = 0.69 min; [M+H]+: 323.10
159.4 2-Chloro-5-(1-hvdroxy-1-(2-methoxypyrimidin-4-yl)ethyl)benzoic acid
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.2), intermediate 159.3 replacing intermediate 1.1 .
LC-MS (B): tR = 0.55 min; [M+H]+: 309.09
159.5 rac-2-Chloro-N-(1-hvdroxy-cvclohexylmethyl)-5-[1-hvdroxy-1-(2-methoxy- Dyrimidin-4-yl)-ethyll-benzamide
This compound was prepared using a method analogous to that of Example 1 (intermediate 1.3), intermediate 159.4 replacing intermediate 1.2.
LC-MS (B): tR = 0.62 min; [M+H]+: 420.10
II. Biological assays
In vitro assay
The P2X7 receptor antagonistic activity of the compounds of formula (I) is determined in accordance with the following experimental method. Experimental method:
Cell line generation and YO-PRO assay
Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole blood using the Qiagen RNeasy kit (Qiagen, CH) according to the manufacturer's instructions. Subsequently cDNA was made (Superscript II, Invitrogen AG, CH) and the human P2X7 gene (genbank ref. BC01 1913) was amplified with the following primers:
ATCGCGGCCGCTCAGTAAGGACTCTTGAAGCCACT and
CGCCGCTAGCACCACCATGCCGGCCTGCTGCAGCTGCA. The amplified sequence was subsequently ligated into a pcDNA3.1 (+) Notl, Nhel digested plasmid. Human embryonic kidney (HEK) cells (ATCC CRL - 1573, Manassas, VA, USA) were transfected with the pcDNA3.1 (+).hP2X7 plasmid using lipofectamine 2000 (Invitrogen AG, CH) according to the manufacturer's instructions. Following a 24h exposure to DNA, cells were trypsinized and re-seeded at low density in the presence of 250 μg Geneticin. Geneticin resistant cells were then selected during two consecutive rounds of cloning by serial limiting dilution with visual inspection. Individual clones were screened for P2X7 expression by applying ATP and recording the resultant uptake of YO-PR01 . Specific cell clones were chosen based on RNA and protein expression. HEK cells stably expressing P2X7 were used to screen drugs using the YO-PR01 assay. Cells were grown to confluency in adherent culture at 37°C in a humidified 5% C02 incubator (split 1/5 every 3 - 4 days with DMEM, 10 % FCS, 1 % Penicillin/Streptomycin, 250 [ig/m\ Geneticin). Adherent cells were detached by incubation with Trypsine (1 ml per 165 cm2 dish) for 2 minutes, then washed off with 10 ml PBS (without Mg2+ and Ca2+), and resuspended in DMEM, 10 % FCS, 1 % Penicillin/Streptomycin, no Geneticin. 10Ό00 cells per well (48 hours before the assay) or 25Ό00 cells per well (Vi-cell XR (Beckman Coulter) (24 hours before the assay) in 50 μΙ full medium were seeded on 384-well black-wall, clear bottom plates, that were coated before with 10 μΙ per well Poly-L-Lysine, incubated for 30 - 60 minutes at 37° C and washed once with PBS. Medium was removed from cells and 50 μΙ of assay buffer containing 0.5 μΜ YO-PRO-1 was added into the wells. Solutions of antagonist compounds were prepared by serial dilutions of a 10 mM DMSO solution of the antagonist into PBS using a BioMek (Beckman Coulter). Each concentration was performed in duplicate. For IC50 measurements 10 concentration points were measured (10 μΜ being the highest concentration followed by 9 serial dilution steps 1/3). The cells were incubated with the antagonists of the present invention together with ATP at a final concentration of 250 μΜ for 90 minutes. During this time period, four time points were taken. Each time point comprised the average of several measurements made within a few seconds. Fluorescence was measured in the FLIPR tetra (Molecular Devices) using the filters appropriate for YO-PRO-1 fluorescence (excitation485/20, emission 530/25). The FLIPR tetra was equipped with Molecular Devices Screen Works system control software to define and run experimental protocols. For antagonist activity measurements, the maximal intensity was expressed as a percentage of that induced by the EC50 value for agonist activation (0.25 mM ATP for HEK-293 cells expressing human recombinant P2X7 receptor). For IC50 measurements the maximum intensity is plotted against the concentration of compound to determine IC50 values.
Antagonistic activities with respect to the P2X7 receptor (IC50 values) of exemplified compounds are displayed in Table 1.
Table 1
ICso ICso ICso
Compound Compound Compound
[nM] [nM] [nM]
Example 1 111 Example 56 74 Example 1 1 1 21
Example 2 315 Example 57 214 Example 1 12 43
Example 3 538 Example 58 51 Example 1 13 96
Example 4 103 Example 59 1810 Example 1 14 100
Example 5 531 Example 60 1027 Example 1 15 191
Example 6 154 Example 61 681 Example 1 16 172 Example 7 876 Example 62 416 Example 1 17 427
Example 8 459 Example 63 307 Example 1 18 14
Example 9 481 Example 64 902 Example 1 19 796
Example 10 890 Example 65 205 Example 120 111
Example 1 1 184 Example 66 158 Example 121 93
Example 12 733 Example 67 337 Example 122 101
Example 13 200 Example 68 288 Example 123 123
Example 14 127 Example 69 326 Example 124 163
Example 15 177 Example 70 373 Example 125 504
Example 16 73 Example 71 1997 Example 126 461
Example 17 35 Example 72 1460 Example 127 58
Example 18 106 Example 73 322 Example 128 30
Example 19 420 Example 74 280 Example 129 80
Example 20 228 Example 75 1023 Example 130 67
Example 21 17 Example 76 418 Example 131 206
Example 22 267 Example 77 1463 Example 132 46
Example 23 18 Example 78 439 Example 133 265
Example 24 236 Example 79 352 Example 134 105
Example 25 109 Example 80 1433 Example 135 266
Example 26 317 Example 81 245 Example 136 640
Example 27 30 Example 82 76 Example 137 8.1
Example 28 353 Example 83 57 Example 138 10
Example 29 456 Example 84 65 Example 139 74 Example 30 181 Example 85 177 Example 140 914
Example 31 566 Example 86 61 Example 141 3895
Example 32 531 Example 87 190 Example 142 80
Example 33 183 Example 88 302 Example 143 377
Example 34 860 Example 89 271 Example 144 1390
Example 35 367 Example 90 905 Example 145 21
Example 36 185 Example 91 354 Example 146 400
Example 37 464 Example 92 82 Example 147 123
Example 38 764 Example 93 111 Example 148 343
Example 39 378 Example 94 160 Example 149 33
Example 40 588 Example 95 351 Example 150 77
Example 41 384 Example 96 123 Example 151 31
Example 42 38 Example 97 317 Example 152 25
Example 43 136 Example 98 332 Example 153 702
Example 44 33 Example 99 148 Example 154 629
Example 45 89 Example 100 217 Example 155 199
Example 46 21 Example 101 319 Example 156 14
Example 47 116 Example 102 37 Example 157 9.0
Example 48 15 Example 103 46 Example 158 66
Example 49 1117 Example 104 100 Example 159 346
Example 50 258 Example 105 47
Example 51 460 Example 106 1715
Example 52 170 Example 107 70 Example 53 576 Example 108 64
Example 54 231 Example 109 53
Example 55 482 Example 1 10 122

Claims

Claims
1. A compound of the formula I),
Figure imgf000145_0001
(I)
wherein
n represents 1 , 2, 3 or 4 (and preferably 2, 3 or 4);
Y represents -C(R7R8)-, -N(R9)-, -0-, -S-, -S(O)-, or -S(0)2-;
R1 represents
• a 5-membered heteroaryl group which is unsubstituted or mono- or di-substituted with (Ci-C4)alkyl;
• a 6-membered heteroaryl group which is unsubstituted or mono- or di-substituted, wherein the substituents are independently selected from the group consisting of halogen, hydroxy, (Ci-C4)alkyl, (Ci-C4)alkoxy, (Ci-C4)alkylthio, (Ci-C4)alkyl- sulfonyl, (Ci-C4)alkyl-amino and di-[(Ci-C4)alkyl]-amino;
· a phenyl group which is unsubstituted or mono- or di-substituted with halogen; or
• a heterocyclyl group which is unsubstituted or mono- or di-substituted with (Ci- C4)alkyl or (C1-C2)alkoxy-(C1-C4)alkyl;
R2 represents chloro or methyl (and preferably chloro);
R3 represents hydrogen and R4 represents hydroxy, hydroxy-(C1-C4)alkyl, -CONH2 or (C1-C4)alkoxy (and preferably hydroxy, hydroxymethyl or methoxy); or
R3 represents (Ci-C4)alkyl or hydroxy-(Ci-C4)alkyl (and preferably methyl or hydroxymethyl) and R4 represents hydrogen;
R5 represents hydrogen or fluoro;
R6 represents hydrogen or fluoro;
R7 and R8 represent independently from each other hydrogen, fluoro, hydroxy or (Ci- C4)alkyl, with the proviso that R8 is different from fluoro or hydroxy if R7 represents hydroxy; or R7 and R8 together represent an oxo-group; and
R9 represents hydrogen, (d-C4)alkyl, (Ci-C2)alkoxy-(Ci-C4)alkyl, (C3-C6)cycloalkyl-(Ci- C4)alkyl, phenyl-(Ci-C4)alkyl, or phenyloxy-(Ci-C4)alkyl;
or a salt of such a compound.
2. A compound of formula (I) according to claim 1 , wherein
n represents 1 , 2, 3 or 4;
Y represents -C(R7R8)-, -N(R9)-, -0-, -S-, -S(O)-, or -S(0)2-;
R1 represents
• a 5-membered heteroaryl group which is unsubstituted or mono- or di-substituted with (d-C4)alkyl;
• a 6-membered heteroaryl group which is unsubstituted or mono- or di-substituted, wherein the substituents are independently selected from the group consisting of halogen, hydroxy, (Ci-C4)alkyl, (Ci-C4)alkoxy, (Ci-C4)alkylthio, (Ci-C4)alkyl- sulfonyl, (Ci-C4)alkyl-amino and di-[(Ci-C4)alkyl]-amino;
· a phenyl group which is unsubstituted or mono- or di-substituted with halogen; or
• a heterocyclyl group which is unsubstituted or mono- or di-substituted with (Ci- C4)alkyl or (Ci-C2)alkoxy-(Ci-C4)alkyl;
R2 represents chloro or methyl;
R3 represents hydrogen and R4 represents hydroxy, hydroxy-(Ci-C4)alkyl, -CONH2 or (Ci-C4)alkoxy;
R5 represents hydrogen or fluoro;
R6 represents hydrogen or fluoro;
R7 and R8 represent independently from each other hydrogen or fluoro; or R7 and R8 together represent an oxo-group; and
R9 represents hydrogen, (d-C4)alkyl, (C1-C2)alkoxy-(C1-C4)alkyl, (C3-C6)cycloalkyl-(C1- C4)alkyl, phenyl-(C1-C4)alkyl, or phenyloxy-(C1-C4)alkyl;
or a salt of such a compound.
3. A compound of formula (I) according to claim 1 , wherein
n represents 1 , 2, 3 or 4; Y represents -C(R7R8)-, -N(R9)-, -0-, or -S-;
R1 represents a 6-membered heteroaryl group which is unsubstituted or mono- or di- substituted, wherein the substituents are independently selected from the group consisting of halogen, hydroxy, (Ci-C4)alkyl, (Ci-C4)alkoxy, (Ci-C4)alkylthio, (Ci-C4)alkyl-sulfonyl, (Ci-C4)alkyl-amino and di-[(Ci-C4)alkyl]-amino;
R2 represents chloro;
R3 represents (Ci-C4)alkyl or hydroxy-(Ci-C4)alkyl and R4 represents hydrogen;
R5 represents hydrogen or fluoro;
R6 represents hydrogen or fluoro;
R7 and R8 represent independently from each other hydrogen or fluoro; or R7 and R8 together represent an oxo-group; and
R9 represents hydrogen, (d-C4)alkyl, (C1-C2)alkoxy-(C1-C4)alkyl, (C3-C6)cycloalkyl-(C1- C4)alkyl, phenyl-(C1-C4)alkyl, or phenyloxy-(C1-C4)alkyl;
or a salt of such a compound.
4. A compound of formula (I) according to any one of claims 1 to 3, wherein
n represents 2, 3 or 4;
or a salt of such a compound.
5. A compound of formula (I) according to any one of claims 1 to 4, wherein
Y represents -C(R7R8)-, -0-, or -S-;
or a salt of such a compound.
6. A compound of formula (I) according to any one of claims 1 to 4, wherein
Y represents -N(R9)-;
or a salt of such a compound.
7. A compound of formula (I) according to any one of claims 1 to 6, wherein
R1 represents a 6-membered heteroaryl group which is unsubstituted or mono- or di- substituted, wherein the substituents are independently selected from the group consisting of halogen, hydroxy, (Ci-C4)alkyl, (Ci-C4)alkoxy, (Ci-C4)alkylthio, (Ci-C4)alkyl-sulfonyl, (C1-C4)alkyl-amino and di-[(C1-C4)alkyl]-amino;
or a salt of such a compound.
8. A compound of formula (I) according to any one of claims 1 to 7, wherein
R2 represents chloro; or a salt of such a compound.
9. A compound of formula (I) according to any one of claims 1 , 2 or 4 to 8, wherein
R3 represents hydrogen and R4 represents hydroxy or hydroxy-(Ci-C4)alkyl;
or a salt of such a compound.
10. A compound of formula (I) according to any one of claims 1 or 3 to 8, wherein
R3 represents (Ci-C4)alkyl or hydroxy-(Ci-C4)alkyl and R4 represents hydrogen;
or a salt of such a compound.
11. A compound of formula (I) according to claim 1 , selected from the group consisting of:
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-phenylamino-benzamide;
2-Chloro-N-((1 -hydroxycyclohexyl)methyl)-5-(methyl(phenyl)amino)benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[(2-methoxy-ethyl)-phenyl-amino]-benzamide;
2-Chloro-5-(2-fluoro-phenylamino)-N-(1-hydroxy-cyclohexylmethyl)-benzamide;
2-Chloro-5-[(2-fluoro-phenyl)-methyl-amino]-N-(1 -hydroxy-cyclohexylmethyl)-benzamide;
2-Chloro-5-(2,4-difluoro-phenylamino)-N-(1-hydroxy-cyclohexylmethyl)-benzamide;
2-Chloro-5-[(2,4-difluoro-phenyl)-methyl-amino]-N-(1-hydroxy-cyclohexylmethyl)- benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(pyrimidin-4-ylamino)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(methyl-pyrimidin-4-yl-amino)-benzamide; 2-Chloro-5-(2-chloro-pyrimidin-4-ylamino)-N-(1-hydroxy-cyclohexylmethyl)-benzamide; 2-Chloro-5-[(2-chloro-pyrimidin-4-yl)-methyl-amino]-N-(1 -hydroxy-cyclohexylmethyl)- benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(2-methoxy-pyrimidin-4-ylamino)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[(2-methoxy-pyrimidin-4-yl)-methyl-amino]- benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[methyl-(2-methylamino-pyrimidin-4-yl)- amino]-benzamide;
2-Chloro-5-[(2-dimethylamino-pyrimidin-4-yl)-methyl-amino]-N-(1 -hydroxy- cyclohexylmethyl)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(2-hydroxypyrimidin-4-ylamino)-benzamide; 2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[methyl-(2-oxo-1 ,2-dihydro-pyrimidin-4-yl)- amino]-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[methyl-(3-methyl-2-oxo-2,3-dihydro- pyrimidin-4-yl)-amino]-benzamide; 2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[methyl-(1-methyl-2-oxo-1 ,2-dihydro- pyrimidin-4-yl)-amino]-benzamide;
2-Chloro-5-[(2-chloro-pyrimidin-4-yl)-ethyl-amino]-N-(1 -hydroxy-cyclohexylmethyl)- benzamide;
2-Chloro-5-[ethyl-(2-oxo-1 ,2-dihydro-pyrimidin-4-yl)-amino]-N-(1-hydroxy- cyclohexylmethyl)-benzamide;
2-Chloro-5-[(2-chloro-pyrimidin-4-yl)-propyl-amino]-N-(1 -hydroxy-cyclohexylmethyl)- benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[(2-oxo-1 ,2-dihydro-pyrimidin-4-yl)-propyl- amino]-benzamide;
2-Chloro-5-[(2-chloro-pyrimidin-4-yl)-isopropyl-amino]-N-(1-hydroxy-cyclohexylmethyl)- benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[isopropyl-(2-oxo-1 ,2-dihydro-pyrimidin-4-yl)- amino]-benzamide;
2-Chloro-5-[(2-chloro-pyrimidin-4-yl)-isobutyl-amino]-N-(1-hydroxy-cyclohexylmethyl)- benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[isobutyl-(2-oxo-1 ,2-dihydro-pyrimidin-4-yl)- amino]-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[isobutyl-(2-methoxy-pyrimidin-4-yl)-amino]- benzamide;
5-[Benzyl-(2-chloro-pyrimidin-4-yl)-amino]-2-chloro-N-(1-hydroxy-cyclohexylmethyl)- benzamide;
5-[Benzyl-(2-oxo-1 ,2-dihydro-pyrimidin-4-yl)-amino]-2-chloro-N-(1 -hydroxy- cyclohexylmethyl)-benzamide;
5-[Benzyl-(2-methoxy-pyrimidin-4-yl)-amino]-2-chloro-N-(1-hydroxy-cyclohexylmethyl)- benzamide;
2-Chloro-5-[(2-chloro-pyrimidin-4-yl)-(2-methoxy-ethyl)-amino]-N-(1-hydroxy- cyclohexylmethyl)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[(2-methoxy-ethyl)-(2-oxo-1 ,2-dihydro- pyrimidin-4-yl)-amino]-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[(2-methoxy-ethyl)-(2-methoxy-pyrimidin-4-yl)- amino]-benzamide;
2-Chloro-5-[(2-chloro-pyrimidin-4-yl)-cyclopentylmethyl-amino]-N-(1-hydroxy- cyclohexylmethyl)-benzamide; 2-Chloro-5-[cyclopentylmethyl-(2-oxo-1 ,2-dihydro-pyrimidin-4-yl)-amino]-N-(1-hy cyclohexylmethyl)-benzamide;
2-Chloro-5-[cyclopentylmethyl-(2-methoxy-pyrimidin-4-yl)-amino]-N-(1-hydroxy- cyclohexylmethyl)-benzamide;
2-Chloro-5-[(2-chloro-pyrimidin-4-yl)-(2-phenoxy-ethyl)-amino]-N-(1-hydroxy- cyclohexylmethyl)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[(2-oxo-1 ,2-dihydro-pyrimidin-4-yl)-(2- phenoxy-ethyl)-amino]-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[(2-methoxy-pyrimidin-4-yl)-(2-phenoxy-ethyl)- amino]-benzamide;
2-Chloro-5-[(2-chloro-pyrimidin-4-yl)-methyl-amino]-N-((R)-1 -cyclohexyl-ethyl)-benzamide;
2-Chloro-N-((R)-1-cyclohexyl-ethyl)-5-[methyl-(2-oxo-1 ,2-dihydro-pyrimidin-4-yl)-amino]- benzamide;
2-Chloro-5-[(2-chloro-pyrimidin-4-yl)-methyl-amino]-N-((S)-1-cyclohexyl-2-hydroxy-ethyl)- benzamide;
2-Chloro-N-((S)-1 -cyclohexyl-2-hydroxy-ethyl)-5-[methyl-(2-oxo-1 ,2-dihydro-pyrimidin-4- yl)-amino]-benzamide;
2-Chloro-5-[(2-chloro-pyrimidin-4-yl)-methyl-amino]-N-(1 -hydroxy-cycloheptylmethyl)- benzamide;
2-Chloro-N-(1-hydroxy-cycloheptylmethyl)-5-[methyl-(2-oxo-1 ,2-dihydro-pyrimidin-4-yl)- amino]-benzamide;
2-Chloro-5-[(2-chloro-pyrimidin-4-yl)-methyl-amino]-N-(1 -hydroxy-cyclooctylmethyl)- benzamide;
2-Chloro-N-(1-hydroxy-cyclooctylmethyl)-5-[methyl-(2-oxo-2,3-dihydro-pyrimidin-4-yl)- amino]-benzamide;
2-Chloro-5-[(2-chloro-pyrimidin-4-yl)-methyl-amino]-N-(1 -hydroxy-cyclopentylmethyl)- benzamide;
2-Chloro-N-(1-hydroxy-cyclopentylmethyl)-5-[methyl-(2-oxo-2,3-dihydro-pyrimidin-4-yl)- amino]-benzamide;
2-Chloro-5-[(2-chloro-pyrimidin-4-yl)-methyl-amino]-N-(1 -methoxy-cyclohexylmethyl)- benzamide;
2-Chloro-N-(1-methoxy-cyclohexylmethyl)-5-[methyl-(2-oxo-2,3-dihydro-pyrimidin-4-yl)- amino]-benzamide;
N-(1-Carbamoyl-cyclohexylmethyl)-2-chloro-5-[(2-chloro-pyrimidin-4-yl)-methyl-amino]- benzamide; N-(1-Carbamoyl-cyclohexylmethyl)-2-chloro
amino]-benzamide;
2-Chloro-5-[(2-chloro-pyrimidin-4-yl)-methyl-amino]-N-(1 -hydroxymethyl- cyclohexylmethyl)-benzamide;
2-Chloro-N-(1-hydroxymethyl-cyclohexylmethyl)-5-[methyl-(2-oxo-2,3-dihydro-pyrimidin-4- yl)-amino]-benzamide;
2-Chloro-5-[(2-chloro-pyrimidin-4-yl)-methyl-amino]-N-(4,4-difluoro-1-hydroxy- cyclohexylmethyl)-benzamide;
2-Chloro-N-(4,4-difluoro-1 -hydroxy-cyclohexylmethyl)-5-[methyl-(2-oxo-2,3-dihydro- pyrimidin-4-yl)-amino]-benzamide;
2-Chloro-N-((R)-1-cyclohexyl-ethyl)-5-(2-methylsulfanyl-pyrimidin-4-ylamino)-benzamide;
2-Chloro-N-((S)-1 -cyclohexyl-2-hydroxy-ethyl)-5-(2-methylsulfanyl-pyrimidin-4-ylamino)- benzamide;
2-Chloro-N-(1 -hydroxy-cycloheptylmethyl)-5-(2-methylsulfanyl-pyrimidin-4-ylamino)- benzamide;
2-Chloro-5-[(2,6-dichloro-pyrimidin-4-yl)-methyl-amino]-N-(1 -hydroxy-cyclohexylmethyl)- benzamide;
2-Chloro-5-[(6-chloro-2-methoxy-pyrimidin-4-yl)-methyl-amino]-N-(1 -hydroxy- cyclohexylmethyl)-benzamide;
2-Chloro-5-[(6-chloro-2-oxo-1 ,2-dihydro-pyrimidin-4-yl)-methyl-amino]-N-(1-hydroxy- cyclohexylmethyl)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[methyl-(6-methylsulfanyl-pyrimidin-4-yl)- amino]-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[(6-methanesulfonyl-pyrimidin-4-yl)-methyl- amino]-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[(6-methoxy-pyrimidin-4-yl)-methyl-amino]- benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[methyl-(6-oxo-1 ,6-dihydro-pyrimidin-4-yl)- amino]-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(pyrimidin-2-ylamino)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(methyl-pyrimidin-2-yl-amino)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[(2-methoxy-ethyl)-pyrimidin-2-yl-amino]- benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(4-methylsulfanyl-pyrimidin-2-ylamino)- benzamide; 2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[methyl-(4-methylsulfanyl-pyrimidin amino]-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[(4-methoxy-pyrimidin-2-yl)-methyl-amino]- benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[methyl-(6-oxo-1 ,6-dihydro-pyrimidin-2-yl)- amino]-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(pyrimidin-5-ylamino)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[(2-methoxy-ethyl)-pyrimidin-5-yl-amino]- benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(pyrazin-2-ylamino)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(methyl-pyrazin-2-yl-amino)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[(2-methoxy-ethyl)-pyrazin-2-yl-amino]- benzamide;
2-Chloro-5-[(6-chloro-pyrazin-2-yl)-methyl-amino]-N-(1-hydroxy-cyclohexylmethyl)- benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[(6-methoxy-pyrazin-2-yl)-methyl-amino]- benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[methyl-(6-methylamino-pyrazin-2-yl)-amino]- benzamide;
2-Chloro-5-[(6-dimethylamino-pyrazin-2-yl)-methyl-amino]-N-(1 -hydroxy- cyclohexylmethyl)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[methyl-(6-oxo-1 ,6-dihydro-pyrazin-2-yl)- amino]-benzamide;
2-Chloro-5-[(3-chloro-pyrazin-2-yl)-methyl-amino]-N-(1-hydroxy-cyclohexylmethyl)- benzamide;
2-Chloro-5-[(5-chloro-pyrazin-2-yl)-methyl-amino]-N-(1-hydroxy-cyclohexylmethyl)- benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[(5-methoxy-pyrazin-2-yl)-methyl-amino]- benzamide;
2-Chloro-5-[(6-chloro-pyridazin-3-yl)-methyl-amino]-N-(1 -hydroxy-cyclohexylmethyl)- benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[methyl-(6-oxo-1 ,6-dihydro-pyridazin-3-yl)- amino]-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[(6-methoxy-pyridazin-3-yl)-methyl-amino]- benzamide; 2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(pyridin-2-ylamino)-benzamid 2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(methyl-pyridin-2-yl-amino)-benzamide; 2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(6-oxo-1 ,6-dihydro-pyridin-2-ylamino)- benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[methyl-(6-oxo-1 ,6-dihydro-pyridin-2-yl)- amino]-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(1-methyl-6-oxo-1 ,6-dihydro-pyridin-2- ylamino)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[1 -(2-methoxy-ethyl)-6-oxo-1 ,6-dihydro- pyridin-2-ylamino]-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-{[1 -(2-methoxy-ethyl)-6-oxo-1 ,6-dihydro- pyridin-2-yl]-methyl-amino}-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(1-methyl-2-oxo-1 ,2-dihydro-pyridin-3- ylamino)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(2-methyl-2H-pyrazol-3-ylamino)-benzamide; 2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[methyl-(2-methyl-2H-pyrazol-3-yl)-amino]- benzamide;
2-Chloro-5-(6-fluoro-pyridin-2-yloxy)-N-(1-hydroxy-cyclohexylmethyl)-benzamide;
2-Chloro-5-(4-fluoro-pyridin-2-yloxy)-N-(1-hydroxy-cyclohexylmethyl)-benzamide;
2-Chloro-5-(2-chloro-pyridin-4-yloxy)-N-(1-hydroxy-cyclohexylmethyl)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(pyridin-2-yloxy)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(pyridin-4-yloxy)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(pyridin-3-yloxy)-benzamide;
2-Chloro-5-(6-chloro-pyridin-2-yloxy)-N-(1-hydroxy-cyclohexylmethyl)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(6-methylamino-pyridin-2-yloxy)-benzamid
2-Chloro-5-(6-dimethylamino-pyridin-2-yloxy)-N-(1 -hydroxy-cyclohexylmethyl)-benzami
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(6-methoxy-pyridin-2-yloxy)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(6-oxo-1 ,6-dihydro-pyridin-2-yloxy)- benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(1 -methyl-6-oxo-1 ,6-dihydro-pyridin-2-yloxy)- benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(pyrimidin-4-yloxy)-benzamide;
2-Chloro-5-(2-chloro-pyrimidin-4-yloxy)-N-(1-hydroxy-cyclohexylmethyl)-benzamide; 2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(2-methylamino-pyrimidin-4-yloxy)- benzamide; 2-Chloro-5-(2-dimethylamino-pyrimidin-4-yloxy)-N-(1-hydroxy-cyclohexylmeth
benzamide;
2-Chloro-N-(4,4-difluoro-1 -hydroxy-cyclohexylmethyl)-5-(2-oxo-1 ,2-dihydro-pyrimidin-4- yloxy)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(2-oxo-2,3-dihydro-pyrimidin-4-yloxy)- benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(2-methoxy-pyrimidin-4-yloxy)-benzamide; 2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(pyrazin-2-yloxy)-benzamide;
2-Chloro-5-(6-chloro-pyrazin-2-yloxy)-N-(1-hydroxy-cyclohexylmethyl)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(6-methoxy-pyrazin-2-yloxy)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(6-methylamino-pyrazin-2-yloxy)-benzamide;
2-Chloro-5-(6-dimethylamino-pyrazin-2-yloxy)-N-(1 -hydroxy-cyclohexylmethyl)- benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(6-oxo-1 ,6-dihydro-pyrazin-2-yloxy)- benzamide;
2-Chloro-5-(6-chloro-pyridazin-3-yloxy)-N-(1-hydroxy-cyclohexylmethyl)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(6-methoxy-pyridazin-3-yloxy)-benzamide; 2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(6-oxo-1 ,6-dihydro-pyridazin-3-yloxy)- benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(pyridazin-3-yloxy)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(5-methoxy-pyridazin-3-yloxy)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(pyridin-2-ylsulfanyl)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(pyridine-2-sulfinyl)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(pyridine-2-sulfonyl)-benzamide;
2-Chloro-5-(2-chloro-pyrimidin-4-ylsulfanyl)-N-(1 -hydroxy-cyclohexylmethyl)-benzamide;
2-Chloro-5-(2-chloro-pyrimidine-4-sulfinyl)-N-(1 -hydroxy-cyclohexylmethyl)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(2-oxo-1 ,2-dihydro-pyrimidin-4-ylsulfanyl)- benzamide;
2-Chloro-N-(4,4-difluoro-1 -hydroxy-cyclohexylmethyl)-5-(2-oxo-1 ,2-dihydro-pyrimidin-4- ylsulfanyl)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(2-methoxy-pyrimidin-4-ylsulfanyl)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(2-methoxy-pyrimidine-4-sulfinyl)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(2-methoxy-pyrimidine-4-sulfonyl)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(2-oxo-2H-pyridin-1-ylmethyl)-benzamide; 2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(2-oxo-2H-pyrimidin-1-ylmethyl)-benzamide; 2-Chloro-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1 -ylmethyl)-N-(1-hydroxy- cyclohexylmethyl)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-pyridin-2-ylmethyl-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(2-methylsulfanyl-pyrimidin-4-ylmethyl)- benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(2-oxo-1 ,2-dihydro-pyrimidin-4-ylmethyl)- benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(2-methoxy-pyrimidin-4-ylmethyl)-benzamide; 2-Chloro-N-(4,4-difluoro-1 -hydroxy-cyclohexylmethyl)-5-(2-oxo-1 ,2-dihydro-pyrimidin-4- ylmethyl)-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-(2-oxo-1 ,2-dihydro-pyrimidine-4-carbonyl)- benzamide;
2-Chloro-5-[difluoro-(2-oxo-1 ,2-dihydro-pyrimidin-4-yl)-methyl]-N-(1 -hydroxy- cyclohexylmethyl)-benzamide;
2-Chloro-5-[fluoro-(2-oxo-1 ,2-dihydro-pyrimidin-4-yl)-methyl]-N-(1 -hydroxy- cyclohexylmethyl)-benzamide;
5-[(2-Chloro-pyrimidin-4-yl)-methyl-amino]-N-(1-hydroxy-cyclohexylmethyl)-2-methyl- benzamide;
N-(1 -Hydroxy-cyclohexylmethyl)-5-[(2-methoxy-pyrimidin-4-yl)-methyl-amino]-2-methyl- benzamide;
N-(1 -Hydroxy-cyclohexylmethyl)-2-methyl-5-[methyl-(2-oxo-1 ,2-dihydro-pyrimidin-4-yl)- amino]-benzamide;
2-Chloro-N-(1 -hydroxy-cyclohexylmethyl)-5-[1-hydroxy-1 -(2-OXO-1 , 2-dihydro-pyrimidin-4- yl)-ethyl]-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[(1 S)-1 -hydroxy-1 -(2-OXO-1 ,2-dihydro- pyrimidin-4-yl)-ethyl]-benzamide;
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[(1 R)-1-hydroxy-1 -(2-oxo-1 ,2-dihydro- pyrimidin-4-yl)-ethyl]-benzamide; and
2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[1 -hydroxy-1-(2-methoxy-pyrimidin-4-yl)- ethyl]-benzamide;
or a salt of such a compound.
12. A compound of formula (I) according to any one of claims 1 to 1 1 , or a pharmaceutically acceptable salt thereof, for use as a medicament.
13. A pharmaceutical composition containing, as active principle, a compound of formula (I) according to any one of claims 1 to 1 1 or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient.
14. Use of a compound of formula (I) according to any one of claims 1 to 1 1 , or of a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the prevention or treatment of a disease selected from pain; neurodegenerative and neuroinflammatory diseases; bone and joint diseases; obstructive diseases of the airways; cardiovascular diseases; eye diseases; skin diseases; abdominal and gastrointestinal tract diseases; genitourinary diseases; cancer; other auto-immune and allergic disorders; and other disorders with an inflammatory or immunological component.
15. A compound of formula (I) according to any one of claims 1 to 1 1 , or a pharmaceutically acceptable salt thereof, for the prevention or treatment of a disease selected from pain; neurodegenerative and neuroinflammatory diseases; bone and joint diseases; obstructive diseases of the airways; cardiovascular diseases; eye diseases; skin diseases; abdominal and gastrointestinal tract diseases; genitourinary diseases; cancer; other auto-immune and allergic disorders; and other disorders with an inflammatory or immunological component.
PCT/IB2012/050780 2011-02-22 2012-02-21 Benzamide derivatives as p2x7 receptor antagonists Ceased WO2012114268A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
KR1020137024559A KR20140009374A (en) 2011-02-22 2012-02-21 Benzamide derivatives as p2x7 receptor antagonists
CA2824415A CA2824415A1 (en) 2011-02-22 2012-02-21 Benzamide derivatives as p2x7 receptor antagonists
EP12709177.5A EP2678317A1 (en) 2011-02-22 2012-02-21 Benzamide derivatives as p2x7 receptor antagonists
CN201280009862XA CN103391923A (en) 2011-02-22 2012-02-21 Benzamide derivatives as p2x7 receptor antagonists
JP2013554962A JP2014513671A (en) 2011-02-22 2012-02-21 Benzamide derivatives as P2X7 receptor antagonists
US14/001,052 US20140073651A1 (en) 2011-02-22 2012-02-21 Benzamide derivatives as p2x7 receptor antagonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IBPCT/IB2011/050728 2011-02-22
IB2011050728 2011-02-22

Publications (1)

Publication Number Publication Date
WO2012114268A1 true WO2012114268A1 (en) 2012-08-30

Family

ID=45841546

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2012/050780 Ceased WO2012114268A1 (en) 2011-02-22 2012-02-21 Benzamide derivatives as p2x7 receptor antagonists

Country Status (7)

Country Link
US (1) US20140073651A1 (en)
EP (1) EP2678317A1 (en)
JP (1) JP2014513671A (en)
KR (1) KR20140009374A (en)
CN (1) CN103391923A (en)
CA (1) CA2824415A1 (en)
WO (1) WO2012114268A1 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014097140A1 (en) 2012-12-18 2014-06-26 Actelion Pharmaceuticals Ltd Indole carboxamide derivatives as p2x7 receptor antagonists
CN104918617A (en) * 2013-01-22 2015-09-16 埃科特莱茵药品有限公司 Heterocyclic amide derivatives as p2x7 receptor antagonists
CN104918946A (en) * 2013-01-22 2015-09-16 埃科特莱茵药品有限公司 Heterocyclic amide derivatives as P2X7 receptor antagonists
US9221832B2 (en) 2011-07-22 2015-12-29 Actelion Pharmaceuticals Ltd. Heterocyclic amide derivatives as P2X7 receptor antagonists
US9409917B2 (en) 2012-01-20 2016-08-09 Actelion Pharmaceuticals Ltd. Heterocyclic amide derivatives as P2X7 receptor antagonists
US9718774B2 (en) 2012-12-12 2017-08-01 Idorsia Pharmaceuticals Ltd Indole carboxamide derivatives as P2X7 receptor antagonist
WO2020017587A1 (en) 2018-07-19 2020-01-23 大日本住友製薬株式会社 Pyridazinone derivative
US10548877B2 (en) 2016-03-11 2020-02-04 Takeda Pharmaceutical Company Limited Aromatic ring compound
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
WO2021141041A1 (en) 2020-01-07 2021-07-15 大日本住友製薬株式会社 Therapeutic agent for tauopathies

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR200486683Y1 (en) 2017-07-10 2018-06-21 주식회사 로스팅 파크 커피 컴퍼니 Drip coffee machine
IL273893B2 (en) * 2017-10-09 2025-11-01 Univ Ramot Preparations that affect potassium channel and TRPV1 channel activity and their uses
CN117304118A (en) * 2023-09-15 2023-12-29 江苏艾迪药业股份有限公司 Synthetic method of anti-AIDS drug anovirine

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061569A1 (en) * 1999-04-09 2000-10-19 Astrazeneca Ab Adamantane derivatives
WO2003042191A1 (en) 2001-11-12 2003-05-22 Pfizer Products Inc. Benzamide and heteroarylamide as p2x7 receptor antagonists
WO2004058270A1 (en) 2002-12-31 2004-07-15 Pfizer Products Inc. 3-(3,5-dioxo-4,5-dihydro-3h-(1,2,4)triazin-2-yl)-benzamide derivatives as p2x7-inhibitors for the treatment of inflammatory diseases
WO2004058731A1 (en) 2002-12-31 2004-07-15 Pfizer Products Inc. Benzamide inhibitors of the p2x7 receptor
WO2004099146A1 (en) 2003-05-12 2004-11-18 Pfizer Products Inc. Benzamide inhibitors of the p2x7 receptor
WO2005019182A1 (en) 2003-08-20 2005-03-03 Bayer Healthcare Ag Pyrazolylmethylbenzamide derivatives as p2xt-receptor antagonists

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061569A1 (en) * 1999-04-09 2000-10-19 Astrazeneca Ab Adamantane derivatives
WO2003042191A1 (en) 2001-11-12 2003-05-22 Pfizer Products Inc. Benzamide and heteroarylamide as p2x7 receptor antagonists
WO2004058270A1 (en) 2002-12-31 2004-07-15 Pfizer Products Inc. 3-(3,5-dioxo-4,5-dihydro-3h-(1,2,4)triazin-2-yl)-benzamide derivatives as p2x7-inhibitors for the treatment of inflammatory diseases
WO2004058731A1 (en) 2002-12-31 2004-07-15 Pfizer Products Inc. Benzamide inhibitors of the p2x7 receptor
US20070281939A1 (en) * 2002-12-31 2007-12-06 Pfizer Inc. Benzamide Inhibitors of The P2X7 Receptor
WO2004099146A1 (en) 2003-05-12 2004-11-18 Pfizer Products Inc. Benzamide inhibitors of the p2x7 receptor
WO2005019182A1 (en) 2003-08-20 2005-03-03 Bayer Healthcare Ag Pyrazolylmethylbenzamide derivatives as p2xt-receptor antagonists

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
"Salt selection for basic drugs", INT. J. PHARM., vol. 33, 1986, pages 201 - 217
BARALDI P G ET AL: "Agonists and antagonists acting at P2X7 receptor", CURRENT TOPICS IN MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS LTD, NETHERLANDS, vol. 4, no. 16, 1 January 2004 (2004-01-01), pages 1707 - 1717, XP008117103, ISSN: 1568-0266, DOI: 10.2174/1568026043387223 *
CHEMISTRY LETT., 1984, pages 937 - 940
CHESSELL, I. P.; HATCHER, J. P. ET AL., PAIN, vol. 114, no. 3, 2005, pages 386 - 96
DEUCHARS, S. A.; ATKINSON, L. ET AL., J. NEUROSCI., vol. 21, no. 18, 2001, pages 7143 - 52
FERRARI, D.; CHIOZZI, P. ET AL., NEUROPHARMACOLOGY, vol. 36, no. 9, 1997, pages 1295 - 301
MARK FURBER, LILIAN ALCARAZ, JANICE E. BENT, ARMIN BEYERBACH, KEITH BOWERS, MARTIN BRADDOCK, MOYA V. CAFFREY: "Discovery of Potent and Selective Adamantane-Based Small-Molecule P2X7 Receptor Antagonists/Interleukin-1beta Inhibitors", JOURNAL OF MEDICINAL CHEMISTRY, vol. 50, 27 October 2007 (2007-10-27), pages 5882 - 5885, XP002678693, DOI: 10.1021/jm700949w *
NORTH, R. A., PHYSIOL. REV., vol. 82, no. 4, 2002, pages 1013 - 67
REMINGTON: "The Science and Practice of Pharmacy", 2005, LIPPINCOTT WILLIAMS & WILKINS, article "Pharmaceutical Manufacturing"
SOLLE, M.; LABASI, J. ET AL., J. BIOL. CHEM., vol. 276, no. 1, 2001, pages 125 - 32
SPERLAGH, B.; KOFALVI, A. ET AL., J. NEUROCHEM., vol. 81, no. 6, 2002, pages 1196 - 211
SURPRENANT, A.; RASSENDREN, F. ET AL., SCIENCE, vol. 272, no. 5262, 1996, pages 735 - 8
SYNTHESIS, vol. 4, 2008, pages 507 - 510
T.W. GREENE; P.G.M. WUTS: "Protective Groups in Organic Synthesis", 1999, WILEY-INTERSCIENCE
VIRGINIO, C.; MACKENZIE, A. ET AL., J. PHYSIOL., vol. 519, 1999, pages 335 - 46
WILEY, J. S.; CHEN, J. R. ET AL., CIBA FOUND SYMP., vol. 198, 1996, pages 149 - 60,160-5
YU, Y.; UGAWA, S. ET AL., BRAIN. RES., vol. 1194, 2008, pages 45 - 55

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9221832B2 (en) 2011-07-22 2015-12-29 Actelion Pharmaceuticals Ltd. Heterocyclic amide derivatives as P2X7 receptor antagonists
US9409917B2 (en) 2012-01-20 2016-08-09 Actelion Pharmaceuticals Ltd. Heterocyclic amide derivatives as P2X7 receptor antagonists
US9718774B2 (en) 2012-12-12 2017-08-01 Idorsia Pharmaceuticals Ltd Indole carboxamide derivatives as P2X7 receptor antagonist
WO2014097140A1 (en) 2012-12-18 2014-06-26 Actelion Pharmaceuticals Ltd Indole carboxamide derivatives as p2x7 receptor antagonists
KR20150095905A (en) * 2012-12-18 2015-08-21 액테리온 파마슈티칼 리미티드 Indole carboxamide derivatives as p2x7 receptor antagonists
JP2016504995A (en) * 2012-12-18 2016-02-18 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Indole carboxamide derivatives as P2X7 receptor antagonists
KR102232744B1 (en) 2012-12-18 2021-03-26 이도르시아 파마슈티컬스 리미티드 Indole carboxamide derivatives as p2x7 receptor antagonists
US9556117B2 (en) 2012-12-18 2017-01-31 Actelion Pharmaceuticals Ltd. Indole carboxamide derivatives as P2X7 receptor antagonists
US9388197B2 (en) 2013-01-22 2016-07-12 Actelion Pharmaceuticals Ltd. Heterocyclic amide derivatives as P2X7 receptor antagonists
CN104918617A (en) * 2013-01-22 2015-09-16 埃科特莱茵药品有限公司 Heterocyclic amide derivatives as p2x7 receptor antagonists
US9388198B2 (en) 2013-01-22 2016-07-12 Actelion Pharmaceuticals Ltd. Heterocyclic amide derivatives as P2X7 receptor antagonists
CN104918946A (en) * 2013-01-22 2015-09-16 埃科特莱茵药品有限公司 Heterocyclic amide derivatives as P2X7 receptor antagonists
CN104918617B (en) * 2013-01-22 2017-05-10 埃科特莱茵药品有限公司 Heterocyclic amide derivatives as P2X7 receptor antagonists
JP2016510325A (en) * 2013-01-22 2016-04-07 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Heterocyclic amide derivatives as P2X7 receptor antagonists
US10548877B2 (en) 2016-03-11 2020-02-04 Takeda Pharmaceutical Company Limited Aromatic ring compound
WO2020017587A1 (en) 2018-07-19 2020-01-23 大日本住友製薬株式会社 Pyridazinone derivative
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
WO2021141041A1 (en) 2020-01-07 2021-07-15 大日本住友製薬株式会社 Therapeutic agent for tauopathies

Also Published As

Publication number Publication date
KR20140009374A (en) 2014-01-22
EP2678317A1 (en) 2014-01-01
CA2824415A1 (en) 2012-08-30
US20140073651A1 (en) 2014-03-13
JP2014513671A (en) 2014-06-05
CN103391923A (en) 2013-11-13

Similar Documents

Publication Publication Date Title
EP2678317A1 (en) Benzamide derivatives as p2x7 receptor antagonists
AU2023255024B2 (en) Sulfone pyridine alkyl amide-substituted heteroaryl compounds
EP2931717B1 (en) Indole carboxamide derivatives as p2x7 receptor antagonists
EP2804865B1 (en) Heterocyclic amide derivatives as p2x7 receptor antagonists
EP2755967A1 (en) Heterocyclic compounds for the treatment of cystic fibrosis
SG184018A1 (en) Pyridine and pyrazine derivative for the treatment of cf
US9556117B2 (en) Indole carboxamide derivatives as P2X7 receptor antagonists
WO2013160419A1 (en) Novel compounds
US10752609B2 (en) GSK-3 inhibitors
US8969389B2 (en) Substituted 6-methylnicotinamides as mGluR5 positive allosteric modulators
KR20230004612A (en) Substituted pyridines for the treatment of inflammatory diseases
JP5124471B2 (en) Substituted bicyclic pyrimidone derivatives
JP7043483B2 (en) Bicyclic proline compound
CA2897459C (en) Heterocyclic amide derivatives as p2x7 receptor antagonists
US20230265094A1 (en) Ripk1 inhibitors and methods of use
CN117715898A (en) Six-membered aryl or heteroaryl amide compound, composition and application thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12709177

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2824415

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2012709177

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2013554962

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 14001052

Country of ref document: US

ENP Entry into the national phase

Ref document number: 20137024559

Country of ref document: KR

Kind code of ref document: A